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In the ancient times, when the hunters and gatherers were living, periods of food scar-
city were very common. It was, therefore, advantageous to have efficient mechanisms 
of energy storage in the body. After all, it was uncertain when the next meal would be 
available. This is in sharp contrast to the current modern 24-hour society we are cur-
rently living in with food readily available. The body has not adapted to this excessive 
presence of nutrients and still efficiently stores excessive energy. This increased storage 
of nutrients, together with the fact that we have adapted a more sedentary lifestyle, led 
to a dramatic increase in people suffering from obesity. The world health organization 
(WHO) defines overweight and obesity as having a body mass index (BMI, kg/m2) equal 
or over 25 or 30, respectively. In 2015, over 600 million adults were obese world-wide. 
Obesity has a great impact on society as it contributes to the development of several 
diseases including type 2 diabetes (T2D), cardiovascular diseases, and even cancer [1]. 
More specifically, having a high BMI (>25) was estimated to contribute to 4 million deaths 
globally with cardiovascular diseases being the leading cause [2, 3]. These numbers are 
expected to further increase in the coming years [4, 5]. Only recently, obesity has been 
proposed to be a chronic relapsing disease with food being the pathological agent [6]. 
OBESiTy: RESuLT OF A POSiTivE ENERgy BALANCE
Obesity results from a long-term positive energy balance, defined as an energy imbal-
ance, with energy intake exceeding energy expenditure. This results in excessive stor-
age of sugar and fat in the form of triglycerides, in adipose tissue and eventually also 
in other organs and tissues. Triglycerides consist of three fatty acids (FA) attached to 
a glycerol backbone. Triglyceride-derived FA are, besides glucose, the most important 
energy source of our body and are transported within triglyceride-rich lipoproteins to 
metabolically active tissues including heart, skeletal muscle as well as white adipose 
tissue (WAT) and brown adipose tissue (BAT). The parenchymal cells of these tissues 
synthesize lipoprotein lipase (LPL) that is translocated to the luminal side of endothe-
lial cells lining the blood vessels within tissues, and which cleaves off the FA from the 
triglyceride molecules. This is followed by FA uptake by FA transporters such as cluster 
of differentiation 36 (CD36) and FA binding protein (FABP) into (cardio)myocytes and 
adipocytes (Fig. 1). Central in the uptake of glucose and lipids is the anabolic hormone 
insulin, which is released by the pancreas upon a rise in plasma glucose or FA levels. 
For instance, insulin stimulates adipocytes to enhance translocation of LPL and glucose 
transporter type 4 (GLUT4) towards the cell surface and thereby increases the uptake of 
triglyceride-derived FA and glucose, respectively [7, 8]. Once taken up, in most cell types 
the FA and glucose are burnt into CO2 to concomitantly generate the body’s usable 
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energy source adenosine triphosphate (ATP). ATP is required for many cellular processes, 
such as contraction of (cardio)myocytes in heart and skeletal muscles. 
TyPES OF ADiPOSE TiSSuES
In case of a positive energy balance, triglycerides are primarily stored in the adipose 
tissue depot. White adipose tissue (WAT) is the most abundant form of adipose tissue 
in the body and can be divided into diff erent subcutaneous and visceral depots [9]. 
Morphologically, the adipocytes within WAT are characterized by a large lipid droplet, 
with a few mitochondria that together with the nucleus reside in the small volume of 
cytoplasm that surrounds the lipid droplet. Adipose tissue is not only composed of 
adipocytes but also contains a so-called ‘stromal-vascular fraction (SVF)’ which consists 
of blood cells, endothelial cells and adipocyte precursor cells (pre-adipocytes) [10]. WAT 
plays a central role in the regulation of energy metabolism. First, WAT has the capacity to 
store excessive glucose and FA in the form of triglycerides via two processes: hyperplasia 
and hypertrophy. Hyperplasia involves the maturation of pre-adipocytes into mature 
adipocytes resulting in an increased number of adipocytes and only occurs in childhood 
and adolescence [11]. In fact the number of fat cells stays rather constant after the age of 
20 years [11]. Hypertrophy refers to the expansion of the size of mature adipocytes, and 
is the process via which WAT stores excessive nutrients in adulthood. Thus, adipocyte 
number and morphology can alter in response to energy balance depending on the 
stage of life. Secondly, during energy shortage, the FA within stored triglycerides can 
be liberated from white adipocytes via intracellular lipolysis, using adipose triglyceride 



















Figure 1. Schematic representation of glucose and lipid fl uxes between intestine, liver, white and 
brown adipose tissue. See text for explanation. BAT, brown adipose tissue; CD36, cluster of diff erentiation 
36; FA, fatty acid; FATP, fatty acid transport protein; FFA, free fatty acid; GLUT4, glucose transporter type 4; 




this will result in shrinkage of the adipocytes and weight loss. Besides its function in 
energy storage, WAT is also an important endocrine organ because it synthesizes and 
secretes several factors (generally called ‘adipokines’), such as leptin, adiponectin, 
cytokines and chemokines [10]. Via these signals, WAT influences a range of metabolic 
processes like satiety, lipid and glucose homeostasis. 
Besides WAT, there is also the functionally and morphologically distinct brown adi-
pose tissue (BAT) depot. BAT is located in the interscapular and subscapular region in 
rodents and human babies [12] and primarily in the neck region, above the clavicles 
and around the aorta in human adults [13-15]. Rodent studies have shown that besides 
brown adipocytes in the classical depots, there are also brown-like adipocytes scattered 
within WAT called beige, brite or recruitable adipocytes. These beige cells tend to have 
low basal uncoupling protein-1 (UCP-1, function described below) expression, which 
however is highly induced upon activation [16]. Although several studies suggest that 
human BAT is mainly composed of beige adipocytes [17, 18], for simplicity it will be 
referred to as BAT. BAT volume in adults has been estimated to range from 50 mL to 300 
mL [19], whereas WAT can comprise 20% of the total body weight [20]. In contrast to the 
unilocular white adipocytes, brown adipocytes possess multiple small lipid droplets and 
many mitochondria. In fact, the many mitochondria give BAT its brownish color. BAT is 
also distinct from WAT in another respect. The mitochondria of brown adipocytes con-
tain the protein UCP-1 within their inner mitochondrial membrane, which ‘uncouples’ 
the electron transport chain from ATP synthesis. This feature enables BAT to burn FA to 
generate heat in a process called ‘adaptive thermogenesis’, described in more detail be-
low [12]. BAT has become a ‘hot’ research topic since five research groups independently 
showed the presence of active BAT in adult humans in 2009 [13-15, 21, 22]. BAT activity, 
as assessed with [18F]fluorodeoxyglucose positron emission tomography-computed 
tomography ([18F]FDG PET/CT) which is the current ‘gold’ standard to determine BAT 
activity in humans, appears to be negatively associated with BMI [13]. Because of this 
association and BAT’s capacity to take up and combust large amounts of glucose and 
triglyceride-derived FA from the circulation [23, 24], BAT has since been regarded as a 
target to combat adiposity and related diseases. Furthermore, it has become clear that 
alike WAT, BAT also secretes factors called ‘batokines’ [25] that are able to influence 
systemic energy metabolism. Also similar to WAT, lipid deposition within BAT increases 
during the development of obesity, which results in BAT whitening and BAT dysfunction 
[26]. This is a process that is not completely understood but may be beneficial to prevent 
in order to enhance the contribution of BAT to energy metabolism in obesity. To this 
end, more research is needed to elucidate what happens to BAT in the early stages of 
overweight or obesity development, which up till now is still largely unknown. 
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THERmOgENESiS By BAT
Since active BAT is able to take up and combust large amounts of glucose and triglyc-
erides from the circulation, BAT activation is regarded as a novel potential target for 
therapy of adiposity and related cardiometabolic disorders [27]. The physiological acti-
vator of BAT is cold, which leads to the release of the neurotransmitter norepinephrine 
(also called ‘noradrenaline’) from sympathetic nerve endings in the vicinity of brown 
adipocytes. Norepinephrine binds to adrenergic receptors on the cell membrane of 
the brown adipocytes and thereby activates an intracellular cascade of events that, 
amongst others, results in the liberation of FA from the intracellular lipid droplets [28]. 
The released FA enter the mitochondria and via β-oxidation generate substrates for the 
citric acid cycle, which in the end activate the electron transport chain to build up a 
proton gradient over the mitochondrial inner membrane, which normally generates ATP 
via activating ATP synthase. In brown and beige adipocytes, the presence of UCP-1 un-
couples the proton gradient, resulting in heat production (Fig. 1) [12, 29]. Prolonged BAT 
activation depletes the intracellular lipid droplets from triglycerides and these therefore 
have to become replenished via the uptake of triglyceride-derived FA and glucose from 
the circulation [24, 30]. Again, insulin appears central in this process as insulin signal-
ing is required for uptake of triglyceride-derived FA [31] and glucose [32] by BAT (Fig. 
1). Liver and muscle cells are also able to oxidize glucose and FA. Energy metabolism 
within these cells follow the principles of Randle, where the intermediate metabolites of 
glucose oxidation inhibits FA oxidation and vice versa [33]. On the contrary, active BAT 
takes up both substrates and concomitantly activates their oxidation pathways, as well 
as triglyceride storage pathways [34, 35]. Therefore, it remains to be studied what the 
fate of these substrates is once taken up by BAT and on which substrate activated BAT 
primarily depends. 
THE ENDOCANNABiNOiD SySTEm
Adipose tissues are not the only contributors to energy balance. The brain and nervous 
system also vividly interact with other organs, including the heart and skeletal muscles, 
in order to impact on whole body metabolism. One of the best known modulators of 
energy balance is the endocannabinoid system (ECS) [36]. This system is comprised of 
the two main endocannabinoids 2-arachidonoylglycerol (2-AG) and anandamide (N-ara-
chidonoyl-ethanolamine, AEA), their G protein-coupled receptors cannabinoid receptor 
1 (CB1R) and 2 (CB2R), and the enzymes responsible for the endocannabinoid synthesis 
and degradation. The CB1R is widely expressed, including in the brain and on WAT and 
BAT, whereas the CB2R is primarily expressed on immune cells [37]. Activation of the 
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ECS results, amongst others, in increased food intake, increased motivation to consume 
palatable food, increased lipid accumulation in WAT, and reduced thermogenesis in BAT 
[36]. In obesity, circulating endocannabinoid levels have been shown to be increased, in 
both mice [38, 39] and humans [40, 41]. However, the specific organs that are responsible 
for the rise in endocannabinoid levels in obesity have not been elucidated as yet [42]. 
Importantly, blocking the endocannabinoid system, by using the inverse CB1R agonist 
rimonabant, has proven to be a very effective approach to combat obesity [43]. Obese 
patients who received rimonabant for 12 months showed reduced body weight, reduced 
waist circumference and improved blood lipid and glucose levels. However, psychiatric 
side effects of rimonabant, likely due to effects on the centrally located CB1R, led to the 
withdrawal of this drug from the market in 2008 [44]. Recently, several preclinical studies 
have been focusing on specifically targeting peripheral endocannabinoid receptors, to 
circumvent the unwanted central side effects of ECS inhibition while preserving (a part 
of ) the beneficial metabolic effects [45-47]. Besides targeting endocannabinoid recep-
tors, regulating local levels of endocannabinoids in the periphery by interfering with 
the activity of the enzymes involved in their biosynthesis and degradation is regarded a 
more direct approach. 
mETABOLiC CONSEquENCES OF OBESiTy
Storage of triglycerides in WAT is not harmful by itself, but the metabolic consequences 
of excessive storage in case of obesity, such as insulin resistance resulting in hypergly-
cemia and hyperlipidemia, ultimately leading to type 2 diabetes and cardiovascular dis-
eases, can pose a health risk. In obesity, increased storage of lipids in white adipocytes 
will lead to hypertrophy, hypoxia and eventually to cell death, and subsequently to the 
recruitment of immune cells such as monocytes that maturate into macrophages [48]. 
The hypertrophic adipocytes and macrophages release the pro-inflammatory cytokines 
tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6). These cytokines can directly 
interfere in the insulin signaling cascade resulting in insulin resistance [49], leading to 
dyslipidemia and hyperglycemia, which can contribute to the development of T2D [50]. 
When the adipose tissue has reached saturation of its expansion capacity, lipids will 
overflow and accumulate in other organs such as muscle and the liver where intracel-
lular FA will interfere with the local insulin sensitivity [51]. Additionally, insulin resistant 
adipocytes have increased intracellular lipolysis, which leads to an increased flux of free 
FA to the liver as substrate for hepatic VLDL-triglyceride production [52]. This, together 
with enhanced VLDL production as a result of reduced hepatic insulin sensitivity, causes 
dyslipidemia [53]. The dyslipidemia is further increased by reduced VLDL catabolism 
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since insulin resistance reduces the expression and translocation of LPL in peripheral 
tissues [54].
Several studies suggest that, besides elevated circulating levels of low-density 
lipoprotein (LDL), elevated levels of remnants of triglyceride-rich lipoproteins (i.e. 
chylomicrons and VLDL), are a risk factor for atherosclerosis [55, 56]. Both the uptake 
of triglyceride-derived FA from the circulation by LPL expressing organs and exchange 
of triglycerides from VLDL with cholesteryl esters from high-density lipoproteins (HDL) 
by the action of the cholesteryl ester transfer protein (CETP) results in the formation 
of atherogenic cholesterol-enriched particles [57]. Atherosclerosis development is 
initiated by local inflammation and the retention of pro-atherogenic cholesterol-rich 
lipoproteins, for which triglyceride-rich lipoproteins are precursors, in the vessel wall. In 
more detail, monocytes are recruited from the circulation, which thereby differentiate 
into macrophages. Macrophages scavenge oxidatively modified and aggregated lipo-
proteins thereby turning into foam cells, which augment the inflammatory response. 
The atherosclerotic plaque grows because of further recruitment of immune cells and 
increased deposition of cholesterol within macrophages in the vessel wall [58-60]. Even-
tually, the plaque can rupture, resulting in formation of a thrombus that can occlude 
vessels that provide oxygen to e.g. the heart or brain, leading to a cardiovascular event, 
i.e. myocardial infarction or stroke, respectively. 
Taken together, the adverse cardiometabolic consequences of excessive storage of 
lipids in WAT and lipid deposition in other organs shows that research should focus on 
developing therapeutic strategies to prevent and treat these unbeneficial metabolic 
effects. 
THERAPEuTiC STRATEgiES TO COmBAT OBESiTy AND RELATED mETABOLiC 
DiSORDERS
Current treatment strategies
Since obesity results from a long term positive energy balance, therapeutic strategies 
aim to tilt the balance in the opposite direction by decreasing energy intake and/or in-
creasing energy expenditure. Current treatment options that have proven to be effective 
in obesity can be subdivided into lifestyle intervention, pharmacotherapy and bariatric 
surgery [61]. Although lifestyle interventions that are aimed at decreasing dietary intake 
in combination with enhancing physical activity are effective on the short term, the 
adherence of patients is very low with drop-out rates of participants up to 80% [62]. With 
respect to pharmacotherapy, the most widely prescribed weight-management medica-
tion, at least in the US, is phentermine, a norepinephrine-releasing agent that primarily 
suppresses food intake. Also the glucagon-like peptide-1 (GLP-1) analogue liraglutide, 
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which is widely prescribed for the treatment of T2D, has been approved by the FDA as 
an anti-obesity drug because of its favorable satiety profile [63, 64]. Orlistat, a pancreatic 
lipase inhibitor that reduces the uptake of fat by the intestine, is commonly used in 
Europe [65]. Although phentermine, liraglutide and orlistat are effective in inducing 
weight loss, use of either therapeutic is often reported to cause adverse events [66]. The 
third and most effective method to treat obesity, albeit with higher risk and selective 
eligibility, is bariatric surgery. This procedure aims at reducing the size of the stomach 
and in the case of gastric bypass surgery also partly bypassing the small intestines [61]. 
Taken together, current treatment methods are either not effective on the long-term, 
often cause adverse events or are invasive. 
Brown(ing) adipose tissue
As outlined above, both preclinical and clinical studies indicate a pivotal role for BAT 
in whole-body metabolism. Rodent studies have shown that BAT activation increases 
energy expenditure and whole-body insulin sensitivity, and decreases fat mass, plasma 
lipid levels and atherosclerosis development [24, 57]. Moreover, increasing whole body 
BAT mass in mice, by performing BAT transplantation, improves glucose tolerance and 
causes a complete reversal of high-fat diet-induced insulin resistance [67]. In humans, 
cold exposure increases BAT activity, as measured by increased uptake of [18F]FDG by 
PET/CT, increases energy expenditure in lean [68] and obese individuals [69] and even 
decreases fat mass in healthy lean participants [68]. Moreover, cold exposure increases 
insulin sensitivity in healthy individuals [70] and in patients with T2D [71]. Besides ac-
tivating the classical BAT depots, cold exposure also induces the expression of beige 
adipocyte markers in WAT in mice [72] and humans [73]. In addition, pharmacological 
agents, via enhancing sympathetic outflow (i.e. centrally mediated) or via direct activa-
tion of adipocytes (e.g. adrenergic receptor agonists and agents that enhance NO avail-
ability) are being studied for their potency to activate BAT and/or induce browning of 
WAT [19, 74]. Taken together, these studies indicate the potential of BAT activation and 
browning of WAT in the search for novel strategies to combat obesity and its related 
disorders by increasing energy expenditure. 
Anti-inflammatory agents
Because of the profound link between inflammation, obesity and T2D, anti-inflammatory 
agents are extensively studied for their therapeutic effectiveness to treat these diseases. 
Salsalate, an anti-inflammatory drug belonging to the salicylate class of drugs, is ap-
plied in the clinic to treat pain and inflammation caused by rheumatoid arthritis (RA). 
Interestingly, salsalate improves glucose and lipid homeostasis in T2D patients [75] and 
increases energy expenditure in healthy subjects [76]. Moreover, salsalate also activates 
BAT as shown in mice [77]. Thus, targeting inflammation might also have beneficial 
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effects on BAT and/or browning [78]. Whereas salsalate inhibits the transcription of 
many inflammatory cytokines, other therapeutics target the functionality of specific 
circulating pro-inflammatory cytokines. Approaches targeting TNF-α and IL-6 have been 
extensively studied in the context of insulin resistance with controversial results [79]. In 
contrast to the numerous studies on the role and therapeutic potential of inhibiting pro-
inflammatory cytokines [79], the potential application of anti-inflammatory cytokines 
such as interleukin-37 (IL-37) are still underexplored. Interestingly, mice with transgenic 
IL-37 expression were shown to be protected from diet-induced obesity and obesity-
associated inflammation and insulin resistance [80]. However, the precise mechanism of 
action leading to these beneficial metabolic effects is not entirely known and requires 
further study. 
Dietary compounds
A more recent research topic in the search for therapeutic strategies to combat obesity 
is the application of dietary components. There is a variety of dietary components that 
exert beneficial effects on plasma lipid and glucose levels and that are able to activate 
BAT and/or increase browning of WAT [81]. Polyphenols are the most extensively studied 
dietary components and these can be found in, amongst others, fruits and vegetables 
[82]. For instance, the polyphenol capsaicin activates transient receptor potential vanil-
loid channel 1 (TRPV1), which is present on many metabolic tissues, and thereby in-
creases fat oxidation, improves insulin sensitivity and decreases body fat mass in animal 
models [83]. Moreover, capsaicin has been shown to activate BAT in mice and men [19]. 
Another well-studied polyphenol is resveratrol which has been shown to induce brown-
ing in obese mice [84], and to improve lipid metabolism and reduce atherosclerosis in 
hypercholesterolemic mice [85]. Although clinical studies into the beneficial metabolic 
effects of resveratrol are less consistent, trials with T2D patients imply an anti-diabetic 
effect of resveratrol [86]. Finally, quercetin, which belongs to the polyphenol subclass of 
flavonoids, has been shown to attenuate body weight [87] and lipid deposition in WAT 
[88] in rodents on a high-fat diet. Moreover, dietary quercetin supplementation lowers 
plasma triglyceride levels in mice [89] and in humans [90]. Of note, recent in vitro experi-
ments showed that quercetin induces browning of white adipocytes [91]. However, the 
mechanism behind the triglyceride-lowering effect of quercetin, including a potential 
role for browning, remains to be studied. 
OuTLiNE OF THiS THESiS
As is evident from this chapter (Chapter 1), obesity and its related T2D and cardiovas-
cular diseases are multifactorial diseases that form a great health risk. Obesity results 
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from a long-term energy imbalance, where energy intake exceeds expenditure. Current 
methods to treat obesity are either not effective on the long term or are invasive with a 
relatively high risk as with bariatric surgery. Increasing energy expenditure via activation 
of BAT seems a promising novel tool. A better understanding of the pathophysiology of 
diet-induced obesity on BAT function and whole body metabolism is thus a prerequisite 
for the development of novel compounds that would activate BAT and thereby target 
these metabolic pathologies. Therefore, we aimed to address four key objectives in this 
thesis: 1) to generate in vitro brown adipocyte models for mice and humans to study and 
better understand brown adipocyte metabolism and potential species differences, 2) to 
gain more insight into the effect and underlying mechanisms of the anti-inflammatory 
cytokine IL-37 on the energy balance, 3) to study the effect of diet-induced obesity on 
BAT function and the ECS, and 4) to study the therapeutic potential of the dietary com-
pound quercetin on triglyceride metabolism, with emphasis on BAT and WAT. 
To address the first key objective, we used an already available murine brown adipocyte 
cell line (T37i) and generated new immortalized murine and human brown preadipocyte 
cell lines. Since activated BAT is thought to primarily burn FA to produce heat, while tak-
ing up glucose, free FA and triglyceride-derived FA from the circulation, the fate of these 
substrates within the adipocytes has not entirely been elucidated. Therefore, the aim of 
Chapter 2 was to assess the effect of β3-adrenergic receptor activation on metabolic 
fluxes in T37i murine brown adipocytes. Current cell culture models for brown adipo-
cytes constitutively express oncoproteins that drive proliferation that at the same time 
might inhibit differentiation capacity. To overcome this caveat, in Chapter 3 we aimed 
to generate murine and human brown preadipocyte cell lines that were conditionally 
immortalized, to relieve these cells from oncoprotein expression during differentiation. 
Inflammation plays an important role in the development of obesity-induced insulin 
resistance. Research has primarily focused on the role of pro-inflammatory cytokines in 
this pathophysiology and only recently attention was drawn to the anti-inflammatory 
cytokine IL-37. IL-37 transgenic mice have been shown to be protected from obesity 
and obesity-associated inflammation and insulin resistance. However, the mechanism 
behind the beneficial metabolic effects of IL-37 was not entirely known. In Chapter 4, 
to address key objective 2, we therefore studied the effect IL-37 on the energy balance 
in more detail. 
To meet our third objective, we performed two studies in which mice were fed a 
high-fat diet in order to study the pathophysiology of diet-induced obesity on BAT and 
the ECS. Long-term high-fat diet feeding leads to whitening and dysfunctional BAT. 
However what happens to BAT on a short-term of high-fat diet feeding, and thus what 
the sequence of events is that causes BAT dysfunction on the long-term is unknown. In 
Chapter 5 we aimed to determine how rapid BAT dysfunction occurs upon high-fat diet 
feeding and what the related mechanisms are. The ECS is seen as a potential therapeutic 
18
target since its tone is elevated in obesity. However, more insight is needed in how fast 
and in which organs the dysregulation of the ECS sets off, in order to be able to develop 
novel and more specific therapeutics. In Chapter 6 we investigated the circulating en-
docannabinoid levels and the gene expression of enzymes involved in endocannabinoid 
synthesis and degradation in several metabolic tissues of mice that were fed a high-fat 
diet ranging from one day up to 18 weeks. 
Although the pathophysiology of dyslipidemia in obesity is multifactorial, the hallmark 
of dyslipidemia in obesity is elevated plasma triglyceride levels [53]. Quercetin has been 
shown to reduce plasma triglyceride levels in mice and humans, whereas the mecha-
nism remained elusive. To meet our last key objective, we investigated the underlying 
mechanism for the quercetin-induced lowering of plasma triglycerides in Chapter 7. 
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ABSTRACT
Activation of brown adipose tissue (BAT) contributes to total body energy expenditure 
through energy dissipation as heat. Activated BAT increases the clearance of lipids 
and glucose from the circulation, but how BAT accommodates large influx of multiple 
substrates is not well defined. The purpose of this work was to assess the metabolic 
fluxes in brown adipocytes during β3-adrenergic receptor (β3-AR) activation.T37i mu-
rine preadipocytes were differentiated into brown adipocytes and we used Seahorse 
respirometry employing a set of specific substrate inhibitors in the presence or absence 
of β3-AR agonist CL316,243. The main substrate used by these brown adipocytes were 
fatty acids, which were oxidized equally during activation as well as during resting 
condition. [U-13C]-glucose tracer-based metabolomics revealed that the flux through 
the TCA cycle was enhanced and regulated by pyruvate dehydrogenase (PDH) activity. 
Based on 13C-tracer incorporation in lipids, it appeared that most glucose was oxidized 
via TCA cycle activity, while some was utilized for glycerol-3-phosphate synthesis to 
replenish the triglyceride pool. Collectively, we show that while fatty acids are the main 
substrates for oxidation, glucose is also oxidized to meet the increased energy demand 





One of the major health threats of today’s society is obesity. Obesity develops as a con-
sequence of a long-term positive energy balance and is associated with the onset and 
progression of dyslipidaemia, type 2 diabetes, cardiovascular disease, and certain types 
of cancer [1]. Brown adipose tissue (BAT) in adult humans is involved in non-shivering 
thermogenesis and thereby contributes to whole body energy expenditure [2–5]. The 
functional relevance of BAT activity in adult humans has been underscored in recent 
years as repeated BAT activation through cold exposure reduces body fat [6], and im-
proves insulin sensitivity in lean [7, 8], obese [9] and type 2 diabetic individuals [10]. BAT 
activation is therefore regarded as a novel therapy to treat obesity and related metabolic 
disorders [11]. 
The therapeutic potential of BAT activation originates from its potent metabolic oxida-
tive capacity that is due to a high number of mitochondria that express uncoupling pro-
tein 1 (UCP-1). UCP-1 activity allows BAT mitochondria to uncouple respiration from ATP 
production and generate heat instead [12]. Physiologically, this thermogenic function 
is induced by cold exposure which results in enhanced sympathetic outflow towards 
brown adipocytes and binding of noradrenaline to the β3-adrenergic receptor (β3-AR) 
on brown adipocytes. BAT activation induces the release of internally stored substrate 
pools as well as the uptake of vast amounts of circulating glucose and lipids [13–17]. 
Despite the large influx of glucose in activated brown adipocytes, fatty acids are sug-
gested to be the preferred substrates during thermogenesis [12], in line with high fatty 
acid oxidation upon BAT activation in mice [16] and in humans [18]. These fatty acids are 
released by lipolysis but also originate from the uptake of circulating lipids. Interestingly, 
inhibition of lipolysis reduces the uptake of glucose and lipids significantly and results in 
a dampened thermogenic response [15, 17]. It has therefore been suggested that sub-
strate uptake is high in activated brown adipocytes to replenish the intracellular lipid 
pool [17, 19]. This metabolic effect in BAT has primarily been studied through PET-CT 
tracer studies and gene expression arrays, which counterintuitively showed concomitant 
increased expression of glycolysis, β-oxidation, glycogen and fatty acid synthesis gene 
[13, 17, 20–22]. This implies that substrate utilization in BAT is regulated in a different 
way as compared to that of liver and muscle, which typically follow the principles of the 
Randle or glucose-fatty acid cycle. These principles are based on the idea that substrates 
compete for their oxidation due to inhibitory effects of intermediate metabolites [23]. 
For example, during fatty acid oxidation the levels of acetyl-CoA increase. The rise of this 
intermediary metabolite has an inhibitory effect on enzymes involved in glucose oxida-
tion. The BAT-specific regulation allowing simultaneous uptake, storage and oxidation of 
glucose and fatty acids is poorly understood. 
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In this study, we used the T37i murine brown adipocyte cell line to determine meta-
bolic fluxes of the most common substrates glucose, fatty acids and glutamine during 
short-term β3-AR activation. We used a set of specific inhibitors to selectively inhibit 
either the uptake or oxidation of substrates and determined the contribution of these 
substrates to cellular oxygen consumption using Seahorse respirometry. Furthermore, 
we applied 13C-stable isotope tracer-based metabolomics to examine the detailed meta-
bolic wiring in these brown adipocytes. We found that pyruvate dehydrogenase plays 
a central role in directing glucose to oxidative metabolism during acute activation in 
brown adipocytes, while glucose is also utilized to replenish the intracellular triglyceride 
pool after long-term stimulation.
mATERiALS AND mETHODS
Cell culture of T37i brown adipocytes and Oil-Red-O staining
T37i cells were cultured and differentiated as described previously [24, 25]. In brief, 
cells were kept in maintenance culture in DMEM/F12 Glutamax supplement (Life 
technologies) containing 10% FBS (BioWhittaker), 100 IU/mL penicillin and 10mg/mL 
streptomycin (Life technologies) until passage 37. For differentiation, cells were kept at 
complete confluency and after two days 2 nM triiodothyronine (Sigma-Aldrich) and 2 
µM insulin (Sigma-Aldrich) was added to the medium for 9 days. During differentiation, 
medium was replaced every two days and cells were used for experiments between 
differentiation day 10-12. Oil-Red-O (Sigma-Aldrich) staining was performed to evalu-
ate lipid droplet accumulation. In short, cells were washed with PBS and fixed in 10% 
(v/v) formalin for 1 h, rinsed in 60% (v/v) isopropanol for 5 min, and stained with filtered 
60% Oil-Red-O solution for 15 min. Excess of Oil Red O was removed and cells were 
maintained in demineralized water during imaging. 
gene expression and protein content in T37i cells
Total RNA was isolated with TRIreagent (Sigma-Aldrich) according to the manufacturer’s 
instructions including addition of DNase treatment (Promega). cDNA synthesis was 
performed with 1 µg RNA using the QuantiTect Reverse Transcription Kit (QIAGEN). 
LightCycler 480 SYBR Green I Master (Roche) was used for qPCR analysis, primers are 
listed in Table 1. Data were analyzed with Light Cycler 480 software release 1.5 and 
LinRegPCR version 2015.3, as previously described [26].
For protein extraction, T37i cells were lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 
150 mM NaCl, 0.1% (w/v) sodium dodecyl sulfate, 0.5% (w/v) sodium deoxycholate, 1% 
(v/v) Triton X-100) with addition of Complete mini protease inhibitor cocktail (Roche) 
and Phosphatase Inhibitor Cocktail 2 and 3 (Sigma-Aldrich). Samples were lysed by tip 
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sonication and protein concentration was measured using the BCA protein assay kit 
(Pierce). For immunoblot analysis, lysates were diluted in NuPAGE LDS Sample Buffer 
and Sample Reducing Agent (Life Technologies) and heated to 70°C. Protein extracts 
were separated on pre-cast NuPAGE 4-12% gradient Bis-Tris gels (Life Technologies), 
and transferred to a nitrocellulose membrane. Membranes were blocked with 3% BSA 
(in PBS containing 0.1% (v/v) Tween-20), and incubated overnight at 4°C with the fol-
lowing primary antibodies: total PDHE1α (#ab67592, Abcam), phospho-Ser232 PDHE1α 
(#AP1063, Calbiochem) and HSP60 (#4870, Cell Signaling). The immunoreactive bands 
were detected with HRP-linked secondary antibodies (Goat anti-rabbit, Goat anti-mouse, 
DAKO) and ECL prime western blotting detection reagent (Amersham) and imaged with 
the ImageQuant LAS4000 (GE Healthcare). Quantification of bands was performed using 
Bio-Rad Quantity one 4.6.6 software.
Oxygen consumption
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) was mea-
sured using the Seahorse XF96 analyzer (Seahorse Bioscience). T37i cells were plated at 
differentiation day 9 in 96-well Seahorse plates at a density of 60,000 cells per well and 
incubated overnight under normal cell culture conditions. The following day, medium 
was replaced by DMEM (Sigma, D5030) containing 17.5 mM glucose (Sigma-Aldrich), 1 
mM sodium pyruvate (Lonza), and 2 mM L-Glutamine (Life technologies). Basal respira-
tion was measured three times followed by six measurements after addition of 10 µM 
β3-AR agonist CL316,243 (Tocris) to induce brown adipocyte activation. ATP-coupled 
respiration and the maximal respiration were determined by the addition of 1.5 µM 
oligomycin and 1.5 µM FCCP (Sigma-Aldrich), respectively. OCR was corrected for non-
mitochondrial respiration determined by simultaneous addition of 2.5 µM antimycin A 
and 1.25 µM rotenone (Sigma-Aldrich).
Glycolytic function was determined in DMEM medium (Sigma, D5030) containing 
2 mM L-Glutamine (Life technologies) according to Seahorse XF Glycolysis stress test 
manufacturer instructions. In brief, basal ECAR was measured three times followed by six 
Table 1. Primer sequences of forward and reverse primers for qPCR
gene Accession Forward primer Reverse primer
Actb NM_007393 AACCGTGAAAAGATGACCCAGAT CACAGCCTGGATGGCTACGTA
Cidea NM_007702 ATCACAACTGGCCTGGTTACG TACTACCCGGTGTCCATTTCT
Dio2 NM_010050 GGCCGTCGGTCCTTCCTT TCCCAGCTGTGTACATGCCTCAAT
Gapdh NM_008084 GGGGCTGGCATTGCTCTCAA TTGCTCAGTGTCCTTGCTGGGG
Ppia NM_008907 CAAATGCTGGACCAAACACAA GCCATCCAGCCATTCAGTCT
Prdm16 NM_027504 CAGCACGGTGAAGCCATTC GCGTGCATCCGCTTGTG
Ucp1 NM_009463 ACGTCCCCTGCCATTTACTGTCA GGCCGTCGGTCCTTCCTT
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measurements after sequential addition of (a) 10 µM CL316,243 or vehicle (medium), (b) 
10 mM glucose, (c) 1.5 µm oligomycin and (d) 100 mM 2-deoxy-glucose (Sigma-Aldrich). 
Substrate dependency and reserve capacity were determined according the Seahorse 
XF Mito Fuel Flex Test user guide protocol. Briefly, after measuring basal OCR and after ad-
dition of 10 µM CL316,243 or vehicle; 100 µM POCA (sodium 2-[5-(4-chlorophenyl)-pentyl]
oxirane- 2-carboxylate), a CPT1 inhibitor (kind gift from BYK Gulden Pharmazeutica); 3 
µM BPTES (Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide), a glutaminase 
inhibitor (Sigma-Aldrich) and 2 µM UK5099, an inhibitor of the mitochondrial pyruvate 
transporter (Sigma-Aldrich) were subsequently injected and OCR was determined six 
times. Data were analysed using Seahorse XF Mito Fuel Flex test report data analysis.
All ECAR and OCR values were adjusted for cell input using the CyQUANT Cell Prolifera-
tion Assay Kit (Thermo Fischer Scientific) according to the manufacturer’s instruction. 
The final measurement point after each compound addition was always used for quan-
tification. 
Pyruvate oxidation
Pyruvate oxidation was determined by measuring the release of 14CO2 from [1-14C]-pyru-
vate [27]. At differentiation day 9, cells were seeded at a density of 500,000 cells in a glass 
liquid scintillation vial under normal cell culture conditions. The following day, cells were 
washed twice with DPBS prior to a 1 h incubation in Dulbecco’s PBS (Life Technologies) 
supplemented with 500 µM [1-14C]-pyruvate (specific activity: 0.55 mCi/mmol) (Perkin 
Elmer) combined with 10 µM CL316,243 or vehicle (PBS). A centre well containing 2 M 
NaOH was placed to trap CO2. After 1 h of shaking at 37°C, medium was acidified with 
2.6 M perchloric acid to stop the reaction. After 3 h of trapping, the 14CO2 collected in the 
centre well was counted by liquid scintillation. Pyruvate oxidation flux was determined 
by the amount of pyruvate oxidized to CO2 normalized to protein content.
isotopic labelling of polar metabolites
Cells were differentiated in 6-well plates. At differentiation day 10, a time course 
incubation was started in DMEM without glucose, pyruvate, glutamine and phenol 
red (Life technologies) with addition of 17.5 mM [U-13C]-glucose (Cambridge Isotope 
Laboratories)in combination with 10 µM CL316,243 or vehicle (medium). Samples were 
harvested by two-phase methanol-water/chloroform extraction as described [28]. 
Briefly, medium was removed, cells were washed twice with ice-cold 0.9% NaCl, and 
metabolism was quenched by the addition of 1 mL ice-cold methanol-water (1:1, v/v). 
Cells were removed from the well by scraping and collected in a centrifuge tube. One 
mL of chloroform was added to the mixture, followed by tip sonication and centrifu-
gation at 10,000 x g for 10 min. The organic phase of the extraction was collected for 
lipidomic analysis (see below). After collection of the aqueous phase, the organic phase 
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and insoluble pellet were re-extracted with 1 mL methanol-water (1:1, v/v). The aque-
ous phases of both extractions were collected and evaporated. The metabolite residue 
was dissolved in 100 µL 60% (v/v) methanol and analyzed by ultra-high-pressure liquid 
chromatography system (Thermo Scientific) with a SeQuant ZIC-cHILIC column (100 x 
2.1 mm, 3 µm particle size, Merck, Darmstadt, Germany) coupled to a Thermo Q Exactive 
Plus Orbitrap mass spectrometer (Thermo Scientific). The column was kept at 15°C and 
the flow rate was 0.250 mL/min. The mobile phase was composed of (A) 9/1 acetonitrile/
water with 5 mM ammonium acetate; pH 6.8 and (B) 1/9 acetonitrile/water with 5 mM 
ammonium acetate; pH 6.8, respectively. The LC gradient program was: beginning with 
100% (A) hold 0-3 min; ramping 3-20 min to 36% (A); ramping from 20-24 min to 20% (A); 
hold from 24-27 min at 20% (A); ramping from 27-28 min to 100% (A); and re-equilibrate 
from 28-35 min with 100% (A). Data were acquired in full-scan negative ionization mode. 
Data interpretation was performed using the Xcalibur software (Thermo Scientific). 13C 
enrichment was calculated based on mass distribution isotopomer analysis (MIDA), all 
results were corrected for their natural 13C abundance by solving the associated set of 
linear equations for each metabolite using non-negative least squares [29]. 
Non-stationary metabolic flux analysis
Non stationary metabolic flux analysis was based on the algorithm described in [30]. In 
short, the carbon transition model of the TCA cycle (Table 2) was converted into a set of 
linear ordinary differential equations describing the time dynamics of the corresponding 
Elementary Metabolite Units (EMUs) using an in-house pipeline developed in MATLAB 
(The MathWorks, Natick, USA). Subsequently, the flux and metabolite concentrations 
were estimated by minimizing the sum of the squared residuals of the measured MID 
time data with respect to the model prediction using the Levenberg-Marquardt algo-
rithm.
Table 2. Carbon transition model used for non-stationary metabolic flux analysis
Substrate Reaction Product
citrate(abcdef ) ➔ alpha-ketoglutarate(abdef) + CO2(c)
pyruvate(abc) ➔ acetyl-CoA(ab) + CO2(c)
acetyl-CoA(ab) + fumarate_malate(cdef ) ➔ citrate(bacdef )
alpha-ketoglutarate(abcde) ➔ succinate(abcd) + CO2(e)
alpha-ketoglutarate(abcde) ➔ succinate(dcba) + CO2(e)
succinate(abcd) ➔ fumarate_malate(abcd)
fumarate_malate(abcd) ➔ succinate(abcd)
pyruvate(abc) + CO2(d) ➔ fumarate_malate(dabc)
pyruvate(abc) + CO2(d) ➔ fumarate_malate(cbad)
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isotopic labelling of lipids
The aforementioned organic phase was processed according to the lipodomic sample 
preparation work flow described previously [31], with minor modifications. A mixture of 
internal standards for multiple lipid classes was added to 250 μL of the organic phase. 
The internal standard mixture (all lipids from Avanti Polar Lipids) contained the follow-
ing lipid concentrations: 7.5 nmol of phosphatidylserine PS(14:0)2; 3.0 nmol of phospha-
tidylcholine PC(14:0)2 and sphingomyelin SM(d18:1/12:0); 0.75 nmol of diacylglycerol 
DAG(14:0)2, triacylglycerol TAG(14:0)3, cholesteryl ester CE(14:0), phosphatidylinositol 
PI(14:0)2, phosphatidylethanolamine PE(14:0)2, phosphatidic acid PA(14:0)2, Lysophos-
phatidylcholine LPC(14:0); 0.3 nmol of bis(monoacylglycero)phosphate BMP(14:0)2; 
0.15 nmol of cardiolipin CL(14:0)4, phosphatidylglycerol PG(14:0)2, lysophosphatidylg-
lycerol LPG(14:0), lyso-phosphatidylethanolamine LPE(14:0) and lysophosphatidic acid 
LPA(14:0). After addition of internal standard mixture, the organic phase was evaporated 
under nitrogen flow. The lipid extract was dissolved in 100 μL of methanol/chloroform 
(1:1, v/v) and analyzed as described [31]. In brief, samples were injected onto a Li-
Chrospher silica-60 (5 μm) HPLC column (Merck) coupled to a Thermo Q Exactive Plus 
Orbitrap mass spectrometer (Thermo Scientific). Data were acquired in negative and 
positive scan mode and processed using in-house developed metabolomics pipeline 
written in the R programming language. The identified peaks were normalized to the 
intensity of the internal standard for each lipid class. 13C enrichment in selected lipids 
was calculated based on MIDA, all results were corrected for their natural 13C abundance 
by solving the associated set of linear equations for each metabolite using non-negative 
least squares [29].
Statistical analysis
Groups were compared using a two-tailed Student’s t-test or one-way ANOVA with post 
hoc Bonferroni correction using GraphPad Prism (GraphPad Software v5.0). P<0.05 was 
considered statistically significant. Data are displayed as mean ± SD or SEM, as indicated 
in the figure legends.
RESuLTS
T37i brown preadipocytes adapt to a BAT bioenergetic profile during 
differentiation
To characterize substrate utilization in brown adipocytes upon acute β3-adrenergic 
activation, we utilized the T37i brown preadipocyte cell line [24, 25]. Prior to differentia-
tion these cells have a fibroblast-like phenotype (Fig. 1A). T37i cells differentiated into 
brown adipocytes after at least nine days of exposure to insulin and triiodothyronine 
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(T3). Successful diff erentiation was characterized by multilocular lipid droplets and in-
duction of the thermogenic gene program (Fig. 1B-C), confi rming the brown adipocyte 
phenotype. 
Inducibility of the β3-adrenergic response serves as ultimate evidence of diff erentia-
tion into mature brown adipocyte. To determine this, we used Seahorse respirometry to 
measure oxygen consumption rate (OCR) in the presence of vehicle or the β3-AR agonist 
CL316,243. First, we determined the mitochondrial bioenergetic profi le by recording res-
Figure 1. T37i bioenergetic profi le during diff erentiation and β3-AR stimulation. (A-B) Oil-Red-O 
stained phase contrast images of undiff erentiated (A) and diff erentiated (B) T37i cells. (C) Induction of 
mRNA expression of brown adipocyte genes after diff erentiation at day 9 relative to expression at day 0. 
(D) Oxygen consumption rate (OCR) of diff erentiated cells and (E) quantifi cation of basal respiration, ATP-
coupled and leak respiration after successive addition of 1.5 µM oligomycin, maximum respiration induced 
by 2 µM FCCP, corrected for non-mitochondrial respiration calculated after addition of 1.25 µM rotenone 
and 2.5 µM antimycin A. (F) OCR after CL316,243 and oligomycin addition and (G) quantifi cation of basal, 
ATP coupled and CL-uncoupled respiration. Data is presented as average of three experiments ± SEM.
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piration under basal, ATP coupled, oligomycin-inhibited (leak) and maximal (uncoupled) 
conditions (Fig. 1D). Without β3-AR stimulation, the ATP-coupled and leak respiration 
represented 66% and 34% of the basal respiration rate, respectively. The chemical 
uncoupler FCCP induced maximal respiration to 334% of basal respiration (Fig. 1E). 
CL316,243 also induced uncoupled respiration but the response was less pronounced 
and acute compared to FCCP (Fig. 1F). CL316,243 reduced the ATP coupled respiration 
to 20% of basal OCR (Fig. 1g). These data confirm that T37i is a bona fide BAT model that 
displays a high mitochondrial activity and a robust β3-AR response [32].
β3-AR activation improves metabolic flexibility in brown adipocytes
Substrate availability and utilization dictate the mitochondrial respiratory capacity. Our 
first approach to determine substrate utilization under basal conditions and upon β3-AR 
activation was to measure respiration in the presence of glutamine oxidation, fatty acid 
oxidation and glucose oxidation inhibitors. The effect of a single substrate inhibitor on 
respiration determines how much this respiration is dependent on a given substrate—a 
parameter known as substrate dependency. Glutamine dependency was determined by 
the response to BPTES, an inhibitor of glutaminase [33]. Fatty acid oxidation dependency 
was estimated with POCA, a CPT1 inhibitor [34]. Finally, glucose oxidation dependency 
was determined by the sensitivity to UK5099, which is an inhibitor of the mitochondrial 
pyruvate carrier [35]. The substrate dependency was calculated as a percentage of the 
total reduction in OCR when all three inhibitors were administered. 
When comparing these three substrates it was evident that addition of BPTES hardly 
affected the OCR and hence that glutamine oxidation contributes the least to mitochon-
drial respiration (Fig. 2A). The T37i brown adipocytes were most sensitive to inhibition 
of fatty acid oxidation, indicating that they primarily depend on fatty acid oxidation to 
maintain mitochondrial respiration (Fig. 2B). This strong reliance on fatty acid oxida-
tion was not further induced by β3-AR activation. It is worth noting that the substrate 
dependency was not influenced by β3-AR stimulation, i.e. resting and activated cells rely 
predominantly on fatty acid oxidation, although the respiration rates were obviously 
higher after CL316,243 treatment (Fig. 2D).
Next, we treated the differentiated T37i cells with combinations of two of the above-
mentioned inhibitors. The residual respiration after the addition of two inhibitors marks 
the capacity to operate on a single substrate—a parameter known as reserve capac-
ity (Fig. 2E-g). As these brown adipocytes depend most on fatty acid oxidation, this 
pathway also had the largest reserve capacity (Fig. 2H). This highlights that fatty acid 
oxidation could compensate for the loss of glutamine and glucose oxidation in both 
rest and activated state (Fig. 2H). The reserve capacity of glutamine oxidation was and 
that of glucose oxidation was marginal during rest (Fig. 2H, g). However, upon β3-AR 
stimulation the reserve capacity of these substrates, especially of glucose oxidation, 
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was markedly induced (Fig. 2H). Taken together, this suggests that brown adipocytes 
strongly rely on fatty acid oxidation but are metabolically more flexible in their substrate 
utilization upon β3-AR activation.
increased glycolytic flux contributes to uncoupled respiration in activated 
brown adipocytes
Despite the large influx of glucose during activation, glucose has been suggested to 
play a minor role in BAT oxidative capacity [12]. For the T37i cells, glucose was indeed 
the second preferred substrate, although activated cells could increase the oxidation 
of glucose markedly if necessary. To establish whether the reduction of ATP-coupled 
respiration after β3-AR activation (Fig. 1E,g) increases the glycolytic rate, we measured 
the extracellular acidification rate (ECAR) as an indicator of glycolysis. Indeed, addition 
of CL316,243 induced glycolysis maximally, as it could not be further induced by the 
addition of glucose or oligomycin (Fig. 3A-B). We next evaluated whether glycolysis 
contributes to uncoupled respiration by β3-AR stimulation. Uncoupled oxygen con-
sumption without adrenergic activation was measured after addition of oligomycin, 
followed by addition of CL316,243 in combination with glucose or the glycolysis inhibi-
tor 2-deoxy-glucose (2DG) (Fig. 3C). The capacity to induce uncoupled respiration was 

































































































































































































Figure 2. β3-AR activation improves metabolic flexibility in brown adipocytes. Representative OCR 
trace showing substrate dependence for maintaining respiration based on individual inhibitor addition 
strategies. Substrate oxidation dependence was determined for (A) glutamine with BPTES, (B) fatty acids 
with POCA and (C) glucose with UK5099. (D) Quantification of substrate dependence highlights that both 
resting and activated T37i adipocytes predominantly rely on fatty acid utilization to sustain OCR. Represen-
tative OCR trace showing (E) glutamine, (F) fatty acid and (G) glucose reserve capacity for maintenance of 
respiration after simultaneous addition of two inhibitors. (H) Quantification of substrate reserve capacity in 
resting and activated T37i cells. Glutamine and glucose oxidation reserved capacity is induced in CL316,243 
stimulated cells. Line graphs show mean ± SD of 6 wells of one representative experiment. Data in bar 
graphs are presented as mean ± SEM of four experiments; *P<0.05 (unpaired Student’s t-test).
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blunted when glycolysis was inhibited (Fig. 3D), supporting the notion that glucose 
utilization contributes to β3-AR induced uncoupled respiration in brown adipocytes. 
The glucose carbon fl ux into the TCA cycle is stimulated in β3-AR activated 
brown adipocytes
Fatty acids are an important carbon source of T37i cells, but upon β3-AR stimulation glu-
cose uptake and glycolysis are greatly induced. Inhibition of glycolysis aff ects uncoupled 
respiration indicating that glucose is oxidized to contribute to uncoupled respiration 
(Fig. 3C-D). Gene expression studies show that short- and long-term cold-induced BAT 
activation increases expression of genes involved in glycolysis, the pentose phosphate 
pathway, fatty acid oxidation but also of fatty acid synthesis [20–22]. To assess through 
which pathways glucose is preferentially utilized during short-term β3-adrenerigic acti-
Figure 3. increased glycolytic fl ux contributes to uncoupled respiration in activated brown adipo-
cytes. (A) Extracellular acidifi cation rate (ECAR) of vehicle and CL316,243-stimulated cells in response to 10 
mM glucose, 1.5 µM oligomycin and 100 mM 2-deoxy-D-glucose (2DG). (B) ECAR fold change compared to 
basal ECAR shows increased initial glycolytic fl ux but unchanged glycolytic capacity. (C) Oxygen consump-
tion rate (OCR) of cells under basal conditions, after addition of 1.5 µM oligomycin and 10 µM CL316,243 
combined with 10 mM D-glucose (in red) or with 100 mM 2DG (in blue). (D) 2DG signifi cantly reduces 
uncoupled respiration in activated brown adipocytes. Line graphs show a representative experiment with 




vation, we incubated cells with [U-13C]-glucose in the presence of CL316,243 or vehicle. 
We reconstructed metabolic flux distribution by measuring 13C-labeled metabolites 
using untargeted metabolomics after 30 min up to 7 h. First, we focused on labelling in 
glycolysis and pentose phosphate pathway (PPP) intermediates after acute activation. 
The PPP gives rise to NADPH that is required for lipid synthesis and glutathione antioxi-
dant defense system, two processes suggested to be upregulated upon BAT activation 
[20]. Indeed, 13C-labeling in PPP intermediates appeared to be increased after 30 min 
of β3-AR activation (Suppl. Table 1). Possibly, the increased PPP activity in activated 
brown adipocytes caused the observed decrease in labelling in glycolytic intermediates 
(Suppl. Table 1). However, after ≥ 2 h, labeling of glycolytic and PPP intermediates were 
equal in vehicle and CL316,243 treated cells (Suppl. Table 1). Interestingly, despite the 
initial reduced label incorporation in pyruvate, TCA cycle intermediates were rapidly 
labelled following [U-13C]-glucose incubation. The rate of label incorporation in TCA 
cycle intermediates was greatly enhanced from 30 min up to 7 h after β3-AR stimulation 
(Fig. 4A). To estimate the flux through the TCA cycle we performed non-stationary flux 
analysis on the 13C label incorporation mass isotopomer distribution (MID) time patterns 
(Fig. 4B-C). Metabolic flux analysis showed that the overall TCA activity was increased 
upon β3-AR activation. Pyruvate entered the TCA cycle via pyruvate dehydrogenase 
(PDH) and pyruvate carboxylase (PC) activity which were both increased upon β3-AR 
activation (Fig. 4D-E). It appears that the overall flux of glucose metabolism is increased 
after β3-AR activation.
Short-term β3-adrenergic activation stimulates pyruvate dehydrogenase 
activity without stimulating de novo lipogenesis
It has been suggested that glucose enters the TCA cycle merely to be exported to the 
cytoplasm as citrate to act as a building block for de novo lipogenesis [19]. Glucose oxida-
tion is tightly regulated at the level of PDH, and increased PDH activity is associated with 
de novo lipogenesis [36, 37]. Metabolic flux analysis estimated a 2.5-fold increase in PDH 
flux (Fig. 4D-E). To estimate this flux through PDH from our flux distribution measure-
ments, we measured the ratio of 13C-labeled citrate to 13C-labeled phosphoenolpyruvate 
(PEP). This ratio was markedly increased in the CL316,243-activated cells which is indeed 
indicative of increased PDH flux. This allows carbons to enter the TCA cycle more rapidly 
in the activated state (Fig. 4A). The activity of PDH is regulated by phosphorylation and 
is influenced by many factors including mitochondrial redox status, intracellular ATP, 
pyruvate and acetyl-CoA levels [38]. The phosphorylated PDH is inactive, preventing 
pyruvate conversion to acetyl-CoA. Stimulation with CL316,243 resulted in a short-term 
dephosphorylation of PDH which peaked after 15-60 min of stimulation (Fig. 5B). In-
deed, in this time window pyruvate oxidation rate was doubled (Fig. 5C), accounting for 
the strong glucose driven respiration after CL316,243 (Fig. 2C, g-H). Interestingly, 1 h 
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stimulation with CL316,243 increased PDH activity to a similar extent as 1 h stimulation 
with the established PDH activator dichloroacetate (DCA), which activates PDH through 
the inhibition of PDH kinase [39].
Our combined data support the idea that glucose acutely serves as a substrate to 
maintain oxygen consumption through increased PDH activity. At the same time, we 
aimed to establish whether glucose also enters lipogenesis. To do this, we examined 
the labelling pattern of the three most abundant triglycerides (TG)—TG(48:3), TG(50:3) 
and TG(54:3)—after incubation with [U-13C]-glucose using our lipidomics platform 
[31,40]. Glucose can contribute to TG synthesis by (1) producing glycerol-3-phosphate 
via glycolysis and thereby providing the TG backbone [41]; and/or (2) acetyl-CoA gen-
eration required for de novo fatty acid synthesis (Fig. 6A) [19, 42]. We analysed the TG 
species of vehicle or CL316,243-stimulated cells for after 1 and 6 h (Fig. 6B-D). The most 
abundant TGs followed a similar labelling pattern, which was particularly enriched with 












































































































































































Figure 4. increased glucose oxidation through TCA cycle activity after β3-AR activation. (A) Time 
course incubation with [U-13C]-glucose results in increased labelling of tricarboxylic acid (TCA) cycle inter-
mediates at early time points after CL316,243 activation, suggesting increased TCA flux. (B) The measured 
MID data in dotted lines and predicted MID data in solid lines of vehicle-treated cells and (C) CL316,243-
treated cells. (D) Results of non-stationary metabolic flux analysis of cells after vehicle and (E) β3-AR stimu-
lation. The flux values have unit [/hr] and are normalized to the alpha-ketoglutarate/glutamate concentra-



































































A B C D
Figure 5. β3-AR stimulation increases glucose flux through PDH. (A) Increased ratio of 13C-labeled ci-
trate over 13C-labeled phosphoenolpyruvate (PEP) after 30 min CL316,243 activation suggests increased 
flux through pyruvate dehydrogenase (PDH). (B) Western blot showing reduced PDH phosphorylation at 
serine-293, which is indicative for PDH activation. (C) The ratio of the quantified phosphorylated PDH E1-α 
serine-293 over the total PDH E1-α. (D) Upon 1 h CL316,243 stimulation pyruvate oxidation (using [1-14C]-
pyruvate as substrate) is increased to a level that is similar as 1 h stimulation with the established PDH acti-
vator dichloroacetate (DCA). Data in (A) is mean ± SD of duplicate experiments, and (B-C) represent mean ± 












































































































Figure 6. Short-term β3-AR stimulation increases fatty acid re-esterification. (A) Schematic illustration 
of label incorporation scenarios in lipids. Ac-CoA, acetyl-CoA; G6P, glucose-6-phosphate; G3P, glycerol-3-
phosphate; FA-CoA, fatty acyl-CoA; mal-CoA, malonyl-CoA; PDH, pyruvate dehydrogenase. Solid lines and 
dashed lines indicate direct and indirect fluxes. Isotope profile of the three most abundant triglycerides (B) 
TG(48:3), (C) TG(50:3) and (D) TG(54:3) after 0, 1 and 6 hours of CL316,243 or vehicle stimulation. Incorpo-
ration of even carbons (13C[n×2]) is relatively low, while the 13C3 is increased over time suggesting glycerol 
incorporation in TG. CL316,243 induces glycerol incorporation significantly after 1 and especially after 6 
hours. Bars represent mean ± SD of three biological replicates samples; *P<0.05 (one-way ANOVA, Bonfer-
roni corrected). 
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even more pronounced in activated brown adipocytes (Fig. 6B-D). The incorporation 
of 13C2-labeled acetyl-CoA—after malonyl-CoA conversion and incorporation leading to 
13C[n×2]-labelled TG —was relatively minor (Fig. 6B-D). Altogether, our results suggest 
that short-term β3-AR stimulation specifically induces glycolysis and glucose oxidation 
which is mediated by increased PDH activity. While the overall increased TCA cycle activ-
ity sustains increased respiration rates, the increased flux through PDH does not seem 
to induce de novo lipogenesis as glucose-derived acetyl-CoA is sparsely incorporated 
in TGs. Rather the increased glycolytic flux favours glycerol production required for 
esterification of fatty acids.
DiSCuSSiON
Brown adipose tissue activation is classically accompanied by increased uptake of glu-
cose and lipids from the circulation. The induced uptake of glucose and lipids is such a 
key event that it is often used as a proxy for BAT activation [43, 44]. The mechanism un-
derlying simultaneous glucose and lipid uptake and utilization is not fully understood, 
despite being at the core of BAT function and its therapeutic potential. In the present 
study, we investigated substrate utilization by brown adipocytes during short-term β3-
AR activation. We show that brown adipocytes indeed oxidize fatty acids and glucose 
simultaneously. β3-AR activation induced partitioned glucose utilization, i.e. allowing 
coinciding glucose oxidization and glucose utilization for alternative metabolic path-
ways, such as glycerol synthesis. 
It has been suggested that the purpose of the increased influx of glucose is not to 
meet the direct increase in energy demand. Rather, it may be utilized as a building block 
for lipid synthesis to replenish the lipid pool for later usage [20, 44]. Our data indicate 
that glucose is the second preferred substrate, but glucose oxidation is clearly induced 
upon β3-AR activation. In mice, glucose uptake and glycolysis are upregulated during 
BAT activation presumably to compensate for the loss of ATP due to UCP-1-mediated 
uncoupling [45]. During short-term activation, the increased glycolytic rate did not only 
give rise to increased lactate levels (Fig. 3C), but also a considerable amount of glucose 
was oxidized into CO2 and thereby contributed to uncoupled respiration (Fig. 5D). It has 
been recently shown that UCP-1 KO mice have diminished uncoupled respiration after 
β3-AR activation but glucose uptake and glycolysis were stimulated to similar extent as 
in the WT [46, 47]. It is therefore likely that next to glucose oxidation, β3-AR stimulation 
also induces glucose metabolism to partly channel glucose to alternative pathways. 
Proposed alternative pathways are the pentose phosphate pathway, glycerol synthesis 
and de novo fatty acid synthesis [20–22]. We observed only a transient increase in PPP 
activity and therefore focused on TGs and fatty acid synthesis. 
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β-adrenergic signalling induces lipolysis via hormone sensitive lipase and adipose 
triglyceride lipase [48]. Genetic and pharmacological inhibition of lipolysis hampers 
UCP-1-mediated uncoupling [49], and thereby promotes cold intolerance in mice [17, 
50, 51] and humans [13]. With this in mind, it was postulated that fatty acids derived 
from intracellular lipid droplets are the main fuel source for brown adipocytes that 
must be continuously replenished. Our lipidomics analysis shows that incubation 
with [U-13C]-glucose predominantly gives rise to 13C3-labeled TGs. This is supportive of 
glucose conversion into glycerol which is subsequently used for TG synthesis [41]. This 
is in contrast to previous suggestions that glucose is primarily ending up in complex 
lipids through de novo fatty acid synthesis [19]. Such de novo lipogenesis would require 
glucose conversion to acetyl-CoA, after which these two-carbon units are utilized as the 
building blocks to elongate fatty acid chains. If such a scenario were true, we would have 
found TGs with two, four, six or more even 13C-labeled TGs (Fig. 6A). This is not the case 
suggesting that glucose is primarily entering the TG pool via glycerol, even though it is 
still possible that differences in growth phase, glucose concentration, intracellular lipid 
content, or specific cellular context affects the metabolic phenotype in BAT [52, 53]. 
Very recently, the principle that lipolysis is required for BAT activation has been chal-
lenged [54, 55]. The loss of thermoregulation upon whole body or adipose-specific loss 
of lipolysis underlines the importance of fatty acids as a substrate for thermogenesis [15, 
17, 50, 51]. However, by selectively inhibiting BAT lipolysis only, it was shown that BAT 
can be very flexible in its substrate utilization leading to increased uptake of circulat-
ing substrates. The increased uptake of exogenous substrates was especially induced 
during cold exposure or specific β3-AR stimulation [54, 55]. We have seen this plasticity 
of brown adipocyte metabolism as well. When using a combination of inhibitors that 
prevent glucose and fatty acid oxidation, we found an increase in glutamine oxidation. 
Similarly, when glutamine and fatty acid oxidation were inhibited, glucose oxidation 
was elevated. This flexibility in substrate utilization was induced after β3-AR activation. 
The loss of fatty acid oxidation and the rise of intracellular fatty acids can activate peroxi-
some proliferator activated receptor (PPAR) signaling [56], and thereby contribute to 
metabolic plasticity to meet the increase energy demands during BAT activation. 
Glucose metabolism is regulated at multiple levels. Pyruvate is a key metabolite in glu-
cose metabolism as it lies at the crossroads of glycolysis and TCA cycle activity. Pyruvate is 
an important substrate to maintain the high respiration rates during uncoupled respira-
tion. Inhibition of pyruvate entrance into mitochondria has previously shown to attenu-
ate noradrenaline-induced uncoupled respiration [57]. Likewise, inhibition of glycolysis 
and thus the reduction of pyruvate levels attenuated uncoupled respiration after β3-AR 
stimulation (Fig. 3A). Pyruvate supports TCA cycle activity through decarboxylation by 
PDH or carboxylation by PC [58]. Our metabolic flux analysis estimated an increase in flux 
through both enzymes. PDH is considered as a gatekeeper for glucose utilization and 
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energy metabolism [58, 59]. PDH senses intermediate metabolites —such as pyruvate 
and acetyl-CoA— and the NAD+/NADH redox state to control glucose metabolism and 
maintain optimal energy homeostasis [38]. In proliferating cells, genetic deletion of PDH 
could be compensated by increased uptake of lipids and increased glutamine utilization 
that is alternatively metabolized to contribute to lipid synthesis [59]. This underlines the 
plasticity of cellular metabolism as well as the contribution of PDH in this process. We 
observed an induction of PDH activity upon β3-AR stimulation resulting in increased 
pyruvate oxidation which was similar to the maximal level reached by stimulation with 
PDH agonist DCA. Activating PDH may therefore favor BAT metabolism to allow optimal 
thermogenesis. 
Collectively, our data demonstrate that glycolysis and glucose oxidation contribute to 
uncoupled respiration, despite that fatty acids are the main fuel for brown adipocytes. 
Glucose metabolism appeared to be heavily regulated upon β3-AR stimulation. We 
identified PDH as a gatekeeper for glucose utilization that directs most glucose towards 
oxidation to maintain uncoupled respiration. The accompanying increase of PC activity 
to convert pyruvate to oxaloacetate replenishes the TCA cycle during this high PDH 
activity. Oxaloacetate could also act as a precursor for glyceroneogenesis, which is the 
formation of glycerol-3-phosphate via phosphoenolpyruvate carboxykinase activity [41, 
60], and thereby allow part of the glucose to be directed to glycerol synthesis and stor-
age of free fatty acids as TGs in lipid droplets as substrates for future use. Pharmacologi-
cal targeting of the PDH holds potential as a novel strategy to potentiate BAT function.
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Supplementary table 1. Fractional contribution of 13C- glucose corrected for natural abundance in pen-
tose phosphate pathway (PPP) and glycolytic intermediates upon vehicle or CL316,243 time course stimu-
lation
metabolite
0.5 h 1 h 2 h 4 h 7 h
veh CL veh CL veh CL veh CL veh CL
PP
P
R5P 0.118 0.049 0.135 0.057 0.173 0.140 0.273 0.277 0.481 0.430
ER-4P 0.800 0.765 0.756 0.930 0.917 0.956 0.947 1.000 0.996 0.977







G6P 0.825 0.682 0.775 0.767 0.881 0.801 0.881 0.903 0.915 0.894
G3P/DHAP 0.746 0.624 0.716 0.643 0.818 0.841 0.884 0.815 0.976 0.916
BPG 0.755 0.532 0.681 0.671 0.868 0.789 0.911 0.940 0.986 0.949
PG 0.751 0.507 0.686 0.635 0.872 0.777 0.872 0.940 0.966 0.945
PEP 0.721 0.528 0.669 0.638 0.847 0.768 0.893 0.930 0.942 0.947
Pyruvate 0.771 0.694 0.742 0.762 0.859 0.830 0.891 0.900 0.916 0.916
Lactate 0.776 0.740 0.775 0.795 0.856 0.840 0.868 0.886 0.911 0.902
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Supplementary table 2 related to figure 4. Fractional distribution of isotopologues corrected for natural 
abundance used to determine metabolite labeling as shown in Figure 4A
Fractional distribution
0.5 h 1 h 2 h 4 h 7 h
metabolite veh CL veh CL veh CL veh CL veh CL
Citrate 13C0 0.579 0.451 0.573 0.382 0.454 0.305 0.378 0.256 0.303 0.199
Citrate 13C1 0.003 0.015 0.011 0.033 0.019 0.032 0.020 0.033 0.020 0.032
Citrate 13C2 0.126 0.191 0.098 0.184 0.159 0.186 0.151 0.176 0.131 0.178
Citrate 13C3 0.096 0.138 0.094 0.157 0.113 0.158 0.141 0.167 0.123 0.167
Citrate 13C4 0.060 0.083 0.067 0.093 0.083 0.119 0.101 0.125 0.125 0.150
Citrate 13C5 0.116 0.102 0.120 0.122 0.146 0.155 0.173 0.189 0.230 0.209
Citrate 13C6 0.019 0.021 0.037 0.030 0.026 0.044 0.034 0.054 0.068 0.065
α-Ketoglutarate 13C0 0.780 0.659 0.718 0.571 0.550 0.439 0.411 0.338 0.278 0.264
α-Ketoglutarate 13C1 0.013 0.032 0.023 0.050 0.046 0.063 0.061 0.069 0.056 0.061
α-Ketoglutarate 13C2 0.132 0.175 0.166 0.202 0.235 0.236 0.273 0.253 0.278 0.254
α-Ketoglutarate 13C3 0.044 0.070 0.055 0.092 0.093 0.114 0.122 0.138 0.146 0.147
α-Ketoglutarate 13C4 0.020 0.041 0.026 0.055 0.050 0.093 0.086 0.127 0.153 0.171
α-Ketoglutarate 13C5 0.011 0.023 0.013 0.031 0.026 0.054 0.047 0.076 0.088 0.104
Succinate 13C0 0.755 0.632 0.697 0.547 0.554 0.448 0.587 0.398 0.367 0.361
Succinate 13C1 0.015 0.048 0.026 0.068 0.051 0.077 0.047 0.076 0.060 0.067
Succinate 13C2 0.145 0.203 0.184 0.240 0.247 0.265 0.210 0.275 0.286 0.266
Succinate 13C3 0.050 0.056 0.048 0.062 0.076 0.079 0.076 0.091 0.116 0.117
Succinate 13C4 0.035 0.061 0.044 0.083 0.073 0.130 0.080 0.160 0.171 0.190
Fumarate 13C0 0.590 0.500 0.557 0.410 0.440 0.333 0.360 0.279 0.256 0.268
Fumarate 13C1 0.022 0.054 0.030 0.067 0.043 0.069 0.052 0.069 0.056 0.065
Fumarate 13C2 0.110 0.160 0.113 0.184 0.149 0.197 0.172 0.198 0.205 0.200
Fumarate 13C3 0.242 0.226 0.260 0.258 0.313 0.286 0.357 0.323 0.365 0.340
Fumarate 13C4 0.035 0.060 0.040 0.081 0.055 0.115 0.059 0.132 0.118 0.127
Malate 13C0 0.625 0.510 0.573 0.419 0.480 0.365 0.401 0.316 0.267 0.284
Malate 13C1 0.047 0.110 0.066 0.119 0.077 0.111 0.090 0.098 0.092 0.084
Malate 13C2 0.087 0.128 0.092 0.153 0.125 0.165 0.147 0.172 0.203 0.176
Malate 13C3 0.211 0.200 0.235 0.237 0.272 0.261 0.311 0.299 0.337 0.348
Malate 13C4 0.030 0.053 0.034 0.072 0.046 0.098 0.051 0.115 0.101 0.108
Glutamate 13C0 0.784 0.666 0.722 0.579 0.556 0.451 0.419 0.347 0.287 0.272
Glutamate 13C1 0.013 0.031 0.024 0.049 0.047 0.063 0.062 0.070 0.057 0.062
Glutamate 13C2 0.129 0.171 0.163 0.201 0.232 0.233 0.269 0.251 0.276 0.254
Glutamate 13C3 0.044 0.069 0.053 0.089 0.091 0.111 0.120 0.135 0.145 0.145
Glutamate 13C4 0.020 0.040 0.025 0.052 0.049 0.090 0.085 0.123 0.149 0.166
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Brown adipose tissue (BAT) is a potential target to treat cardiometabolic disorders 
because of its capacity to take up and combust glucose and fatty acids for thermoregu-
lation. Its cellular and molecular investigation in humans is hampered by the limited 
availability of cell material and the heterogeneity of BAT between and within individu-
als. In this study, monoclonal lines of conditionally immortalized brown preadipocytes 
(iBPAs) of both mouse and human origin were generated. Conditional immortalization 
was achieved by doxycycline-controlled expression of simian virus 40 large T antigen 
with a Tet-On system. In the presence of doxycycline, both the murine and human cell 
lines showed long-term proliferation capacity with a cell doubling time of approx. 24 h. 
Shutdown of large T expression by removal of doxycycline and concomitant exposure to 
an adipogenic differentiation cocktail, resulted in the acquirement of brown adipocyte 
properties in cells of both species. This was evidenced by the accumulation of multilocu-
lar lipid droplets, the upregulation of brown adipocyte markers including uncoupling 
protein 1 and the induction of lipolysis and oxygen consumption following adrenergic 
stimulation. Notably, shutdown of large T expression prior to the onset of differentiation 
appeared to be only critical to induce adipogenesis in the human iBPAs, while their mu-
rine counterparts showed adipogenesis upon exposure to the adipogenic differential 
cocktail regardless of large T expression. We suggest that conditionally iBPAs represent 




Activation of brown adipose tissue (BAT) represents a therapeutic tool to reduce 
cardiometabolic disease by enhancing energy expenditure with increased clearance 
of circulating glucose and lipids [1-3]. Cold is the physiological activator of BAT, upon 
which the sympathetic nerves that innervate BAT release noradrenaline (NA) that binds 
to β-adrenergic receptors on the cell membrane of brown adipocytes [4]. This promotes 
intracellular lipolysis leading to liberated fatty acids being directed towards the mito-
chondria for oxidation. This process produces heat in the presence of uncoupling protein 
1 (UCP-1), which is uniquely expressed by brown/beige adipocytes [5-10]. In order to re-
plenish the intracellular lipid pools, BAT takes up large amounts of triglyceride-derived 
fatty acids and glucose from the circulation.
In recent years many (pharmacological) approaches have been identified to promote 
BAT activity, at least in rodents. The development of fundamental and applied research 
into human BAT is hampered by the lack of high-throughput brown adipocyte cell 
culture models. The use of (primary) brown (pre-)adipocytes, obtained from biopsies, 
has important constraints: the amount of available cells is limited and there is a large 
heterogeneity of human BAT not only between subjects but also within one subject 
depending on the anatomical location from where the biopsy is taken [11]. Moreover, 
mature adipocytes are post-mitotic and lipid-laden causing them to be very fragile and 
of low buoyant density. As a consequence, it is challenging to bring mature adipocytes 
into culture because they float and require ceiling culturing to adhere [12]. Therefore, 
the formation of sufficient brown adipocytes for experiments requires proliferation and 
differentiation of adipocyte precursors.
To overcome these problems, a number of different mouse brown preadipocyte (BPA) 
lines have been generated such as HB2 [13], HIB 1B [14, 15] and T37i [16]. HB2 cells are 
brown preadipocytes isolated from the interscapular BAT of p53 knockout mice, while 
HIB 1B and T37i cells were derived from transgenic mice expressing the simian virus 40 
(SV40) large T (LT) antigen using constitutively active, lineage-restricted promoters to 
drive transgene expression. These cell lines have been helpful in increasing our under-
standing of adipocyte biology. However, the absence of the cellular gatekeeper protein 
p53 or the constitutive expression of oncoproteins limits their usefulness as model 
systems to study the properties of BAT. In addition, in order to study human brown 
adipocyte function, Shinoda et al. [17] and Xue et al. [18] generated human BPA lines 
by transducing the stromal vascular fraction of human supraclavicular adipose tissues 
with retroviral vectors encoding SV40 LT antigen and hTERT (i.e. the catalytic subunit of 
telomerase), respectively. Following adipogenic differentiation, these cells express UCP1 
and respond to stimulation with noradrenaline and forskolin with an increase in lipolysis 
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and mitochondrial respiration. These human BPA lines have been successfully used to 
identify BAT-specific genes and to investigate their function.
We postulated that generating conditionally immortalized monoclonal BPA (iBPA) 
lines is the next step towards the development of a high-throughput model for human 
brown adipocytes. The reasons for this were as follows: 1) Previous constitutive expres-
sion of oncoproteins such as SV40 LT to immortalize cells may affect the differentia-
tion capacity of brown adipocytes through interactions of LT with pocket proteins (in 
particular the retinoblastoma protein [pRB]) and with the tumor suppressor protein p53 
[19, 20]. 2) Proliferation and differentiation are two opposing processes that generally 
do not occur simultaneously. In other words, continuous proliferation pressure due to 
permanent immortalization may reduce the differentiation capacity of BPAs. 3) The ad-
ipogenic capacity of existing BPA lines has been shown to be rapidly lost with increasing 
passage numbers [13].
These drawbacks prompted us to generate iBPA lines of both mouse and human origin 
by using a lentiviral vector (LV) expressing LT in a doxycycline (dox)-dependent manner 
to control cell proliferation [21, 22]. The resulting monoclonal cell lines were charac-
terized in terms of their dox-dependent LT expression level and proliferation capacity 
and their ability to undergo adipogenic differentiation using multilocular lipid droplet 
formation and expression of BAT marker genes as read-out systems. Finally, the effects of 
adrenergic stimulation on glycerol secretion, Ucp1/UCP1 mRNA expression and oxygen 
consumption rate of adipogenically differentiated iBPAs were studied.
mATERiALS AND mETHODS
Lentiviral vector (Lv) production
LV particles were produced as detailed before [22]. The molecular structure of the shuttle 
plasmids used for LV production are depicted in Suppl. Fig. 1. The construction of these 
plasmids is described in the Suppl. Materials and Methods.
isolation and culture of primary mouse and human BPAs
Mouse tissue was collected in accordance with the Institute’s Guide for the Care and Use 
of Laboratory Animals and had received approval from the Animal Experiments Com-
mittee of the Leiden University Medical Center (LUMC). Prior to the collection of human 
BAT, patients scheduled for surgery in the thyroid region gave written informed consent 
for taking biopsies and the procedure was approved by the Medical Ethical Committee 
of the Oxford Centre for Diabetes and performed in accordance with the principles of 
the revised Declaration of Helsinki.
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Primary mouse BPAs were isolated from pooled interscapular BAT depots of 5 male, 
5-week-old C57Bl/6J mice (Charles River Laboratories International, Wilmington, MA). 
Human primary BPAs were isolated from biopsies obtained from four patients (Suppl. 
Table 1). Biopsies of adipose tissue of brown-red color were obtained from an area close 
to the isthmus region of the thyroid gland. Isolated tissue was minced with a scissor into 
3- to 4-mm pieces, washed once with DMEM/F-12 GlutaMAX (Thermo Fisher Scientific; 
catalogue number: 10565018) and cells were separated by incubation in DMEM/F-12 Glu-
taMAX containing 1 mg/mL collagenase type I (Thermo Fisher Scientific; catalog number: 
17018029) at 37°C for 45 min. The resulting cell suspensions were filtered through a 200-
µm pore-sized nylon filter (Sefar, Lochem, the Netherlands; catalogue number: 03-200/39) 
and the cells were pelleted by low-speed centrifugation. The cell pellets were suspended 
in red blood cell lysis buffer (Thermo Fisher Scientific; catalogue number: 00433357) and 
incubated for 5 min (Thermo Fisher Scientific; catalogue number: 00433357) at room 
temperature with occasional shaking. After pelleting, the cells were suspended in growth 
medium (DMEM/F-12 GlutaMAX supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), 100 U/mL penicillin and 100 µg/mL streptomycin) for in vitro culture. Growth 
medium was replaced the following day and then every other day.
Transduction of primary BPAs and generation of lines of conditionally 
immortalized mouse and human BPAs
The primary mouse BPAs at population doubling (PD) 2 and human BPAs at approxi-
mately PD 6 were transduced with the plasmids LV.iHsEEF1A1.SV40-LT-tsA58.WHVPRE 
and LV.iHsUBC.LT-tsA58.WHVPRE (see Suppl. Materials and Methods), respectively. The 
next day, the inoculum was replaced by growth medium containing 100 ng/mL dox 
(Sigma-Aldrich) to induce LT expression. The cells were subsequently given fresh growth 
medium with dox every other day. After 1 week of culture, the transduced cells were 
trypsinized and plated at a low density of approx. 10-20 cells/cm2 to allow formation 
of single-cell clones. Two to three weeks later, individual cell colonies were picked and 
separately expanded in the presence of dox.
Culture, differentiation and adrenergic stimulation of mouse and human iBPAs
Mouse and human iBPA clones were cultured in growth medium supplemented with 
100 ng/mL dox. Growth medium was replaced every other day and cells were split 1:8 
after reaching approximately 70% confluency. For differentiation of the mouse iBPAs, 
cells were grown confluent in 2% gelatin (Sigma-Aldrich; catalogue number: G9391)-
coated wells and 2 days later exposed to growth medium containing 5.6 nM bovine 
insulin (Sigma-Aldrich; catalogue number: I0305000), 126 µM sodium ascorbate (Sigma-
Aldrich; catalogue number: A-7631), 1 µM of the peroxisome proliferator-activated 
receptor γ (PPARγ) agonist rosiglitazone (Sigma-Aldrich; catalogue number: R2408) and 
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10 mM HEPES (adjusted to pH 7.40 with NaOH). This medium was replaced every other 
day for up to 14 days. For differentiation of the human iBPAs, cells were grown conflu-
ent in 2% gelatin-coated wells. After reaching confluence, the medium was replaced 
by growth medium without dox. Two days later, differentiation was induced by growth 
medium supplemented with 150 nM human insulin (Sigma-Aldrich; catalogue number: 
I9278), 1 μM dexamethasone (Sigma-Aldrich; catalogue number: D2915), 1 μM rosi-
glitazone, 1 nM triiodothyronine (T3, Sigma-Aldrich; catalogue number: T6397), 500 μM 
3-isobutyl-1-methylxanthine (IBMX, Sigma-Aldrich; catalogue number: I7018) and 125 
μM Indomethacin (Sigma-Aldrich; catalogue number: I7378), which was refreshed after 
48 hours and replaced on day 4 by growth medium supplemented with 150 nM insulin, 
1 nM T3, and 1 μM rosiglitazone. The latter medium was replaced every other day up to 
day 16. Exposing the murine and human iBPA clones to these differentiation cocktails 
will be referred to as culturing under adipogenic culture/differentiation conditions.
The various clones were screened for their adipogenic capacity, i.e. their ability to 
develop multilocular lipid droplets and to express the BAT marker gene Ucp1/UCP1. 
Every other day during the differentiation process of the selected mouse and human 
iBPAs, pictures were taken to capture cellular morphology using the ZOE fluorescent cell 
imager (Bio-Rad, Hercules, CA) and cells were collected in Tripure (Roche Life Science, 
Almere, the Netherlands) for RNA isolation and gene expression analysis as described 
below (n=4 cultures per time point and experimental group).
Differentiated iBPAs (at differentiation day 14 and 16 for the mouse and human iBPAs, 
respectively) were stimulated with 1 µM noradrenaline (Sigma-Aldrich; catalogue num-
ber: A7257) or vehicle for 8 hours. Subsequently, supernatant was collected for colo-
rimetric determination of glycerol production (Instruchemie, Delfzijl, the Netherlands) 
and cells were lysed in TriPure. All data was generated using cells that underwent 40-50 
PDs.
Analysis of cell proliferation
To draw growth curves, the primary mouse BPAs and conditionally immortalized murine 
cells were subcultured 1:4 and 1:8 on reaching confluency so that each passage corre-
sponded to 2 and 3 PDs, respectively. To assess their proliferation rate and dependence 
on the activity of SV40 LT antigen, the mouse iBPAs were cultured at low density in 
medium with or without 100 ng/mL dox. At different days after culture initiation, cells 
were collected in medium and counted using an Accuri flow cytometer (BD Biosciences, 
Breda, the Netherlands).
Western blotting
Western blotting was carried out as detailed before [23] with primary mouse monoclonal 
antibodies directed against LT (1:2,000; Santa Cruz Biotechnology, Dallas, TX; catalogue 
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number: sc-147) or glyceraldehyde 3-phosphate dehydrogenase (GAPDH; loading con-
trol; 1:100,000; Merck Millipore, Burlington, MA; catalogue number: MAB374) and goat 
anti-mouse IgG secondary antibodies linked to horseradish peroxidase (1:15,000; Santa 
Cruz Biotechnology). Data was analyzed by Quantity One software (Bio-Rad Laborato-
ries) using the GAPDH signals for normalization purposes.
RNA isolation and reverse transcription-quantitative PCR (RT-qPCR) analysis
Total RNA was isolated using TriPure Isolation reagent according to the manufacturer’s 
protocol. cDNA synthesis was performed using M-MLV reverse transcriptase (Promega 
Benelux, Leiden, the Netherlands; catalogue number: M1705), random primers, dNTPs 
and RNasin ribonuclease inhibitor (all from Promega Benelux) and 1 µg of input RNA. 
Real-time quantitative PCR was carried out on a CFX96 Real-time PCR machine (Bio-Rad 
Laboratories) using GoTaq qPCR master mix (Promega Benelux; catalogue number: 
A6002). mRNA expression of the mouse iBPAs was normalized to that of the ribosomal 
protein-encoding reference gene Rplp0, also known as 36b4. mRNA expression of the 
human iBPAs was normalized to reference gene LRP10. The primer pairs used for mouse 
and human iBPAs are listed in Tables 1 and 2, respectively. The forward and reserve 
primer of each primer pair were located in different exons except for the primers of 
murine Pparg.
Table 2. Nucleotide sequences of primer pairs used for RT-qPCR of human mRNAs








Table 1. Nucleotide sequences of primer pairs used for RT-qPCR of murine mRNAs










Oxygen consumption rate was measured using the Seahorse XF96 analyzer (Agilent 
Technologies, Santa Clara, CA). Mouse and human iBPAs were cultured and differenti-
ated in Seahorse cell culture plates as described in the section ‘Culture, differentiation 
and adrenergic stimulation of mouse and human iBPAs’. One hour prior to the oxygen 
consumption measurement, the differentiation medium was replaced by Seahorse 
XF Base Medium (Agilent; catalogue number: 102353-100) containing 5 mM glucose 
(Sigma-Aldrich; catalogue number: G8769), 0.5 mM sodium pyruvate (Life Technolo-
gies Europe; catalogue number: 11370-070), 1x GlutaMAX (Life technologies Europe; 
catalogue number: 35050061) and 10% FBS (Life Technologies Europe). Basal respira-
tion was measured three times followed by six measurements after addition of 1 μM 
noradrenaline or vehicle.
Oxygen consumption rate values were adjusted for cell input using the CyQUANT Cell 
Proliferation Assay Kit (Thermo Fischer Scientific; catalogue number: C7026) according 
to the manufacturer’s instruction. The last measurement point before compound addi-
tion was used for quantification.
Statistical analysis
Data are represented as means ± standard error of the mean (SEM). Effect of adrenergic 
stimuli on iBPAs was analyzed by Student’s t-test. GraphPad Prism version 6.0 (GraphPad 
Software, La Jolla, CA) was used for all calculations. Differences at P values < 0.05 were 
considered statistically significant.
RESuLTS
generation of conditionally immortalized mouse BPAs
Mouse primary BPAs were isolated from the pooled interscapular BAT depots of 5 mice 
and transduced with an LV conferring dox-dependent expression of the SV40 LT (Suppl. 
Fig.1). Immunocytological staining (Fig. 1A) and western blotting (Fig. 1B) showed LT 
expression in the transduced BPAs but not in primary BPAs following the exposure of 
both cell types to dox. Primary BPAs gradually stopped proliferating after about 18 PDs 
(Fig. 1C), whereas the transduced LT-expressing BPAs kept proliferating for at least 60 
PDs without showing any obvious decrease in their proliferative capacity (Fig. 1C).
Low-density cultures of the LT-expressing murine BPAs were used for isolating 
single-cell clones, which were picked and numbered in order of appearance. From over 
50 rapidly growing cell clones, clone #6 was selected to further study the long-term 
dox-dependent proliferation capacity of iBPAs since it was one of the most adipogenic 
clones (see below). LT expression of clone #6 cells before (day 0) and 2, 4, 6 and 8 days 
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after dox removal was analyzed by immunocytological staining and western blotting. 
Clone #6 displayed dox-inducible LT expression; LT was highly expressed in the presence 
of dox, and LT levels gradually declined in its absence, being no longer detectable 6 
days after dox removal (Fig. 1D, E and F). Consistent with these findings iBPAs showed 
Figure 1. Conditional immortalization of mouse BPAs. (A, B) Confirmation of LT expression in dox-ex-
posed transduced BPAs (18 PDs) by immunocytological staining (A) and western blotting (B). In both cases, 
dox-treated primary BPAs that underwent 18 PDs served as negative controls. Cell nuclei were visualized by 
Hoechst 33342 (blue) and stained for LT (red). (C) Growth curves of primary BPAs and transduced BPAs. Cells 
were cultured in the presence of dox. (D-F) Analysis by immunocytology (D) and western blotting (E, F) of 
LT expression in clone #6 iBPAs before (day 0) and at 2, 4, 6 and 8 days after dox removal. (G) Quantification 
of cell numbers in cultures of clone #6 iBPAs exposed for the indicated days to medium with or without dox. 
BPA, brown preadipocyte; LT, large T; dox, doxycycline; PD, population doubling; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase.
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dox-inducible proliferation capacity as shown by immunostaining for the cellular 
proliferation marker Ki-67, which was no longer detectable 6 days after dox removal 
(Suppl. Fig.2). In the presence of dox, cells proliferated with an average doubling time 
of approx. 24 hours, whereas in the absence of dox, the cell number slightly increased 
up to day 4 and then remained constant (Fig. 1g). The small increase in the number of 
iBPAs during the first 4 days after dox removal is likely due to the slow decline of the 
LT expression level following transgene silencing. Taken together, the expression of LT 
enabled BPAs to continuously proliferate and bypass senescence.
mouse iBPAs possess adipogenic capacity
In order to assess their adipogenic capacity, cells from each clone were cultured in 
growth medium and when these clonal preadipocyte cell lines reached 100% conflu-
ence (day 0), dox was removed from the culture medium at which time point the cells 
were induced to differentiate to brown adipocytes under adipogenic culture conditions 
for 14 days (Fig. 2A). Cells from clones #6 and #7 exhibited the highest differentiation ca-
pacity based on the extent of lipid droplet formation and highest Ucp1 expression level 
(data not shown). To better characterize the adipogenic potential of these two clones, 
microscopic images of cell cultures subjected to adipogenic differentiation conditions 
were taken every two days (Fig. 2B). The cells of both clones gradually accumulated 
small lipid droplets acquiring the multilocular phenotype typical for brown adipocytes 
and after 14 days of adipogenic differentiation > 90% of the cells was lipid-laden (Fig. 
2B). Interestingly, proliferation pressure (i.e. the presence of dox) did not seem to reduce 
the adipogenic potential of mouse iBPAs (Fig. 2B).
Mouse iBPAs were further analyzed by RT-qPCR to assess the expression of brown 
adipocyte markers during adipogenesis without proliferation pressure (i.e. in absence 
of dox). Expression of the unique BAT marker Ucp1 showed a robust induction starting 
at day 4 of adipogenic differentiation for both clones (Fig. 3A). The Ucp1 mRNA level 
peaked at differentiation day 12 for clone #6 and at differentiation day 10 for clone 
#7 (Fig. 3A). The transcriptional coactivators PR domain containing 16 (Prdm16) and 
peroxisome proliferator-activated receptor gamma coactivator 1-α (Ppargc1α), the per-
oxisome proliferator-activated receptor γ (Pparg), fatty acid binding protein 4 (Fabp4) 
and lipoprotein lipase (Lpl) followed similar patterns of expression, i.e. expression of all 
these markers was induced from the start of adipogenic differentiation and, peaked at 
differentiation day 12, except for Lpl that showed bimodal expression (Fig. 3A). Based 
on these data, we conclude that conditionally immortalized murine BPAs possess adipo-




Noradrenaline activates adipogenically differentiated mouse iBPAs
To investigate the response of adipogenically differentiated iBPAs to adrenergic stimula-
tion, the cells were stimulated with the non-selective adrenergic agonist noradrenaline 
[24] upon which glycerol release was quantified and Ucp1 expression was determined. 
As expected, the glycerol concentration in the culture medium was significantly in-
creased after 8 hours of stimulation with noradrenaline (17.6-fold, P<0.001 for clone 
#6; 21.3-fold, P<0.001 for clone #7) pointing to increased intracellular lipolysis (Fig. 
3B). Consistent with the increased lipolysis, Ucp1 expression was significantly increased 
after noradrenaline stimulation in both clones (+3.3-fold, P<0.001 for clone #6; 2.2-fold, 
P<0.05 for clone #7, Fig. 3C). Furthermore, oxygen consumption was measured using 
Seahorse respirometry before and after the addition of noradrenaline. Both clones 
acutely increased their oxygen consumption rate in response to noradrenaline (up to 
Figure 2. Adipogenic capacity of mouse iBPAs. (A) Protocol used to differentiate mouse iBPAs into brown 
adipocytes. (B) Phase-contrast images showing the morphological changes associated with the adipogenic 
differentiation of murine clone #6 and #7 iBPAs in the presence or absence of dox. iBPA, conditionally im-
mortalized brown preadipocyte; PD, population doubling; dox, doxycycline.
62
+67% for clone #6 and +78% for clone #7 from the basal respiration rate, Fig. 3D and E). 
Together, these data demonstrate that the differentiated mouse iBPAs are responsive to 
adrenergic stimulation.
Human iBPAs possess adipogenic capacity only after shutdown of LT 
expression
Human primary BPAs were isolated from a biopsy taken from an area close to the 
isthmus region of the thyroid gland and monoclonal cell lines of human BPAs were 
generated in a similar fashion as for the mouse iBPAs (Suppl. Fig. 1). From patient 1, 
clones #2 and #3 were selected for further characterization as they exhibited the highest 
proliferative capacity, lipid droplet formation and UCP1 expression. They were cultured 
under adipogenic culture conditions in the absence or presence of dox to relieve or 
exert proliferation pressure (Fig. 4A). Consecutive microscopic images taken two days 
apart revealed that cells from both clones gradually accumulated small lipid droplets 
only in the absence of dox (Fig. 4B). After 16 days of differentiation in the absence of dox 
80-90% of the cells were lipid-laden, while cells cultured in the presence of dox did not 
show any signs of lipid droplet formation (Fig. 4B).
Since dox negatively impacted on the formation of lipid droplets by the human iBPAs 
as determined by microscopy, we next analyzed the expression patterns of brown adi-
pocyte markers by RT-qPCR in both clones cultured in both the absence and presence of 
dox (Fig. 4C). The expression of UCP-1 increased starting at day 4 of adipogenic differen-
tiation for both clones cultured without dox (-dox), whereas the UCP1 expression of cells 
cultured in the presence of dox remained constant and low (+dox). UCP1 expression of 
clone #3 peaked at day 14 of adipogenic differentiation and at this time point was more 
than 4 times higher than the UCP1 expression of clone #2. PRDM16 mRNA levels took 
an unexpected course being similar at differentiation day 0 and lower at differentiation 
day 16, with a peak in PRDM16 mRNA levels at differentiation day 8 of clone #3 in the 
absence of dox. When the cells were cultured in the absence of dox, PPARGC1A, FABP4 
and LPL expression robustly increased between differentiation day 4 and 8, after which 
PPARGC1A expression stabilized at a somewhat lower level. FABP4 and LPL expression 
further increased after differentiation day 8, peaking around differentiation day 10-12 
and day 10-14, respectively. When the cells were cultured in the presence of dox, expres-
sion of these three markers did not significantly change/increase during the entire dif-
ferentiation period. Lastly, PPARG expression showed a similar induction during the first 
4 days of adipogenic differentiation under all culture conditions. Subsequently, PPARG 
expression of clone #3 cultured without dox further increased and peaked at differentia-
tion day 8. In contrast, PPARG expression of clone #2 cultured without dox remained fairly 
stable while in both clones cultured in the presence of dox PPARG expression declined 
again. Based on these data, we conclude that conditionally immortalized human BPAs 
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Figure 3. genetic profiles and functional properties of adipogenically differentiated mouse iBPAs. 
(A) RT-qPCR analysis of Ucp1, Prdm16, Ppargc1α, Pparg, Fabp4 and Lpl gene expression in clone #6 and 
#7 mouse iBPAs on the indicated days of adipogenic differentiation normalized to Rplp0 expression. (B-E) 
Effect of adrenergic stimulation on clone #6 and #7 mouse iBPAs. Both clones were stimulated with 1 µM 
noradrenaline for 8 hours, at differentiation day 12, after which glycerol in the culture medium (B) and 
Ucp1 mRNA levels in the cells (C) were measured. Oxygen consumption rate in adipogenically differenti-
ated mouse iBPAs upon injection of vehicle or noradrenaline using Seahorse respirometry (D, E). Data are 
means ± SEM (n=4 in A, B, C, D; n=7-12 in D, E). ** P<0.01; *** P<0.001. iBPA, conditionally immortalized 
brown preadipocyte; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; OCR, oxygen 
consumption rate; veh, vehicle.
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Figure 4. Adipogenic capacity of human iBPAs. (A) Protocol used to differentiate human iBPAs into 
brown adipocytes. (B) Phase-contrast images showing the morphological changes induced by adipogenic 
stimulation of clone #2 and #3 human iBPAs cultured with (+dox) and without (-dox) continuous prolifera-
tion pressure. (C) RT-qPCR analysis of UCP1, PRDM16, PPARGC1A, PPARG, FABP4 and LPL gene expression in 
clone #2 and #3 human iBPAs on the indicated days of culturing under adipogenic culture conditions with 
and without dox. Expression levels were normalized to LRP10 expression. Data are means ± SEM (n=4). iBPA, 
conditionally immortalized brown preadipocyte; dox, doxycycline; RT-qPCR, reverse transcription-quanti-
tative polymerase chain reaction; T3, triiodothyronine; IBMX, 3-isobutyl-1-methylxanthine.
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were able to adapt a multilocular phenotype and a gene expression pattern compatible 
with brown adipocytes only in the absence of dox and that optimal differentiation is 
reached at 14-16 days after initiation of adipogenesis.
Noradrenaline activates adipogenically differentiated human iBPAs
Similar to the mouse iBPAs, we also investigated the response of adipogenically differ-
entiated human iBPAs to adrenergic stimulation. Stimulation of differentiated iBPAs with 
noradrenaline increased the glycerol concentration in the culture medium with +43% 
(P<0.01, Fig. 5A) and +200% (P<0.001, Fig. 5A) over basal values for clone #2 and clone 
#3, respectively. Although UCP1 expression levels were lower in clone #2 compared to 
clone #3, noradrenaline stimulation increased UCP1 expression in both clones (clone #2: 
+292%, P<0.05 and clone #3: +198%, P<0.05, Fig. 5B). Also, oxygen consumption rate 
was increased in both clones in response to noradrenaline stimulation (up to +106% for 
clone #2 and +93% for clone #3 from the basal respiration rate, Fig. 5C-D).
Subsequently, monoclonal cell lines from BAT biopsies of three other adult humans 
were generated by conditional immortalization as described above. One clone was 
selected from each patient based on its differentiation capacity and UCP1 expression 
to investigate their response to adrenergic stimulation. During adipogenic culture 
conditions, clones from all three patients showed an increase in UCP1 expression from 
differentiation day 4 onwards with the clone from patient 4 reaching the higher level of 
UCP1 mRNA (Fig. 5E). Moreover, all three clones also showed increased glycerol release 
(Fig. 5F) and UCP1 expression (Fig. 5g) 8 hours following noradrenaline stimulation. 
Together, these data demonstrate that differentiated human iBPAs derived from differ-
ent patients are responsive to adrenergic stimulation.
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Figure 5. Functional properties of adipogenically differentiated human iBPAs. (A-D) Effect of adrener-
gic stimulation on clone #2 and #3 human iBPAs. Both clones were stimulated with 1 µM noradrenaline for 
8 hours, at differentiation day 16, after which glycerol in the culture medium (A) and UCP1 mRNA levels in 
the cells (B) were measured. Oxygen consumption rate in adipogenically differentiated human iBPAs upon 
injection of vehicle or noradrenaline using Seahorse respirometry (C, D). RT-qPCR analysis of UCP1 expres-
sion (E) during adipogenic differentiation in human iBPA clones derived from 3 additional patients (i.e. 
patients 2-4). Effect of adrenergic stimulation on human iBPA clones from patients 2, 3 and 4 (F, G). These 
clones were stimulated with 1 µM noradrenaline for 8 hours, at differentiation day 16, and glycerol in the 
culture medium (F) and UCP1 mRNA levels in the cells (G) were measured. Data are means ± SEM (n=4 in A, 
B; n=10-12 in C, D; n=3 in E, F, G). * P<0.05; ** P<0.01; *** P<0.001. iBPA, conditionally immortalized brown 





In this study, we used a system enabling the robust and tightly controlled expansion of 
monoclonal populations of mouse and human BPAs by endowing the cells with a dox-
regulated SV40 LT expression. The presence of dox in the culture medium induced LT 
expression and caused rapid iBPA expansion, while removing dox released the prolifera-
tion pressure and prepared the cells for subsequent adipogenic differentiation. Our iBPA 
lines have adipogenic capacity and respond to adrenergic stimulation with an increase 
in lipolytic activity and oxygen consumption.
Permanent immortalization of murine BPAs has been proven to be a useful tool for 
studying brown adipocyte biology and responses to pharmacological treatments [13-
16, 25]. However, these cells generally display a rapid loss of robust adipogenic capacity 
upon repeated cell divisions [13], limiting their applicability in high-throughput assays. 
Also, several important differences have been observed between murine and human 
BAT [26], which may limit the usefulness of immortalized murine BPAs as a model 
system for human brown adipocytes. Hence, the permanent immortalization of human 
BPAs was pursued, which yielded disparate cell lines [17, 18, 27] rather than providing 
standardized and ready-to-use cell clones that could be massively expanded without 
a substantial loss of adipogenic differentiation. In favorable contrast, our mouse and 
human iBPA lines retained full adipogenic capacity for at least 64 PDs, thereby provid-
ing abundant cell sources for high-throughput studies. Another limitation of non-
conditionally immortalized BPAs is the potential influence of permanent expression of 
immortalization genes on the differentiation potential of BPAs or on the phenotype of 
the brown adipocytes derived from the immortalized cells. Conditional immortalized 
mouse BPAs have been generated using the temperature-sensitive LT mutant tsA58 
[28]. However, even at the non-permissive temperature of 39°C, the binding of LT-tsA58 
to p53 is only partially inhibited whereas its ability to repress pRB remains unaltered 
[29]. Lastly, immortalization of cells without clonal selection might result in unstable 
cell lines, since faster proliferating cells will overgrow the slower proliferating cells and 
thereby change the composition of the lines over serial passaging. On the other hand, 
using clonal selection may introduce selection bias since the fastest proliferating clones 
might not automatically give the best differentiating clones. Our monoclonal iBPA lines 
proved easy to culture and exhibited controlled expression of immortalization genes. 
Altogether, these assets provide a clear advantage in the assessment of differentiation 
stage-dependent gene expression profiles over existing models.
Gene expression profiles of mouse and human iBPA during differentiation showed 
several similarities with rising mRNA expression levels of the genes encoding UCP1, 
PPARGC1A, FABP4 and LPL. Interestingly, while in murine iBPAs PRDM16 expression was 
induced during adipogenic differentiation, this was not the case for the human iBPAs. 
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PRDM16 is a known transcriptional coregulator of BAT development and is suggested 
to repress white adipocyte gene expression and to promote the expression of beige/
brown adipocyte genes [30, 31]. Using mouse adipocytes, Ohno et al. [32] have shown 
that PRDM16 is required for PPARγ agonist-induced brown adipogenesis. In line with 
this finding and considering the fact that UCP1 is a target gene of PRDM16, it might 
be expected that the mRNA expression patterns of UCP1 and PRDM16 would follow a 
similar trend. Indeed, others have reported a strong correlation between PRDM16 ex-
pression and UCP1 expression in human brown adipocytes from the perirenal depot 
[33]. Nonetheless, even though our human iBPA do not show a clear adipogenic differ-
entiation-dependent increase in PRDM16 expression, they efficiently differentiate into 
multilocular brown adipocytes that are responsive to adrenergic stimulation. Perhaps, 
PRDM16 activity during the differentiation of our human iBPAs is post-transcriptionally 
regulated. However, since to date most studies on the regulation of BAT formation have 
been performed in mice and given the differences between murine and human BAT, ad-
ditional studies are required to determine the precise role of PRDM16 and other factors 
in human brown adipogenesis.
We found that continuous LT expression, as induced by dox, inhibited the adipogenic 
differentiation of the human BPAs, whereas the presence of dox in the culture medium 
did not inhibit adipogenesis of the mouse BPAs. Previously dox has been shown to 
negatively impact on mitochondrial function [34, 35], which could theoretically impact 
differentiation capacity. However, since the concentration of dox used in our iBPA cul-
tures (i.e. 100 μg/μL) was well below the concentration shown to disturb mammalian 
mitochondrial function [35] and the mouse iBPAs readily differentiated into brown adi-
pocytes at this concentration, it is more likely that another mechanism is underlying the 
discrepancy between mouse and human cells. Since the preadipocytes were isolated 
from young mice versus from middle-aged humans, perhaps the age of the preadipo-
cytes affects the capacity to differentiate under continuous proliferation pressure. More-
over, two different promoters were used to drive LT expression in murine and human 
BPAs and this may have resulted in different expression levels of LT, thereby contributing 
to differences in the adipogenic differentiation potential between dox-exposed murine 
and human iBPAs. The interspecies difference may also be caused by less pronounced ef-
fects of the pRB pathway on human cells compared to mouse adipocytes with respect to 
adipogenesis. Several studies have shown that inactivation of the pRB pathway inhibits 
white adipogenesis but facilitates brown adipogenesis in mice [20, 36, 37], whereas no 
correlation was found between RB1, the gene encoding pRB, and UCP1 gene expression 
in human adipose tissue [38].
To immortalize human BPAs, Shinoda et al. [17] previously used a retrovirus which 
contains a UTR promoter-driven LT gene without intron, while our human iBPAs were 
generated using a lentiviral vector that contains an HsUBC promoter-driven LT gene with 
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intron. Pre-mRNA that contains the intron, via alternative splicing, gives rise to LT, 17kT 
and small tumor antigen (ST) [39, 40]. The lack of the intron results in depletion of small 
tumor antigen [39]. ST contains a cellular protein phosphatase 2A (PP2A) binding region 
which inhibits the pro-apoptotic activity of PP2A, thereby increasing the viability of cells 
[41, 42]. Xue et al. [18] used a comparable transfection method but LT was replaced by 
hTERT. A clear advantage of our cells is the proliferation speed and capacity. The cell 
lines of Xue et al. [18] exhibit slow proliferation speed and very limited PD, while Shinoda 
et al. [17] showed no data on proliferation capacity. We were able to generate murine 
and human cell lines from one clone that retain adipogenic capacity until at least PD 64.
Our iBPA cell lines provide many opportunities for future research. The mouse iBPA 
clone #6 retained full adipogenic capacity for at least 64 PDs, implying that > 1018 brown 
adipocytes could be generated from a single preadipocyte. This provides an abundant 
cell source for fundamental and applied research [43]. The tightly controlled LT expres-
sion/proliferation used in this study provided a safeguard against tumor development 
and creates an opportunity for this iBPAs to become a transplantable cell source. In 
addition, our iBPAs could be used to further explore the recently proposed hypothesis 
that mature brown adipocytes of mice retain proliferative capacity in vivo [44, 45], al-
though the mechanism(s) involved is/are largely unknown. It will hence be of interest to 
investigate what happens when adipogenically differentiated iBPAs are re-exposed to 
dox. If this would cause them to start dividing again, it might (i) provide a good model 
system to gain more insight into the pathways involved in BAT hyperplasia and (ii) allow 
dox-dependent regulation of the size of the BAT compartment in vivo. Besides, a better 
understanding of the species-specific role of LT and pRB in adipogenesis will help to 
further understand the mechanisms of brown adipogenesis as well as the conversion of 
white into brown adipocytes and vice versa. iBPAs are unique in their ability to vary the 
timing of LT expression and therefore vary the pocket protein activity in relation to the 
moment of adipogenic stimulation. This property makes iBPAs particularly attractive for 
studying the role of cell cycle regulators including those directly targeted by LT in BPA 
differentiation.
In conclusion, we established lines of conditionally immortalized mouse and human 
BPAs with long-term proliferation ability and adipogenic capacity. Following adipo-
genesis, these cells display a multilocular lipid droplet appearance as well as a gene 
expression signature and metabolic capacity akin to brown adipocytes. The generated 
cell lines have many potential applications and can, for example, be used to investigate 
BPA proliferation and differentiation, brown (pre)adipocyte metabolism and regulation 
of Ucp1/UCP1 activity and thermogenesis, for brown (pre)adipocyte-based disease 
modelling, BPA transplantation studies and drug development.
70
ACKNOWLEDgEmENTS
The authors also thank Kevin Brewster and Trea Streefland (LUMC, Dept. Internal Medi-
cine, Div. Endocrinology) for their valuable technical assistance.
FuNDiNg
This work was supported by the Netherlands Heart Institute (grant 230.148-04 to A.A.F.V); 
the Royal Netherlands Academy of Arts and Sciences (Chinese Exchange Programme 
grant 10CDP007 to A.A.F.V); the research programme More Knowledge with Fewer Ani-
mals (MKMD; grant 114022503 to A.A.F.V); a research grant from the Rembrandt Institute 
of Cardiovascular Science; the Dutch Diabetes Foundation (grant 2015.81.1808 to M.R. 
Boon); the Dutch Heart Foundation (grant 2017T016 to S. Kooijman) and the European 
Foundation for the Study of Diabetes (EFSD Rising Star Fellowship Programme to S. 




 1. Bartelt, A.; Bruns, O. T.; Reimer, R.; Hohen-
berg, H.; Ittrich, H.; Peldschus, K.; Kaul, M. 
G.; Tromsdorf, U. I.; Weller, H.; Waurisch, C., 
et al. Brown adipose tissue activity controls 
triglyceride clearance. Nat Med 2011, 17, 
(2), 200-5.
 2. van den Berg, R.; Kooijman, S.; Noordam, 
R.; Ramkisoensing, A.; Abreu-Vieira, G.; 
Tambyrajah, L. L.; Dijk, W.; Ruppert, P.; Mol, 
I. M.; Kramar, B. A, et al. Diurnal Rhythm in 
Brown Adipose Tissue Causes Rapid Clear-
ance and Combustion of Plasma Lipids at 
Wakening. Cell Rep 2018, 22, (13), 3521-
3533.
 3. Hoeke, G.; Kooijman, S.; Boon, M. R.; 
Rensen, P. C.; Berbée, J. F. Role of brown fat 
in lipoprotein metabolism and atheroscle-
rosis. Circ Res 2016, 118, (1), 173-82.
 4. Cannon, B.; Nedergaard, J. Brown adipose 
tissue: function and physiological signifi-
cance. Physiol Rev 2004, 84, (1), 277-359.
 5. Townsend, K.; Tseng, Y. H. Brown adipose 
tissue: Recent insights into development, 
metabolic function and therapeutic po-
tential. Adipocyte 2012, 1, (1), 13-24.
 6. Schulz, T. J.; Tseng, Y. H. Brown adipose 
tissue: development, metabolism and 
beyond. Biochem J 2013, 453, (2), 167-78.
 7. Zhang, H.; Schulz, T. J.; Espinoza, D. O.; 
Huang, T. L.; Emanuelli, B.; Kristiansen, K.; 
Tseng, Y. H. Cross talk between insulin and 
bone morphogenetic protein signaling 
systems in brown adipogenesis. Mol Cell 
Biol 2010, 30, (17), 4224-33.
 8. Kajimura, S.; Seale, P.; Kubota, K.; Lunsford, 
E.; Frangioni, J. V.; Gygi, S. P.; Spiegelman, 
B. M. Initiation of myoblast to brown fat 
switch by a PRDM16-C/EBP-beta transcrip-
tional complex. Nature 2009, 460, (7259), 
1154-8.
 9. Seale, P.; Bjork, B.; Yang, W.; Kajimura, S.; 
Chin, S.; Kuang, S.; Scime, A.; Devarakonda, 
S.; Conroe, H. M.; Erdjument-Bromage, H., 
et al. PRDM16 controls a brown fat/skeletal 
muscle switch. Nature 2008, 454, (7207), 
961-7.
 10. Cannon, B.; Nedergaard, J. Developmental 
biology: Neither fat nor flesh. Nature 2008, 
454, (7207), 947-8.
 11. Kiefer, F. W. The significance of beige and 
brown fat in humans. Endocr Connect 
2017, EC-17-0037.
 12. Zhang, J.; Thomas, T. Z.; Kasper, S.; Matusik, 
R. J. A small composite probasin promoter 
confers high levels of prostate-specific 
gene expression through regulation by 
androgens and glucocorticoids in vitro 
and in vivo. Endocrinology 2000, 141, (12), 
4698-4710.
 13. Irie, Y.; Asano, A.; Canas, X.; Nikami, H.; 
Aizawa, S.; Saito, M. Immortal brown 
adipocytes from p53-knockout mice: dif-
ferentiation and expression of uncoupling 
proteins. Biochem Biophys Res Commun 
1999, 255, (2), 221-5.
 14. Kozak, U. C.; Held, W.; Kreutter, D.; Kozak, L. 
P. Adrenergic regulation of the mitochon-
drial uncoupling protein gene in brown 
fat tumor cells. Mol Endocrinol 1992, 6, (5), 
763-72.
 15. Klaus, S.; Choy, L.; Champigny, O.; Cassard-
Doulcier, A. M.; Ross, S.; Spiegelman, B.; 
Ricquier, D. Characterization of the novel 
brown adipocyte cell line HIB 1B. Adren-
ergic pathways involved in regulation of 
uncoupling protein gene expression. J Cell 
Sci 1994, 107 ( Pt 1), 313-9.
 16. Zennaro, M. C.; Le Menuet, D.; Viengcha-
reun, S.; Walker, F.; Ricquier, D.; Lombes, 
M. Hibernoma development in transgenic 
mice identifies brown adipose tissue as a 
novel target of aldosterone action. J Clin 
Invest 1998, 101, (6), 1254-60.
 17. Shinoda, K.; Luijten, I. H.; Hasegawa, Y.; 
Hong, H.; Sonne, S. B.; Kim, M.; Xue, R.; 
Chondronikola, M.; Cypess, A. M.; Tseng, 
Y. H., et al. Genetic and functional charac-
terization of clonally derived adult human 
72
brown adipocytes. Nat Med 2015, 21, (4), 
389-94.
 18. Xue, R.; Lynes, M. D.; Dreyfuss, J. M.; 
Shamsi, F.; Schulz, T. J.; Zhang, H.; Huang, 
T. L.; Townsend, K. L.; Li, Y.; Takahashi, H. , 
et al. Clonal analyses and gene profiling 
identify genetic biomarkers of the ther-
mogenic potential of human brown and 
white preadipocytes. Nat Med 2015, 21, 
(7), 760-8.
 19. Molchadsky, A.; Ezra, O.; Amendola, P. 
G.; Krantz, D.; Kogan-Sakin, I.; Buganim, 
Y.; Rivlin, N.; Goldfinger, N.; Folgiero, V.; 
Falcioni, R., et al. p53 is required for brown 
adipogenic differentiation and has a pro-
tective role against diet-induced obesity. 
Cell Death Differ 2013, 20, (5), 774-83.
 20. Hansen, J. B.; Jørgensen, C.; Petersen, R. 
K.; Hallenborg, P.; De Matteis, R.; Bøye, H. 
A.; Petrovic, N.; Enerbäck, S.; Nedergaard, 
J.; Cinti, S., et al. Retinoblastoma protein 
functions as a molecular switch determin-
ing white versus brown adipocyte differen-
tiation. Proc Natl Acad Sci U S A 2004, 101, 
(12), 4112-7.
 21. Szulc, J.; Wiznerowicz, M.; Sauvain, M. O.; 
Trono, D.; Aebischer, P. A versatile tool for 
conditional gene expression and knock-
down. Nat Methods 2006, 3, (2), 109-16.
 22. Liu, J.; Volkers, L.; Jangsangthong, W.; Bart, 
C. I.; Engels, M. C.; Zhou, G.; Schalij, M. J.; 
Ypey, D. L.; Pijnappels, D. A.; de Vries, A. A. 
Generation and primary characterization 
of iAM-1, a versatile new line of condition-
ally immortalized atrial myocytes with 
preserved cardiomyogenic differentiation 
capacity. Cardiovasc Res 2018, 114, (14), 
1848-1859.
 23. Neshati, Z.; Liu, J.; Zhou, G.; Schalij, M. J.; 
de Vries, A. A. Development of a lentivirus 
vector-based assay for non-destructive 
monitoring of cell fusion activity. PloS One 
2014, 9, (7), e102433.
 24. Cannon, B.; Nedergaard, J. Brown adipose 
tissue: function and physiological signifi-
cance. Physiol Rev 2004, 84, (1), 277-359.
 25. Forest, C.; Doglio, A.; Ricquier, D.; Ailhaud, 
G. A preadipocyte clonal line from 
mouse brown adipose tissue. Short- and 
long-term responses to insulin and beta-
adrenergics. Exp Cell Res 1987, 168, (1), 
218-32.
 26. Liu, X.; Cervantes, C.; Liu, F. Common and 
distinct regulation of human and mouse 
brown and beige adipose tissues: a prom-
ising therapeutic target for obesity. Protein 
Cell 2017, 8, (6), 446-454.
 27. Markussen, L. K.; Isidor, M. S.; Breining, P.; 
Andersen, E. S.; Rasmussen, N. E.; Petersen, 
L. I.; Pedersen, S. B.; Richelsen, B.; Hansen, 
J. B. Characterization of immortalized 
human brown and white pre-adipocyte 
cell models from a single donor. PloS One 
2017, 12, (9), e0185624.
 28. Rosell, M.; Kaforou, M.; Frontini, A.; Okolo, 
A.; Chan, Y. W.; Nikolopoulou, E.; Millership, 
S.; Fenech, M. E.; MacIntyre, D.; Turner, J. 
O., et al. Brown and white adipose tissues: 
intrinsic differences in gene expression 
and response to cold exposure in mice. Am 
J Physiol Endocrinol Metab 2014, 306, (8), 
E945-64.
 29. Ray, S.; Anderson, M. E.; Tegtmeyer, P. 
Differential interaction of temperature-
sensitive simian virus 40 T antigens with 
tumor suppressors pRb and p53. J Virol 
1996, 70, (10), 7224-7227.
 30. Seale, P.; Kajimura, S.; Yang, W.; Chin, S.; 
Rohas, L. M.; Uldry, M.; Tavernier, G.; Lan-
gin, D.; Spiegelman, B. M. Transcriptional 
control of brown fat determination by 
PRDM16. Cell Metab 2007, 6, (1), 38-54.
 31. Seale, P. Transcriptional regulatory circuits 
controlling brown fat development and 
activation. Diabetes 2015, 64, (7), 2369-75.
 32. Ohno, H.; Shinoda, K.; Spiegelman, B. 
M.; Kajimura, S. PPARγ agonists induce a 
white-to-brown fat conversion through 
stabilization of PRDM16 protein. Cell Metab 
2012, 15, (3), 395-404.
 33. Nagano, G.; Ohno, H.; Oki, K.; Kobuke, K.; 
Shiwa, T.; Yoneda, M.; Kohno, N. Activation 
73
3
of classical brown adipocytes in the adult 
human perirenal depot is highly correlated 
with PRDM16–EHMT1 complex expression. 
PloS One 2015, 10, (3), e0122584.
 34. Chatzispyrou, I. A.; Held, N. M.; Mouchir-
oud, L.; Auwerx, J.; Houtkooper, R. H. 
Tetracycline antibiotics impair mitochon-
drial function and its experimental use 
confounds research. Cancer Res 2015, 75, 
(21), 4446-9.
 35. Moullan, N.; Mouchiroud, L.; Wang, X.; Ryu, 
D.; Williams, E. G.; Mottis, A.; Jovaisaite, V.; 
Frochaux, M. V.; Quiros, P. M.; Deplancke, B., 
et al. Tetracyclines Disturb Mitochondrial 
Function across Eukaryotic Models: A Call 
for Caution in Biomedical Research. Cell 
Rep 2015.
 36. Cherington, V.; Morgan, B.; Spiegelman, B. 
M.; Roberts, T. M. Recombinant retroviruses 
that transduce individual polyoma tumor 
antigens: effects on growth and differen-
tiation. Proc Natl Acad Sci U S A 1986, 83, 
(12), 4307-11.
 37. Higgins, C.; Chatterjee, S.; Cherington, V. 
The block of adipocyte differentiation by 
a C-terminally truncated, but not by full-
length, simian virus 40 large tumor antigen 
is dependent on an intact retinoblastoma 
susceptibility protein family binding do-
main. J Virol 1996, 70, (2), 745-52.
 38. Moreno-Navarrete, J. M.; Petrov, P.; Ser-
rano, M.; Ortega, F.; Garcia-Ruiz, E.; Oliver, 
P.; Ribot, J.; Ricart, W.; Palou, A.; Bonet, M. 
L., et al. Decreased RB1 mRNA, protein, and 
activity reflect obesity-induced altered 
adipogenic capacity in human adipose 
tissue. Diabetes 2013, 62, (6), 1923-31.
 39. Berk, A. J.; Sharp, P. A. Spliced early mRNAs 
of simian virus 40. Proc Natl Acad Sci U S A 
1978, 75, (3), 1274-78.
 40. Zerrahn, J.; Knippschild, U.; Winkler, T.; 
Deppert, W. Independent expression of 
the transforming amino‐terminal domain 
of SV40 large I antigen from an alterna-
tively spliced third SV40 early mRNA. EMBO 
J 1993, 12, (12), 4739-46.
 41. Pallas, D. C.; Shahrik, L. K.; Martin, B. L.; 
Jaspers, S.; Miller, T. B.; Brautigan, D. L.; 
Roberts, T. M. Polyoma small and middle 
T antigens and SV40 small t antigen form 
stable complexes with protein phospha-
tase 2A. Cell 1990, 60, (1), 167-76.
 42. Pallas, D. C.; Weller, W.; Jaspers, S.; Miller, 
T.; Lane, W.; Roberts, T. The third subunit of 
protein phosphatase 2A (PP2A), a 55-kilo-
dalton protein which is apparently substi-
tuted for by T antigens in complexes with 
the 36-and 63-kilodalton PP2A subunits, 
bears little resemblance to T antigens. J 
Virol 1992, 66, (2), 886-93.
 43. Kroon, J.; Koorneef, L. L.; van den Heuvel, J. 
K.; Verzijl, C. R.; van de Velde, N. M.; Mol, I. 
M.; Sips, H. C.; Hunt, H.; Rensen, P. C.; Meijer, 
O. C. Selective glucocorticoid receptor 
antagonist CORT125281 activates brown 
adipose tissue and alters lipid distribution 
in male mice. Endocrinology 2017, 159, (1), 
535-546.
 44. Okamatsu-Ogura, Y.; Fukano, K.; Tsubota, 
A.; Nio-Kobayashi, J.; Nakamura, K.; Mori-
matsu, M.; Sakaue, H.; Saito, M.; Kimura, 
K. Cell-cycle arrest in mature adipocytes 
impairs BAT development but not WAT 
browning, and reduces adaptive thermo-
genesis in mice. Sci Rep 2017, 7, (1), 6648.
 45. Fukano, K.; Okamatsu-Ogura, Y.; Tsubota, 
A.; Nio-Kobayashi, J.; Kimura, K. Cold Expo-
sure Induces Proliferation of Mature Brown 
Adipocyte in a ß3-Adrenergic Receptor-




Supplementary materials and methods
Construction of plasmids
DNA constructions were carried out with enzymes from Fermentas (Thermo Fisher 
Scientific, Breda, the Netherlands) or from New England Biolabs (Bioké, Leiden, the 
Netherlands) and with oligodeoxyribonucleotides from Sigma-Aldrich (Zwijndrecht, the 
Netherlands) using established procedures or following the instructions provided with 
specific reagents.
To generate pLV.iHsEEF1A1.LT-tsA58.WHVPRE, plasmid pAT153.SV40ori(-)tsA58, which 
codes for the temperature-sensitive mutant of the oncogenic SV40 LT antigen designated 
tsA58 [1], was used as template in a polymerase chain reaction (PCR) with VELOCITY DNA 
polymerase (GC Biotech, Alphen a/d Rijn, the Netherlands) and primers 5’ AAGGATCC-
GTGCACCATGGATAAAGTTTTAAACAGAGAGGA 3’ and 5’ CCGAATTCTTTATGTTTCAG-
GTTCAGGG 3’ (the LT initiation codon and the complement of its termination codon are 
underlined). The resulting PCR fragment was inserted into plasmid pJET1.2/blunt using 
the CloneJET PCR cloning kit (Thermo Fisher Scientific) to generate pJet1.2.LT-tsA58. 
pJet1.2.LT-tsA58 was incubated with BamHI and EcoRI and the 2.5-kb digestion prod-
uct was combined with the 11.5-kb BamHI×EcoRI fragment of SIN-LV shuttle plasmid 
pLVET.tTS.dEcoRI to generate pLV.iHsEEF1A1.LT-tsA58. pLVET.tTS.dEcoRI is a derivative of 
pLVET-tTR-KRAB [2] (Addgene, Cambridge, MA; plasmid number: 116444). It was made 
by digestion of pLVET-tTR-KRAB with EcoRI and NheI and ligation of the resulting 1.6-kb 
fragment encoding the encephalomyocarditis virus internal ribosomal entry site and the 
tetracycline-controlled transrepressor protein TetR-KRAB [3] to the 10.8-kb EcoRI×BcuI 
fragment of pLVET-tTR-KRAB.
pLV.ihUBC.LT-tsA58.WHVPRE is a derivative of pLV.iHsEEF1A1.LT-tsA58.WHVPRE. It was 
generated by replacing the human eukaryotic translation elongation factor 1A1 gene 
promoter in pLV.iHsEEF1A1.LT-tsA58.WHVPRE by the promoter of the human ubiquitin 
C gene.
immunocytology
Cells were processed for immunostaining as previously described [4]. Detection of LT 
was done with the same primary antibody as used for the analysis of LT expression by 
western blotting. Actively replicating cells were detected using polyclonal rabbit anti-
Ki-67 antibodies (Abcam, Cambridge, United Kingdom; catalogue number: ab15580). 
The primary antibodies were diluted 1:200 in PBS containing 0.1% normal donkey serum 
(Sigma-Aldrich) and incubated overnight at 4°C. Bound antigens were detected using 
Alexa 488-conjugated donkey anti-rabbit IgG (H+L) (Thermo Fisher Scientific; catalogue 
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number: A21206) and Alexa 568-coupled donkey anti-mouse IgG (H+L) (Thermo Fisher 
Scientific; catalogue number: A10037). These secondary antibodies were diluted 1:400 
in PBS. Hoechst 33342 (10 µg/µL; Thermo Fisher Scientific) was used to counterstain 
nuclei. Stained cells were visualized using a digital color camera-equipped fluorescence 
microscope (Nikon Eclipse 80i; Nikon Instruments Europe, Amstelveen, the Netherlands).
Supplementary table 1. Clinical characteristics of patients whose adipose biopsies were used to isolate 
human primary BPAs
Age (year) Sex Bmi (kg/m2)
Patient 1 36 M > 30
Patient 2 65 F 27.3
Patient 3 54 F < 30
Patient 4 38 F 25.2
Supplementary figure 1. Schematic representation of Lv shuttle plasmids and protocol to generate 
conditionally immortalized BPAs. Ori, bacterial origin of replication. AmpR, Escherichia coli ß-lactamase 
gene. LTR, human immunodeficiency virus type 1 (HIV1) long terminal repeat. Ψ, HIV1 packaging signal. 
RRE, HIV1 Rev-responsive element. cPPT, HIV1 central polypurine tract and termination site. HsEEF1A1, hu-
man eukaryotic translation elongation factor 1A1 gene promoter. HsUBC, human ubiquitin C gene promot-
er. LT, coding sequence of the temperature-sensitive mutant LT protein tsA58. IRES, encephalomyocarditis 
virus internal ribosome entry site. tTS, coding sequence of the hybrid tetracycline-controlled transcription-
al repressor TetR-KRAB. WHVPRE, woodchuck hepatitis virus posttranscriptional regulatory element. TRE, 
tetracycline-responsive promoter element consisting of 7 repeats of a 19-nucleotide tetracycline operator 
(tetO) sequence. LV, lentiviral vector; BPA, brown preadipocyte; iBPAs, conditionally immortalized BPAs.
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Supplementary figure 2. Dox-inducible proliferation capacity of clone #6 mouse iBPAs. Fluorographs 
images of iBPAs maintained in growth medium before (0) and 6 days after dox removal immunostained for 
the proliferation marker Ki-67 (green). Nuclei are visualized with Hoechst 33342 (blue). Dox, doxycycline; 
iBPA, conditionally immortalized brown preadipocyte.
Supplementary figure 3. growth curves of primary human BPAs and transduced human BPAs. Cells 
were cultured in the presence of dox. BPA, brown preadipocyte; PD, population doubling.
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ABSTRACT
The human cytokine IL-37 is an anti-inflammatory member of the IL-1 family of 
cytokines. Transgenic expression of IL-37 in mice protects them from diet-induced 
obesity and associated metabolic complications including dyslipidemia, inflammation 
and insulin resistance. The precise mechanism of action leading to these beneficial 
metabolic effects is not entirely known. Therefore, we aimed to assess in detail the ef-
fect of transgenic IL-37 expression on energy balance, including food intake and energy 
expenditure. Feeding homozygous IL-37 transgenic mice and wild-type (WT) control 
mice a high-fat diet (HFD; 45% kcal palm fat) for 6 weeks showed that IL-37 reduced 
body weight related to a marked decrease in food intake. Subsequent mechanistic 
studies in mice with heterozygous IL-37 expression versus WT littermates, fed the HFD 
for 18 weeks, confirmed that IL-37 reduces food intake, which led to a decrease in lean 
body mass, but did not reduce fat mass and plasma lipid levels or alterations in energy 
expenditure independent of lean body mass. Taken together, this suggests that IL-37 




The worldwide prevalence of obesity, defined as a body mass index (BMI) > 30 kg/m2, 
has nearly doubled since 1980 and at least 2.7 million people die each year as a result of 
obesity [1]. This number is expected to further increase over the next decade. Obesity 
has a great impact on public health as it leads to disorders such as dyslipidemia, type 2 
diabetes and cardiovascular disease [2, 3]. Obesity is caused by a positive energy balance 
that leads to excessive fat accumulation in adipose tissue, hypertrophy of adipocytes, 
hypoxia, and in the end cell death. This results in recruitment of inflammatory cells 
by white adipose tissue (WAT), which eventually leads to adipose tissue dysfunction, 
preceding dyslipidemia and type 2 diabetes [4, 5].
It has been shown that release of pro-inflammatory cytokines by adipocytes and/or 
immune cells in adipose tissue, including IL-1β, IL-6, TNFα and CCL2, is higher during 
obesity compared to the lean state. More specifically, TNFα has been repeatedly shown 
to hamper insulin signaling and to result in insulin resistance, which may eventually lead 
to type 2 diabetes (reviewed in [6]). Inhibiting pro-inflammatory cytokines to counteract 
their disadvantageous metabolic effects is extensively being studied [7, 8]. In contrast, 
anti-inflammatory cytokines that could potentially ameliorate the inflammatory micro-
environment in obesity have been less well studied. IL-37, a cytokine previously known 
as IL-1 family member 7 (IL-1F7), is a member of the IL-1 family of cytokines that includes 
amongst others IL-1α, IL-1β, IL-1Ra, IL-18 and IL-33 [9]. The first studies into the func-
tion of IL-37 showed that it is a natural suppressor of innate inflammatory and immune 
responses [10]. In humans, several tissues and cell types express IL-37, including blood 
monocytes [11, 12], epithelial cells [13], endothelial cells [14] and, importantly, also adi-
pocytes [9, 15]. IL-37 mRNA is degraded in the absence of inflammation, but upon LPS 
stimulation, i.e. a pro-inflammatory stimulus, IL-37 expression increases [16-18]. In vitro, 
it was shown that IL-37 suppresses expression of pro-inflammatory factors in monocytes 
and macrophages [10, 17]. These studies indicate that IL-37 expression counteracts pro-
inflammatory cytokine expression through controlled mechanisms that ensure balance 
between host defense functions of inflammation and adverse effects [10, 16, 17].
Since a mouse homolog of IL-37 is unknown, in vivo studies into IL-37 function have 
employed a mouse model with transgenic (tg) expression of the most abundant isoform 
of human IL-37 (IL-37b; IL-37tg mice) [10, 11, 15, 19-21]. IL-37tg mice are protected 
from LPS-induced shock related to lower levels of inflammatory cytokines upon LPS 
treatment [10]. Strikingly, IL-37 expression in mice also protects against obesity and 
obesity-associated inflammation and insulin resistance [15]. IL-37tg mice fed a high-fat 
diet (HFD) showed a markedly lower gain in body weight and lower plasma lipid levels 
compared to wild-type (WT) control mice [15]. Although IL-37 was shown to induce 
metabolic changes in adipocytes and immune cells [15, 22, 23], it is still not entirely 
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known how the beneficial metabolic effects are instigated. Therefore, the aim of this 
study was to investigate the effect of IL-37 on energy balance, i.e. energy intake and 
energy expenditure, in more detail. To this end, IL-37tg and WT mice were fed a HFD to 
induce obesity. Homozygous IL-37tg mice showed lower body weight and food intake. 
Mechanistic studies in heterozygous mice demonstrated that IL-37 lowers food intake 
and specifically reduces lean body mass without reducing fat mass or plasma lipid levels. 




For the first study, male C57Bl/6J mice and IL-37tg mice homozygously overexpressing 
human IL-37 on a C57Bl/6J background were used. IL-37tg mice were generated as previ-
ously described [10], and C57Bl/6J mice were purchased from Jackson Laboratories (Bar 
Harbor, ME, USA). For the second study, male IL-37tg mice heterozygously expressing 
human IL-37 and WT littermates (both C57Bl/6J background) were bred. In both studies, 
mice were individually housed under standard conditions with a 12:12 h light-dark cycle 
and access to food and water. Animals were approximately 10 weeks of age at the start 
of high-fat diet (HFD; D12451, of which lard fat was replaced by palm fat, purchased 
from Ssniff, Soest, The Netherlands and Research Diet Services, Wijk bij Duurstede, The 
Netherlands) feeding. The HFD contained 45% kcal from palm fat, 20% of kcal derived 
from protein and 35% kcal derived from carbohydrates and was given for 6 or 18 weeks, 
as indicated. Mouse experiments were performed in accordance with the Institute for 
Laboratory Animal Research Guide for the Care and Use of Laboratory Animals and 
had received approval from the University Ethical Review Boards (DEC 13159, Radboud 
University Medical Centre, Nijmegen and Leiden University Medical Centre, The Nether-
lands).
Body weight, body composition and food intake
At indicated time points, body weight and food intake were measured. Body composi-
tion was measured using an EchoMRI-100 analyser (EchoMRI, TX, USA). Because IL-37 
expression induced hypophagia in the first experiment with IL-37tg homozygous mice, 
in the second experiment an additional group of C57Bl/6J mice that was pair-fed to the 
heterozygous IL-37tg group was taken along. To achieve pair-feeding, food intake of the 
ad libitum-fed IL-37tg mice was monitored daily and the pair-fed mice were given the 
average amount of diet that the IL-37tg mice had consumed the previous day, at the 
end of the light phase.
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Plasma glucose and lipids
At the indicated time points, 6 h-fasted blood samples were collected by tail vein bleed-
ing into chilled capillaries that were coated with paraoxon (Sigma-Aldrich, MO, USA) 
to prevent ongoing lipolysis [24]. Isolated plasma was assayed for glucose (Instruche-
mie, Delfzijl, The Netherlands), total cholesterol and triglycerides (Roche Diagnostics, 
Mannheim, Germany), and free fatty acids (Wako Diagnostics; Instruchemie, Delfzijl, The 
Netherlands) following the manufacturers’ protocols.
Energy metabolism
Heterozygous IL-37tg mice and WT littermates were housed in fully automatic metabolic 
cages (LabMaster System; TSE Systems, Bad Homburg, Germany) several days before 
HFD feeding and the first week of HFD-feeding, as indicated. Metabolic cages measured 
oxygen uptake (VO2) and carbon dioxide production (VCO2). Glucose oxidation and fat 
oxidation were calculated from VO2 and VCO2 as described previously [25]. Total energy 
expenditure was calculated from VO2 and VCO2 using the Weir equation [26]. Physical 
activity was measured with infrared sensor frames.
Statistical analysis 
All data are expressed as means ± SEM. Differences between groups were determined 
using a two-tailed unpaired Student’s t-test and food intake measurements in the het-
erozygous IL-37tg mice using a one-tailed unpaired Student’s t-test. Statistical analyses 
were performed using Excel or SPSS 20.0 software package for Windows. Probability 
values less than 0.05 were considered statistically significant.
RESuLTS
iL-37 expression alleviates diet-induced weight gain and reduces food intake
To assess the effect of IL-37 expression on the development of HFD-induced obesity, 
homozygous IL-37tg mice were fed a HFD for 6 weeks. Body weight of the IL-37tg mice 
was already 3.6 g lower compared to the WT control mice before initiation of the HFD 
(Fig. 1A) and this difference was magnified during HFD feeding resulting in a body 
weight difference of 10.5 g after 6 weeks of HFD (P<0.001). Even when corrected for 
body weight at the start of HFD feeding, IL-37tg mice gained substantially less weight 
compared to WT mice during 6 weeks of HFD (Fig. 1B). Next, we measured whether the 
energy intake in IL-37tg mice was different compared to WT controls. Quite surprisingly, 
food intake in IL-37tg mice was markedly lower throughout the HFD intervention period 
(-21 to -32%, P<0.001, Fig. 1C). This suggests that IL-37tg expression might alleviate 
diet-induced weight gain by reducing food intake.
84
Reduced food intake in heterozygous iL-37tg mice decreases lean body mass 
To further investigate the effect of the reduced food intake in IL-37tg mice on body 
weight and composition independent of genetic background, a second study was set 
up that included a group of HFD-fed heterozygous IL-37tg mice and WT littermates that 
was pair-fed to these IL-37tg mice. Although less pronounced, heterozygous IL-37tg 
mice also had reduced food intake compared to WT littermates (-8% cumulative food 
intake after 18 weeks, P<0.05, Fig. 2A, B). Compared to homozygous IL-37tg mice, het-
erozygous IL-37tg mice only showed a tendency towards reduced body weight (Fig. 2C). 
Estimation of body composition by EchoMRI revealed that, while heterozygous IL-37tg 
mice had similar fat mass compared to WT littermates (Fig. 2D), their lean body mass 
was reduced (-7% after 18 weeks of HFD, P<0.05). Remarkably, lean body mass of the 
pair-fed group aligned with the WT control group until pair-feeding was started, upon 
which it dropped towards the lean body mass of the IL-37tg mice (Fig. 2E), suggesting 
that the reduction in food intake underlies the reduced lean body mass. To determine 
whether heterozygous IL-37 expression affects plasma glucose and lipid levels, blood 
was drawn after 0, 6 and 18 weeks of HFD feeding. Plasma glucose, total cholesterol, free 
fatty acids and triglyceride levels did not differ between the groups (Fig. 3A-D). These 
data suggest that heterozygous IL-37 overexpression primarily affects lean body mass 
via reducing food intake without affecting plasma glucose and lipid levels.
iL-37 expression decreases energy expenditure in conjunction with lean body 
mass reduction
To assess the effect of IL-37 expression on energy metabolism in more depth, energy 
expenditure, substrate utilization and activity levels were monitored by metabolic cages 
two days before and during the first week of HFD feeding. IL-37 expression did not affect 
physical activity levels (Suppl. Fig. 1A, B). Fat oxidation during the light period tended to 
be lower in IL-37tg mice compared to WT littermate controls (-12%, P=0.08, Fig. 4A, B). 
Figure 1. iL-37 expression alleviates diet-induced weight gain and reduces food intake. 10-week old 
male C57Bl/6J mice and homozygous IL-37tg mice on a C57Bl/6J background were fed a high-fat diet (HFD) 
for 6 weeks. Body weight (A, B) and food intake (C) were measured at indicated time points. Values repre-
sent means ± SEM (n=10 animals per group). **P<0.01, ***P<0.001 vs wild-type (WT).
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Glucose oxidation during the dark period, in which mice are active, was lower in the IL-
37tg mice compared to the control group (-12%, P<0.05, Fig. 4C, D). Energy expenditure 
during the light period tended to be lower in IL-37tg mice compared to WT littermate 
controls (-5%, P=0.07, Suppl. Fig. 1C, D). Since IL-37 expression reduced lean body mass, 
which is an important contributor to energy expenditure, we corrected the fat oxidation, 
glucose oxidation and total energy expenditure for lean body mass and found that dif-
ferences in substrate utilization and total energy expenditure lost significance between 
IL-37tg and WT control mice (Fig. 4E-H, Suppl. Fig. 1E, F). These data suggest that het-
erozygous overexpression of IL-37 decreases glucose oxidation and tends to decrease 
fat oxidation and energy expenditure as a consequence of reduced lean body mass.
Figure 2. Reduced food intake in heterozygous iL-37tg mice decreases lean mass. 10-week old male 
C57Bl/6J mice and heterozygous IL-37tg mice on a C57Bl/6J background were fed a high-fat diet (HFD) for 
18 weeks. Pair-feeding of wild-type (WT) mice (PF group) was initiated after 5.5 weeks of HFD feeding and 
is indicated by the dotted line (A-D). Food intake (FI; A, B), body weight (C), fat mass (D) and lean mass (E) 
were measured at indicated time points. Values represent means ± SEM (n=10 animals per group). *P<0.05 
IL-37tg vs wild-type (WT).
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Figure 3. Heterozygous iL-37 expression does not affect plasma glucose and lipid levels. 10-week 
old male C57Bl/6J mice and heterozygous IL-37tg mice on a C57Bl/6J background were fed a high-fat diet 
(HFD) for 18 weeks. Pair-feeding of wild-type (WT) mice (PF group) was initiated after 5.5 weeks of HFD 
feeding. Plasma glucose (A), total cholesterol (B), free fatty acids (C) and triglycerides (D) were measured at 
indicated time points. Values represent means ± SEM (n=10 animals per group).
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Figure 4. Heterozygous iL-37 expression decreases glucose oxidation in conjunction with lean body 
mass reduction. 10-week old male C57Bl/6J mice and heterozygous IL-37tg mice on a C57Bl/6J back-
ground were fed a high-fat diet (HFD). From 2 days before initiation of HFD until 1 week after the switch to 
HFD, mice were housed in fully automatic metabolic cages, which measured oxygen uptake (VO2) and car-
bon dioxide production (VCO2). Fat (A, B) and glucose (C, D) oxidation was calculated and were corrected for 
lean mass (fat oxidation; E, F; glucose oxidation; G, H). Bar graphs were based on calculations of the mean 
from day 1.5 to 7. Values represent means (A, C, E, G) and bar graphs represent means ± SEM (B, D, F, H) (n=8 
animals per group). *P<0.05 IL-37tg vs wild-type (WT).
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DiSCuSSiON
IL-37 is an anti-inflammatory cytokine of the immune system, and transgenic expres-
sion of IL-37 in mice protects them from diet-induced obesity and associated metabolic 
complications including dyslipidemia, inflammation and insulin resistance [15]. In the 
current study, we investigated the effect of transgenic IL-37 expression on energy bal-
ance in more detail. We confirmed that mice homozygously expressing IL-37 had lower 
body weight upon HFD feeding, and went on to show that these animals had a marked 
decrease in food intake. Subsequent mechanistic studies in mice with heterozygous 
expression showed that IL-37 reduces food intake which led to a decrease in lean 
body mass, but did not reduce fat mass and plasma lipid levels or alterations in energy 
expenditure independent of lean body mass. Taken together, this indicates that IL-37 
expression lowers lean body mass at least partly via reducing food intake.
We found that mice homozygously expressing IL-37 were leaner than WT control 
mice already before onset of the HFD, and this difference became more evident dur-
ing HFD feeding for 6 weeks. These body weight curves differ from the course of body 
weight found previously by Ballak et al. [15] for which the exact explanation is currently 
unknown to us. Despite the fact that the diet, age of the animals and the experimental 
facility were the same in both studies, IL-37tg and WT control mice in the previous study 
had a similar weight before onset of the HFD and lower body weight in IL-37tg mice was 
not evident until 6 weeks of HFD feeding [15]. Strikingly, the previous study reported 
similar food intake between IL-37tg and WT control mice. The difference in results be-
tween our results and the previous experiments published by Ballak et al. [15] may be 
due to differences in methods to monitor food intake. In addition, non-littermates were 
used in the first experiment in this paper and in the study by Ballak et al. [15]. Therefore, 
the reduction in fat mass and metabolic phenotype that were found initially could also 
be due to differences in genetic make-up or composition of gut microbiota [27, 28]. 
For subsequent mechanistic studies into the beneficial metabolic phenotype observed 
in IL-37tg mice independent of genetic makeup we used heterozygous IL-37tg and WT 
littermate control animals. The reason we switched to a heterozygous mouse model 
was because a breeding that generated WT littermate controls was needed and it was 
impossible to distinguish homozygous from heterozygous mice by PCR, a heterozygous 
breeding was kept in which heterozygous IL-37tg mice were crossed with WT mice. We 
observed no obvious difference in behavior between transgenic and WT animals as de-
scribed before [10]. Although we attempted to investigate whether reduced food intake 
in IL-37tg animals was causal to the beneficial metabolic phenotype by performing a 
study in which we included a pair-fed group, we could not reproduce the marked effect 
on total body weight that we found initially and that was also reported previously [15]. A 
downside of using this approach is that expression of IL-37 in heterozygous IL-37tg mice 
89
4
will be lower than in homozygous IL-37tg mice, explaining the reduced effect observed 
on body weight. Indeed, in heterozygous IL-37tg mice the IL-37 mRNA expression has 
shown to be lower and the concomitant beneficial effects milder than the expression 
and effects of homozygous IL-37tg mice [10, 29]. Since there seems to be a gene dose-
dependent effect of IL-37 on food intake and total body weight, and heterozygous 
IL-37 expression lowers specifically lean body mass, it might be that homozygous IL-37 
expression lowers body weight by reducing both fat and lean body mass. Unfortunately, 
we did not take measures of body composition of the homozygous IL-37tg mice to con-
firm this. To circumvent the use of transgenic mouse models, an alternative approach for 
future studies on IL-37 function would be the use of recombinant IL-37 [30]. 
IL-37 production has been reported to be low and it is mainly induced and detected 
upon pro-inflammatory stimuli, such as LPS [10] or others that would accumulate 
during the development of obesity. Even though the animals in our study were fed a 
pro-inflammatory diet containing palm oil, which may have led to higher LPS exposure 
in our models [31], heterozygous IL-37 expression might not have been sufficient to 
counterbalance inflammation upon the pro-inflammatory diet. Nevertheless, het-
erozygous IL-37tg mice still had a reduction in food intake and less lean body mass. 
Restricting energy intake in mice with roughly 26%, which is three times higher than the 
energy restriction in our study, has been shown to decrease lean body mass by about 
11% (compared to -7% in our study) without affecting fat mass before [32]. Since in our 
study the pair-fed mice also showed a reduction in lean body mass from the moment 
the pair-feeding was initiated, lower lean body mass in IL-37tg mice is probably a result 
of lower food intake.
How IL-37 might reduce food intake is as yet unknown and would be an interesting 
subject of future investigation. Extracellular IL-37 interacts with IL-1R8 (SIGIRR) and 
IL-18Rα. The latter is also the receptor of the pro-inflammatory cytokine IL-18, which 
is a member of the IL-1 family of cytokines as well [22]. Interestingly, IL-18 deficiency 
leads to increased food intake and body weight. In addition, intracerebral administra-
tion of rIL-18 reduces food intake, suggesting that IL-18 acts centrally [33]. Very recently, 
Francesconi et al. [34] discovered that the IL-18 receptor is highly expressed in the bed 
nucleus of the stria terminalis, a part of the extended amygdala that is known to influ-
ence feeding by projecting on the lateral hypothalamus. It is therefore possible that 
IL-37 inhibits food intake by acting on the IL-18 receptor in the brain. Furthermore we 
cannot exclude the possibility that IL-37 modulates the expression of other cytokines 
and thereby influences food intake.
Whether IL-37 affects food intake in humans, who naturally express IL-37, is unknown. 
IL-37 gene expression in adipose tissue of humans was found to be higher in subjects 
with low adipose tissue leptin protein levels [15], which could suggest that high IL-37 
expression lowers food intake and consequently reduces levels of the satiety hormone 
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leptin in adipose tissue. Elevated IL-37 levels in humans are generally found in pa-
tients with inflammatory diseases such as nonallergic asthma [35] and systemic lupus 
erythematosus (SLE) [36]. SLE patients have indeed been reported to have inadequate 
food intake [37], which would be consistent with higher IL-37, but the complexity and 
versatility of the immune system makes it challenging to attribute this effect to a specific 
inflammatory component. Recent genetic studies on body mass index revealed that a 
majority of the tissues and cell types in which genes near BMI-associated SNPs are highly 
expressed, are part of the central nervous system [38]. This provides strong support for 
an important role of the central nervous system, which contains the key sites of central 
appetite regulation, in obesity susceptibility and therefore highlights the importance of 
research into factors that influence appetite, such as IL-37. Future studies for therapeu-
tics in humans will focus on recombinant IL-37 linked to the Fc domain of mouse IgG1 
(fusion protein), in order to increase the in vivo efficacy of IL-37 on inflammatory and 
immune-mediated diseases.
In conclusion, IL-37 expression in mice reduces food intake, which may underlie the 
beneficial metabolic effects including fat mass reduction that have previously been 
reported in IL-37 transgenic mice. The mechanisms behind these findings and the 
pathophysiological significance of these findings in obesity in humans remain to be 
determined.
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SuPPLEmENTARy APPENDix
Supplementary figure 1. Heterozygous iL-37 expression decreases energy expenditure in conjunc-
tion with lean mass reduction. 10-week old male C57Bl/6J mice and heterozygous IL-37tg mice on a 
C57Bl/6J background were fed a high-fat diet (HFD). From 2 days before initiation of HFD until 1 week 
after the switch to HFD, mice were housed in fully automatic metabolic cages, which measured oxygen 
uptake (VO2) and carbon dioxide production (VCO2). Physical activity (A, B) was measured with infrared sen-
sor frames. Total energy expenditure (C, D) and the energy expenditure were corrected for lean mass (E, 
F) was calculated from VO2 and VCO2 using the Weir equation. Bar graphs were based on calculations of the 
mean from day 1.5 to 7. Values represent means (A, C, E) and bar graphs represent means ± SEM (B, D, F) 
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Brown adipose tissue (BAT) catabolizes glucose and fatty acids to produce heat and 
thereby contributes to energy expenditure. Long-term high fat diet (HFD) feeding 
results in so-called ‘whitening’ of BAT characterized by increased lipid deposition, mi-
tochondrial dysfunction and reduced fat oxidation. The aim of the current study was 
to unravel the rate and related mechanisms by which HFD induces BAT whitening and 
insulin resistance. Wild-type mice were fed a HFD for 0, 1, 3 or 7 days. Within one day of 
HFD BAT weight and lipid content were increased. HFD also immediately reduced insulin-
stimulated glucose uptake by BAT, indicating rapid induction of insulin resistance. This 
was accompanied by a tendency towards a reduced uptake of triglyceride-derived fatty 
acids by BAT after 1 day of HFD. Mitochondrial mass and Ucp1 expression were unaltered, 
while after 3 days of HFD markers of mitochondrial dynamics suggested induction of a 
more fused mitochondrial network. In addition, HFD also increased macrophage mark-
ers in BAT after 3 days of HFD. Counterintuitively, the switch to HFD was accompanied 
by an acute rise in core body temperature. In conclusion, we showed that a single day 
of HFD feeding is sufficient to induce the first signs of whitening and insulin resistance 
in BAT, which reduces the uptake of glucose and triglyceride-derived fatty acids. BAT 
whitening and insulin resistance is likely sustained by reduced mitochondrial oxidation 
due to changes in mitochondrial dynamics and macrophage infiltration, respectively. 
Likely, the switch to HFD swiftly induces thermogenesis in other metabolic organs, 




Obesity results from an imbalance between energy intake and energy expenditure, 
with energy intake exceeding expenditure. In the case of such a positive energy bal-
ance, excess fatty acids (FA) are initially stored in the form of triglycerides (TG) in white 
adipose tissue, and eventually also in other organs such as the liver and skeletal muscles. 
Especially ectopic fat deposition is thought to be an important link between obesity 
and the development of whole-body insulin resistance and, eventually, type 2 diabetes 
(T2D) [1]. 
About a decade ago, energy-combusting brown adipose tissue (BAT) was discovered 
to be present and active in adult humans [2-4]. BAT is seen as a new therapeutic target to 
combat adiposity and T2D because of its large capacity to take up and combust glucose 
and FA for heat production [5-7]. Physiologically, BAT is activated by cold stimulation, 
which results in intracellular lipolysis and release of FA from lipid stores in brown adi-
pocytes [6]. These FA enter the mitochondria where they are broken down and used to 
generate the proton gradient which is dissipated as heat by the action of uncoupling 
protein 1 (UCP-1). The depleted intracellular lipid stores need to be replenished by the 
uptake of TG-derived FA and glucose from the circulation [6] for which insulin signaling 
is required [8]. The proof-of-principle that activation of BAT is indeed capable of reduc-
ing body fat comes from studies in which healthy lean humans were acclimated to cold 
(~16°C) for 2-6 weeks [9, 10], resulting in recruitment and higher activity of BAT, accom-
panied by increased energy expenditure and lowered fat mass. Interestingly, in subjects 
with obesity and/or type 2 diabetes, uptake of the glucose tracer 18F-fluorodeoxyglucose 
(FDG) by BAT as visualized by PET-CT scan is consistently lower when compared to the 
glucose uptake in lean subjects, suggesting development of BAT insulin resistance and 
possibly BAT dysfunction in obesity [4, 11]. 
Indeed, in mice, long-term high fat diet (HFD) feeding results in insulin resistance [12], 
and whitening of BAT [13]. BAT whitening characteristics include increased lipid deposi-
tion, fewer and dysfunctional mitochondria and reduced fat oxidation [14, 15]. Moreover, 
HFD-fed mice have reduced ability to maintain their body temperature when exposed to 
cold. Interestingly, we previously found that during diet-induced obesity (DIO) develop-
ment, BAT weight and BAT lipid content are elevated [16]. However, the speed at which 
BAT whitening and insulin resistance occurs, and what the related mechanisms are, have 
not been extensively studied yet. Therefore, we aimed to study the acute effects of FA 




Animals and diet 
Male wild-type (WT) C57Bl/6J mice (Charles River Laboratories, Wilmington, MA, USA), all 
15-weeks old at sacrifice, were housed under standard conditions in conventional cages. 
Animals were housed in groups of two or three mice per cage in a 12:12 h light:dark cycle 
with ad libitum access to food and water. Based on body weight, mice were randomized 
into 4 groups, that received 0, 1, 3 or 7 days of high fat diet (HFD). Thus, at the age of 14 
weeks, the first group of mice received an HFD (45% kcal fat, 35% kcal carbohydrate, 20% 
kcal protein, Special Diets Services, Witham, UK), other groups still remained on a chow 
diet. The remaining groups started the HFD 3 days or 1 day prior to sacrifice or remained 
on a chow diet (control group). At the day of sacrifice, after 4 hours of fasting, the mice 
were sacrificed by means of cervical dislocation after either an injection with radiola-
beled lipoprotein-like TG-rich emulsion particles (n=10 mice per dietary treatment 
group) or an injection with insulin and radiolabeled 2-deoxy-D-glucose (n=7-8 mice per 
dietary treatment group) (experimental details described below). An additional 3 male 
C57Bl/6J mice (8-weeks old) underwent surgery for placement of a dual-lead telemetry 
transmitter (Stellar Telemetry; TSE Systems Inc.; details explained below). In all analyses 
the interscapular BAT depots were used for analysis unless stated otherwise. 
Whole body Toll-like receptor 4 knockout mice (TLR4-/-), also on a C57Bl/6J background 
(The Jackson Laboratory, Bar Harbor, Maine, USA), were bred locally (LUMC). Male TLR4-/- 
and WT mice were housed under standard conditions as described above and random-
ized into 4 groups based on body weight to receive 0 or 7 days of HFD (n=7-8 mice per 
group). At the day of sacrifice, after 4 hours of fasting the mice were sacrificed by means 
of cervical dislocation and BAT was isolated. 
All mouse experiments were performed in accordance with the Institute for Labora-
tory Animal Research Guide for the Care and Use of Laboratory Animals and have re-
ceived approval from the Departmental Ethical Review Board (Leiden University Medical 
Center, Leiden, the Netherlands).
Body weight and food intake
Body weight was determined before the dietary intervention for randomization and at 
the end of the experiment. Food intake was assessed by daily weighing of the food that 
was added versus left in the cages. 
Plasma parameters
Blood was drawn after 4 hours of fasting in paraoxon (Sigma, St. Louis, MO) coated 
capillaries. Capillaries were immediately placed on ice and centrifuged. Plasma glucose 
was measured using an enzymatic kit from Instruchemie (Delfzijl, the Netherlands) and 
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insulin levels were measured in plasma by ELISA (Crystal Chem Inc., Downers grove, IL, 
USA), following manufacturers’ protocols. The homeostasis model assessment of insulin 
resistance (HOMA-IR) adjusted to rodents was calculated as: ([glucose (mg/dL)/18] × 
[insulin (ng/mL)/0.0347])/108.24.
Histology
BAT and subcutaneous white adipose tissue (sWAT) were dissected and immediately 
fixed in 4% paraformaldehyde for 24 h, overnight dehydrated, embedded in paraffin 
blocks and cut in sections. Hematoxylin-eosin (H-E) staining was performed and the area 
of intracellular lipid droplets in BAT and sWAT was quantified using ImageJ (National 
Institutes of Health). To determine sympathetic activation of BAT, a tyrosine hydroxylase 
(TH) staining was performed. First, sections were rehydrated and incubated with 10 
mM citrate buffer for 15 min (pH 6.0) at 120°C for antigen retrieval. Next, sections were 
blocked with 5% (wt/vol) BSA/PBS followed by overnight incubation with anti-TH anti-
body (1:2000, AB-112; Abcam) at 4°C. The following day, sections were incubated with 
a secondary antibody (anti-rabbit antibody, DAKO enVision), stained with NovaRed and 
counterstained with Mayer’s hematoxylin. Percentage of area positive for TH staining 
was quantified using ImageJ software.
In vivo glucose uptake upon insulin stimulation
Mice were fasted for 4 h and injected via the tail vein with 1 µCi 2-[1-14C]-deoxy-D-glu-
cose (Perkin Elmer) and 0.5 U/kg body weight insulin (NovoRapid, Novo Nordisk). After 
15 min, mice were sacrificed by cervical dislocation and liver, BAT, gonadal WAT (gWAT), 
sWAT and quadriceps muscle were isolated. Organs were dissolved overnight at 60°C 
in Solvable (Perkin Elmer, Waltham, MA, USA), and the uptake of [14C]-2-deoxyglucose-
derived radioactivity was quantified and expressed per gram wet tissue weight.
Protein isolation and western blot
Snap-frozen BAT samples were lysed in ice-cold buffer containing 50 mmol/L HEPES (pH 
7.6), 50 mmol/L KCl, 50 mmol/L NaF, 5 mmol/L NaPPi, 1 mmol/L EDTA, 1 mmol/L EGTA, 
1 mmol/L dithiothreitol, 5 mmol/L β-glycerophosphate, 1 mmol/L vanadate, 1% NP40 
and protease inhibitors cocktail (cOmplete; Roche). LPL western blots were performed 
using 8 µg of protein/lane as described previously [17]. For western blots of the mito-
chondrial dynamics markers, 20 μg protein/lane were separated on a 10% SDS-PAGE gel 
and transferred onto nitrocellulose blotting membranes by means of Trans-Blot Turbo 
blotting (Bio-Rad). Blotting membranes were blocked with 5% BSA for the pDRP1Ser637 
antibody and with 5% milk powder for the LPL, MFN2, OPA1, and FIS1 antibodies. After 
overnight incubation with primary antibodies at 4°C, blots were incubated with the 
secondary antibody (anti-rabbit IgG HRP conjugate; 1:5,000; Promega; 1:5000 rabbit 
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anti-goat secondary Ab (LPL)) for 1 h at room temperature. SuperSignal Western Blot 
Enhancer (Thermo Scientific) was added and proteins band were visualized using a Bio-
Rad Imaging system (ChemiDoc Touch, Bio-Rad). Analysis was performed using Bio-Rad 
Image Lab v5.2 software. 
Lysates of 0.8 mg/mL protein extracted from BAT samples obtained after insulin injec-
tion were used for western blot using the Wes ProteinSimple apparatus to determine PKB, 
pPKBSer473, PDHE1α and pPDHE1αSer232 content according to manufacturer’s protocol. Data 
were normalized to GAPDH or Tubulin. The primary antibodies used are given in Table 1. 
In vivo clearance of radiolabeled lipoprotein-like emulsion particles
Lipoprotein-like particles (80 nm) labeled with glycerol tri[3H]oleate (Perkin Elmer, 
Waltham, MA, USA) were prepared and characterized as described previously [18]. To 
study the in vivo clearance of the lipoprotein-like particles, mice were fasted for 4 h (from 
8.00 to 12.00h) and injected via the tail vein with 200 μL of emulsion particles (1.0 mg TG 
per mouse). After 15 minutes, mice were cervically dislocated and perfused with ice-cold 
PBS with 10 U/mL heparin via the heart for 5 min. Subsequently, the liver, heart, spleen, 
quadriceps muscle, gastrocnemius muscle, gWAT, sWAT, and BAT were collected. Organs 
were dissolved overnight at 60°C in Solvable (Perkin Elmer, Waltham, MA, USA), and the 
uptake of glycerol tri[3H]oleate-derived radioactivity was quantified and expressed per 
gram wet tissue weight.
RNA isolation and RT-PCR analysis
Tissue and cells were lysed in TriPure (Roche) for RNA isolation. For cDNA synthesis, 1 µg 
of RNA was reverse-transcribed using Promega solutions kit (Promega). Real-time PCR 
Table 1. Primary antibodies for western blot
Primary antibody Residue Supplier Reference Dilution
FIS1 - Atlas Antibodies HPA017430 1:1000
GAPDH - Santa Cruz #25778 1:50 (Wes ProteinSimple)
1:1000 (Western blot)
MFN2 - Cell Signaling #9482 1:1000
OPA1 - Cell Signaling #67589 1:1000
PDHE1α - Abcam #ab67592 1:50
pPDHE1α Ser232 Calbiochem AP1063 1:50
pDRP1 Ser637 Cell Signaling #6319 1:1000
PKB - Millipore #07-416 1:50
pPKB Ser473 Cell Signaling #9271 1:100
α/β Tubulin Cell Signaling #2148 1:1000





(RT-PCR) was carried out on a CFX96 PCR machine (Bio-Rad) using SYBR green (Promega). 
mRNA expression was normalized to Beta2-microglobulin (B2m) as housekeeping gene 
and expressed as a fold change compared to the 0 days of HFD (control) group using the 
ΔΔCT method. The primer sequences are listed in Table 2. 
Citrate synthase activity measurement
Subscapular BAT was homogenized by sonication in ice cold PBS and diluted to 0.3 mg/
mL protein (using Pierce BCA Protein Assay Kit, Thermo Scientific). Citrate synthase activ-
ity was determined using a colorimetric assay, in which citrate synthase catalyzes the 
formation of citric acid and CoA-SH from acetyl CoA and oxaloacetic acid. The formation 
of CoA-SH is coupled to a chemical reaction with DTNB which is spectrophotometrically 
measured at 412 nm. The absorbance intensity is proportional to the citrate synthase ac-
tivity. Reactions were performed at 37°C using Tecan Freedom EVO100 and a Tecan Infinite 
200 PRO plate reader. The reaction mix contained 10-30 µg/mL sample, 100 mM Tris-HCl 
Table 2. Primer sequences of forward and reverse primers for RT-PCR





















Tlr4 (Fig 4A) TCAGAACTTCAGTGGCTGGA GAGGCCAATTTTGTCTCCAC
Tlr4 (Suppl. Fig. 2) ACCTGGCTGGTTTACACGTC CTGCCAGAGACATTGCAGAA
Ucp1 TCAGGATTGGCCTCTACGAC TGCATTCTGACCTTCACGAC
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pH 7.6, 100 mM KCl, 100 µM DTNB, 200 µM Acetyl-CoA and 0.1% (w/v) Triton X-100 and 
was started by the addition of 200 µM oxaloacetic acid, reaching the final reaction volume 
of 250 µL. Citrate synthase activity expressed in mmol/min/mg was calculated based on 
Lambert-Beer’s law using the slope of the reaction (i.e. absorbance change per minute).
Determination of mtDNA/nDNA ratio
Total DNA was isolated from BAT with QIAamp DNA Mini Kit (no. 51306; Qiagen, Hilden 
Germany) following the provided manufacturer’s protocol. The PCR reaction was per-
formed in a LightCycler 480 (Roche). The reaction mix contained 500 pg DNA, 1.25 µM 
forward and reverse primer, and 4 µL 2x SYBR green master mix (Roche) in a final volume 
of 8 µL. 16S and Cox2 were used as mitochondrial encoded genes, Hk2 and Ucp2 for 
nuclear encoded genes. Primer sequences are listed in Table 3. Data were analyzed with 
LightCycler software release 1.5.0 (Roche). The mean PCR efficiency was calculated to 
assess gene expression levels using LinRegPCR program version 12.17 [19]. 
Telemetry measurements
WT mice were pre-operatively anaesthetized and a midline incision was made to expose 
the abdominal cavity after which a dual-lead telemetry transmitter (Stellar Telemetry; TSE 
Systems Inc.) was subcutaneously inserted. The first lead was inserted in the abdominal 
cavity and an additional incision was made between the shoulder blades to be able to 
insert the second lead below the left lobe of the interscapular BAT and sutured to the sur-
rounding tissue. Both incisions were sutured before the anesthetics were antagonized. 
After a recovery period of one week, a one-day baseline measurement was performed. 
Subsequently, mice were fed a HFD for 7 days while core body temperature and BAT tem-
perature were being registered with a sampling duration of 6 seconds and a frequency of 
200 Hz at an interval of 15 min in AcqKnowledge software (Biopac Systems Inc.).
Statistical analysis
Data are presented as means ± SEM. Differences between the 1, 3, 7 days HFD groups 
compared the 0 days HFD (control) group in WT mice were determined using ANOVA 
with Dunnett’s post hoc test. Differences between 0 and 7 days HFD in TLR4-/- and WT 
mice were determined using a two-tailed unpaired Student’s t-test in each genotype. 
Table 3. DNA primer sequences of forward and reverse primers for PCR 







Data analysis was performed with SPSS v20 software package for Windows (SPSS, Chi-
cago, USA). Differences at P values < 0.05 were considered statistically significant.
RESuLTS
HFD feeding increases BAT weight and lipid content within 1 day
To investigate the short-term effect of HFD feeding on lipid accumulation in BAT, WT 
mice were fed a HFD for 0, 1, 3 or 7 days. HFD feeding markedly increased fat mass, 
reaching statistical significance after 7 days (+99%, P<0.001, Fig. 1A), while lean mass 
was not affected. Even though HFD did not significantly increase plasma glucose levels 
(Fig. 1B), it transiently increased insulin levels and HOMA-IR which peaked after 1 day of 
HFD feeding (+84%, P<0.001, Fig. 1C  and +115%, P<0.001, Fig. 1D, respectively). Also 
within 1 day of HFD feeding, BAT weight increased (+29%, P<0.05, Fig. 1E) and remained 
elevated up to 7 days of HFD. Histological sections of BAT showed that the increase in 
Figure 1. High fat diet feeding rapidly increases plasma insulin, BAT weight and BAT lipid content. 
Male wild-type mice were fed a HFD for 0, 1, 3 or 7 days to study the short-term effect of a HFD on brown 
fat. Body composition (i.e. lean and fat mass, g) was measured at the end of the dietary interventions (A). 
Plasma glucose (B) and insulin (C) were measured after a four hour fast and used to calculate HOMA-IR 
(D). BAT weight (E) was determined at the end of the dietary intervention. Representative pictures of BAT 
stained with hematoxylin and eosin are shown (F, bars indicate 50 µm) and BAT lipid content (G) was quanti-
fied by use of ImageJ. Values are mean ± SEM (n=9-10). * P<0.05, ** P<0.01 and *** P<0.001 compared to 
the control group. BAT, brown adipose tissue; HFD, high fat diet; HOMA-IR, homeostasis model assessment 
of insulin resistance.
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BAT weight was due to increased lipid content (+35%, P<0.01, Fig. 1F, g) already after 
1 day. Besides BAT, short-term HFD also increased weight of other metabolic organs, 
including liver (Suppl. Fig. 1A), gWAT (Suppl. Fig. 1B) as well as lipid content in sWAT 
(Suppl. Fig. 1C).
HFD feeding rapidly decreases insulin-stimulated glucose uptake by BAT
Accumulation of intracellular lipids can directly interfere with insulin signaling [20]. To 
determine whether short-term HFD feeding impairs insulin signaling, we injected WT 
mice that were fed a HFD for 0, 1, 3 or 7 days with insulin and 2-[1-14C]-deoxy-D-glucose 
and measured the uptake of the radiolabel in various metabolic organs. Interestingly, HFD 
feeding markedly decreased the insulin-stimulated uptake of 2-[1-14C]-deoxy-D-glucose 
by BAT after 1 day of HFD feeding (-61%, P<0.001, Fig. 2A). We next determined protein 
content of insulin-induced phosphorylation of protein kinase B (PKB) and pPKBSer473 
tended to increase after 1 day HFD and thereafter tended to decrease compared to the 
Figure 2. High fat diet feeding rapidly decreases insulin-stimulated glucose uptake by BAT. Mice were 
fasted for four hours and injected with insulin and 2-[1-14C]-deoxy-D-glucose and uptake per gram organ 
(A) was determined by [14C]-activity analysis. Protein levels of PKB, phosphorylation (p) state of Ser473-PKB, 
PDH and phosphorylation (p) state of Ser232-PDH were determined in insulin stimulated BAT and were 
normalized to GAPDH (B). The phosphorylated-to-total ratios of pPKBSer473/PKB (C) and pPDHSer232/PDH (D) 
were calculated and expressed as fold change relative to the 0 days of HFD group. Values are mean ± SEM 
(A, F; n=9-10, B-E; n=6-8); * P<0.05, ** P<0.01 and *** P<0.001 compared to the control group. HFD, high fat 
diet; BAT, brown adipose tissue; gWAT, gonadal white adipose tissue; PDH, pyruvate dehydrogenase; PKB, 
protein kinase B; sWAT, subcutaneous white adipose tissue.
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chow fed group (Fig. 2B, C). Because we recently showed that pyruvate dehydrogenase 
(PDH) plays a central role in glucose utilization during brown adipocyte activation [21], 
we determined protein content of PDH and its inactive phosphorylated form pPDHSer232. 
We found increased pPDHSer232/PDH after 3 days of HFD (+51%, P<0.01, Fig. 2B, D). These 
data point towards a rapid reduction in BAT insulin sensitivity upon HFD feeding.
HFD feeding tends to decrease Tg-derived FA uptake by BAT
A recent study revealed that insulin signaling is required for TG-derived FA uptake by 
BAT [8]. Therefore, we next studied lipid uptake by BAT by injecting 4h fasted mice with 
glycerol tri[3H]oleate-labeled lipoprotein-like particles. The HFD fed groups showed 
a tendency towards a decreased uptake of [3H]oleate by BAT (P=0.067, Fig. 3A). BAT 
Cd36 expression increased after 3 days of HFD feeding (+66%, P<0.001, Fig. 3B), while 
Lpl expression remained unchanged (Fig. 3B). In line with the decreased uptake of TG-
derived FA by BAT, expression of the LPL inhibitor Angptl4 progressively increased upon 
HFD feeding (up to +138% at 7 days, P<0.01, Fig. 3B), and protein content of LPL in BAT 
decreased (Fig 3C).
Figure 3. High fat diet feeding tends to decrease Tg-derived FA uptake by BAT, accompanied by de-
creased LPL in BAT. Mice were fasted for 4 hours, injected with glycerol tri[3H]oleate-labeled lipoprotein-
like particles, and after 15 min uptake of 3H was determined per gram organ (A). Also, expression in BAT 
was determined of genes involved in lipid uptake (Cd36, Lpl, Angptl4), lipolysis (Atgl, Hsl) and lipogenesis 
(Srebp1c, Fasn and Acaca) (B) and expressed as fold change relative to the 0 days of HFD group. Protein lev-
els of LPL were determined in BAT by western blot (C). Coomassie Blue staining served as loading control. 
Values are mean ± SEM (n=9-10 in A-B; n=5 in C); expression of genes was corrected for the housekeeping 
gene β2m, * P<0.05, ** P<0.01 and *** P<0.001 compared to the control group. BAT, brown adipose tissue; 
gWAT, gonadal white adipose tissue; HFD, high fat diet; LPL, lipoprotein lipase; sWAT, subcutaneous white 
adipose tissue.
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We reasoned that the increased lipid accumulation in BAT upon short-term HFD feed-
ing could be the result of, or sustained by, several processes. These include (a) decreased 
intracellular lipolysis, (b) increased lipogenesis and/or (c) decreased oxidation of lipids 
due to decreased BAT activity. Therefore, we next determined gene expression of adi-
pose TG lipase (Atgl) and hormone-sensitive lipase (Hsl), both involved in intracellular 
lipolysis in BAT. We found an increased rather than decreased Hsl expression, up to +61% 
after 7 days of HFD (P<0.01, Fig. 3B). The expression of genes involved in de novo lipo-
genesis were not consistently up- or downregulated except for an increased expression 
of sterol regulatory element -binding protein 1c (Srebp1c) from 3 days HFD onwards 
(+222%, P<0.01, Fig. 3B). Fatty acid synthase (Fasn) expression was downregulated after 
3 days of 3B). Thus, the rapid increase in BAT lipid content upon HFD is unlikely to be 
explained by increased uptake of TG-derived FA by BAT, decreased intracellular lipolysis 
or increased lipogenesis.
HFD feeding increases mitochondrial dynamics markers
We next investigated whether decreased mitochondrial functional capacity could 
contribute to the increased lipid content in BAT. The expression of Ucp1 remained 
unchanged while expression of the mitochondrial biogenesis gene Ppargc1a was mark-
edly downregulated after 3 and 7 days HFD (up to -77%, P<0.01, Fig 4A). To determine 
whether the decreased Ppargc1a expression resulted in a decreased mitochondrial 
content, we next determined citrate synthase activity (Fig. 4B) and mtDNA/nDNA ratio 
(Fig. 4C), both of which were unchanged. Instead, we hypothesized that mitochondrial 
network morphology might be altered given that insulin resistance affects mitochon-
drial dynamics [22-24]. Mitochondrial fusion genes Mfn2 and Opa1 increased up to 
+117% and +51% and the mitochondrial fragmentation gene Fis1 increased up to + 
59% after 7 days of HFD (Fig. 4D). Furthermore, we found increased protein content of 
the pro-fusion long form of OPA1 (top band, +40% after 7 days of HFD, P<0.05, Fig. 4E, 
Suppl. Fig. 2A), whereas OPA1 short form remained unchanged (lower band, Fig. 4F). 
The phosphorylated form of DRP1 that inhibits mitochondrial fission (pDRP1Ser637) in-
creased up to +40% (P<0.01, Fig. 3g, Suppl. Fig. 2A) after 7 days of HFD. Protein content 
of MFN2 and FIS1 was unaltered by the HFD (Suppl. Fig. 2B-D). Mitochondrial dynamics 
has also been shown to be influenced by sympathetic nervous system activation of BAT 
[25], therefore we studied whether sympathetic outflow towards BAT was changed. To 
this end, we stained BAT slices for tyrosine hydroxylase (TH), the rate limiting enzyme 
in the synthesis of norepinephrine and found no difference in TH levels upon HFD 
(Suppl. Fig. 3A-C). These data imply that short term HFD does not affect mitochondrial 
content but rather alters the mitochondrial network morphology to a more fused state 
which might underlie a decreased activity of BAT with respect to FA oxidation (FAO). 
Therefore, we next determined the expression of acetyl-CoA carboxylase 2 (Acacb) and 
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carnitine palmitoyltransferase 1A (Cpt1a), both involved in FAO, and glucose transporter 
type 4 (Slc2a4) and hexokinase 1 (Hk1), both involved in carbohydrate oxidation (CHO). 
Counterintuitively, after 1 day HFD Cpt1a expression and Hk1 expression were increased 
(+51%, P<0.01, and +49%, P<0.01, respectively, Fig. 4H). These data suggest that whit-
ening causes a compensatory upregulation of genes involved in nutrient oxidation.
Figure 4. High fat diet feeding increases mitochondrial dynamics markers in BAT. In BAT, expression 
was determined of Ucp1, Ppargc1a (A), Mfn2, Opa1, Fis1, Dnm1l (D), Acacb, Cpt1a, Slc2a4, and Hk1 (H), and 
expressed as fold change relative to the control group. Citrate synthase activity (B) and mitochondrial DNA 
(mtDNA) versus nuclear DNA (nDNA) ratio (C) was determined in BAT. Protein levels of OPA1 top band (E), 
OPA1 lower band (F) and pDRP1Ser637 (G) in BAT were normalized to GAPDH and expressed relative to the 
0 days of HFD group. Values are mean ± SEM (n=9-10 in A-H); expression of genes was corrected for the 
housekeeping gene β2m, * P<0.05, ** P<0.01 and *** P<0.001 compared to the control group. CHO, carbo-
hydrate oxidation; FAO, fatty acid oxidation; HFD, high fat diet; mtDNA, mitochondrial DNA; nDNA, nuclear 
DNA.
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HFD induced lipid accumulation in BAT is not prevented by the absence of TLR4
HFD feeding results in an overload of FA that are not only able to induce lipid accumula-
tion but also able to induce local inflammation, which is associated with reduced func-
tion of several organs including muscle and liver, and possibly also BAT [26]. Therefore, 
we next assessed inflammatory markers in BAT and found increased expression of the 
macrophage markers F4/80 and Cd68 from 3 days HFD feeding on (up to +57%, P<0.01 
and +51%, P<0.05, respectively, Fig. 5A). Furthermore, the gene encoding toll-like 
receptor 4 (Tlr4), involved in several inflammatory pathways in cells, was increased in 
BAT (up to +112% after 7 days; P<0.001, Fig. 5A). To assess whether intact TLR4 signaling 
is a prerequisite for HFD induced lipid accumulation in BAT, both WT and TLR4-/- mice 
were placed on either a chow or HFD for 7 days. We reproduced that Tlr4 expression was 
Figure 5. High fat diet feeding rapidly increases the expression of macrophage markers and Tlr4 
in BAT however, the absence of TLR4 does not protect from high fat diet induced lipid deposition 
in BAT. Gene expression in BAT was determined of F4/80, Cd68 and Tlr4 (A) and expressed as fold change 
relative to the 0 days of HFD group. Wild-type (WT) and TLR4-/- mice were fed a chow or a HFD for 7 days 
to study the involvement of TLR4 in the effect of a HFD on BAT. Body composition (B) in lean and fat mass 
(g) and BAT weight (C) (g) were measured at the end of the dietary intervention. Representative pictures of 
BAT stained with hematoxylin and eosin are shown (D, bars indicate 50 µm) and BAT lipid content (E) was 
quantified by use of ImageJ. Values are mean ± SEM (A; n=9-10, B-E; n=7-8). Expression of genes was cor-
rected for the housekeeping gene B2m * P<0.05, ** P<0.01 and *** P<0.001 indicates significant differences 
between chow and HFD fed in WT mice. # P<0.05 and ## P<0.01 indicated significant differences between 




increased in WT mice upon HFD whereas Tlr4 was undetectable in TLR4-/- mice (Suppl. 
Fig. 4). In both genotypes, 7 days of HFD feeding increased total fat mass (Fig. 5B), BAT 
weight (Fig 5C) and BAT lipid content (Fig 5D, E) compared to the chow diet fed groups. 
These data imply that the HFD-induced lipid accumulation in BAT is not mediated by 
TLR4. 
HFD feeding immediately increases core body temperature
Next, we determined core body and BAT temperature simultaneously using a dual lead 
telemetry system in WT mice. Temperature was recorded during 1 day on a chow diet 
after which the animals were switched to a HFD for 7 days (Fig. 6). Core body tempera-
ture showed a clear circadian rhythm. After the switch to the HFD, the body temperature 
increased, most pronounced during the light phase, and amplitude of the oscillation 
slightly decreased for 3 days (Fig. 6). Counterintuitively, BAT temperature accurately fol-
lowed the core body temperature. Since whitening and insulin resistance of BAT and the 
fused mitochondrial network within BAT all suggest lowered BAT activity, the increase in 
core body temperature after the switch to HFD is probably caused by increased whole-
body thermogenesis, which indirectly increases the temperature measured in BAT.
DiSCuSSiON
Long-term HFD feeding has been shown to result in BAT dysfunction associated with 
tissue-specific whitening, impaired insulin sensitivity, reduced functional mitochondria, 
and disturbed thermoregulation [12, 13]. In this study, we showed that the first signs of 
BAT whitening occur already within a single day of HFD feeding, accompanied by insulin 
resistance of BAT with respect to uptake of glucose and FA. Secondarily, HFD feeding 
Figure 6. High fat diet feeding immediately increases core body temperature. Mice were implanted 
with a dual-lead telemetry transmitter and core body temperature (black line) and BAT temperature (gray 
line) were measured during 1 day before and 7 days after a switch from chow to a HFD. Values are mean ± 
SEM (n=3). BAT, brown adipose tissue; HFD, high fat diet.
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increases mitochondrial fusion markers and influx of macrophages, both contributing to 
a sustained reduced BAT functionality and accumulation of lipids within BAT.
One of the most striking findings of the current study is the rapid lipid accumulation 
within BAT that occurred upon only one day of HFD feeding. It is likely that the initial 
whitening is caused by an initial rapid influx of FA into metabolic organs including BAT 
upon HFD feeding. We recently showed that lipid deposition in BAT rapidly drives the 
synthesis of endocannabinoids, with increased expression of endocannabinoid synthe-
sis enzymes within one week [16]. Even though we now observed that HFD does not 
affect sympathetic outflow to BAT, as TH levels were unchanged, locally synthesized 
endocannabinoids might inhibit noradrenergic signaling in brown adipocytes [27]. Re-
duced noradrenergic signaling probably sustains whitening by inhibiting the liberation 
of intracellular FA from lipid droplets for FAO and thermogenesis [28]. Whitening was 
associated with a rapid and marked decrease in insulin-stimulated glucose uptake by 
BAT, suggesting impaired insulin sensitivity already after one day of HFD feeding. Rapid 
insulin resistance is probably caused by intracellular accumulation of lipids that interfere 
with the insulin signaling cascade [20]. Recently, proper insulin signaling appeared to be 
also crucial for the uptake of TG-derived FA uptake by BAT [8]. Indeed, we now showed 
that the uptake of TG-derived FA by BAT after a bolus of injected TG-rich lipoproteins is 
rapidly reduced (Fig. 7). In line with this, we observed an increased Angptl4 expression 
and decreased LPL content in BAT after HFD feeding. Taken together, HFD feeding likely 
causes immediate lipid accumulation in BAT, which probably drives endocannabinoid 
synthesis by and insulin resistance in BAT, as a consequence of which the uptake of 
circulating glucose and TG-derived FA by BAT is decreased.
Besides whitening, we obtained evidence for altered mitochondrial function in BAT 
after HFD feeding. While we did not observe an effect of HFD on mitochondrial mass, 
we did show an increased expression of Mfn2 and Opa1, accompanied by an increased 
long form OPA1 and pDRP1Ser637, suggesting a more fused mitochondrial network [29, 
30] after three days of HFD feeding (Fig. 7). Interestingly, BAT activation usually results 
in fragmentation of the mitochondrial network [25, 31]. In fact, in vitro experiments 
with brown adipocytes showed that mitochondrial fragmentation is a prerequisite 
for norepinephrine-induced uncoupling of mitochondrial oxidative phosphorylation 
[25]. Norepinephrine-induced BAT mitochondrial fission is hypothesized to increase 
mitochondrial sensitivity to FA, thereby increasing BAT uncoupling potential [32]. On 
the other hand, long-term HFD feeding of mice results in less and dysfunctional mi-
tochondria in BAT, rendering mice less cold tolerant [13]. Thus, in the short-term HFD 
fed condition as applied in our study, a higher degree of fused mitochondrial network 
might contribute to decreased mitochondrial surface area and BAT activity, leading to a 
sustained intracellular accumulation of TG within lipid droplets.
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After three days of HFD feeding, we observed increased F4/80 and Cd68 expression in 
BAT, which might indicate an influx of monocyte-derived macrophages into the tissue. 
This is consistent with data of a mouse model showing that hyperlipidemia promotes the 
infiltration of monocytes into peripheral tissues [33], by lipid-induced monocyte activa-
tion and/or increased tissue expression of chemotactic factors. Likewise, ingestion of a 
high fat, high caloric diet by humans for only five days increases macrophage markers in 
muscle [34]. Infiltration of macrophages in BAT is known to induce insulin resistance via 
the secretion of inflammatory cytokines [12]. Roberts-Toler et al. [12] showed that insulin 
resistance is associated with decreased uptake of insulin-stimulated glucose in HFD fed 
mice accompanied by decreased BAT insulin signaling via PKB. In contrast, cold induced 
BAT activation leads to increased pPKBSer473 levels and subsequent glucose uptake by 
BAT [35]. We found that HFD feeding tended to increase the insulin-stimulated pPKBSer473 
after one day and thereafter its content tended to decrease in BAT. Therefore, reduced 
PKB activity might have added to a lower glucose uptake after three days HFD. However, 
in the present study the rise in macrophage markers expression in BAT occurred only 
after the onset of reduction in insulin-stimulated glucose uptake. This suggests that the 
initial reduction in insulin sensitivity is not due to enhanced local inflammation, but 
that the inflammation is rather involved in sustained insulin resistance (Fig. 7). This is in 
agreement with previous findings of Shimobayashi et al. [36], who recently showed that 
obesity-mediated insulin resistance precedes WAT inflammation. The hypothesis that 
inflammation is not involved in the immediate lipid accumulation and insulin resistance 
is further corroborated by the fact that an intact TLR4 axis was not required for the lipid 
accumulation by BAT since TLR4-/- mice also showed whitening of BAT upon short-term 
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Figure 7. Schematic representation of the high fat diet induced effects in time. Different measures 
represented as approximate effects relative to 0 days of HFD feeding over the time course of 7 days. Dashed 
lines indicate gene expression patterns in BAT, solid lines indicate either measures in BAT or plasma insu-
lin levels. The blue area around the middle line indicates non-significant effects compared to the control 
group. BAT, brown adipose tissue; FA, fatty acid; HFD, high fat diet; TG, triglyceride.
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HFD feeding. Although TLR4 plays an important role between immunity and insulin 
resistance [37], the initial lipid accumulation in BAT is thus unlikely to involve increased 
local inflammation.
Despite the fact that HFD rapidly inactivates BAT, we found that core body tem-
perature immediately increased after the switch to a HFD. This is in line with previously 
observed rapid increases in core body temperature [38, 39] and energy expenditure [40] 
after switching to HFD feeding. A switch to HFD feeding not only leads to a high flux 
of FA to BAT, but also to other metabolic tissues including intestine and liver. Indeed, 
we observed that liver weight was increased already after one day of HFD. It should be 
realized that, in contrast to intestinal absorption of glucose, absorption of TG requires 
breakdown in 2-monoacylglycerol and FA, which are re-esterified within enterocytes 
and packed into chylomicrons. These in turn deliver FA to extrahepatic tissues after LPL-
mediated breakdown to glycerol and FA, and to the liver where TG are broken down and 
partly reassembled [41, 42]. All of these combined catabolic and anabolic reactions are 
exothermic processes generating heat [43]. The fact that both telemetry-leads, in the 
abdominal cavity and in BAT, measured similar increased temperatures might thus be 
the result of thermogenesis through exothermic processes in organs other than BAT 
(e.g. in intestine and liver) coupled to delivery of blood with increased temperature to 
BAT via efficient perfusion. Although the increase in body temperature is relatively small, 
the slightly higher temperature of the blood perfusing BAT might decrease activation 
of temperature sensitive transient receptor potential (TRP) channels in BAT thereby de-
creasing BAT activity [44]. In fact, locally produced endocannabinoids might also partly 
deactivate BAT via TRP channels of the vanilloid subfamily [45].
In conclusion, HFD feeding rapidly induces whitening and insulin resistance of BAT 
within one day, accompanied by decreased uptake of glucose and TG-derived FA. Sec-
ondarily, HFD feeding promotes a fused BAT mitochondrial network, an influx of macro-
phages and heat production by other metabolic organs, all contributing to a sustained 
reduced BAT functionality and accumulation of lipids within BAT.
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Supplementary figure 1. High fat diet feeding increases liver weight, gWAT weight and sWAT lipid 
content. Weight (g) of the liver (A) and gWAT (B) was measured at the end of the dietary interventions. 
sWAT sections were stained with hematoxylin and used to quantify lipid content (C) by use of ImageJ. Val-
ues are mean ± SEM (n=9-10); * P<0.05 and *** P<0.001 compared to the control group. HFD, high fat diet; 
gWAT, gonadal white adipose tissue; sWAT, subcutaneous white adipose tissue.
Supplementary figure 2. High fat diet feeding does not affect mFN2 and FiS1 protein content in BAT. 
Protein levels of OPA1, pDRP1Ser637, GAPDH (A), MFN2, FIS1 and tubulin (B) in BAT were determined and 
representative bands are shown. Protein levels of MFN2 (C), FIS1 (D) were normalized to tubulin and shown 
as relative to the control group. Values are mean ± SEM (n=9-10); HFD, high fat diet.
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Supplementary figure 3. High fat diet feeding does not affect sympathetic outflow to BAT. BAT sec-
tions were stained for tyrosine hydroxylase (TH). Representative pictures are shown (A, bar indicates 50µm). 
Stained sections were quantified using ImageJ and shown as percentage staining per area (B) and per 
whole BAT pad (C) relative to the control group. Values are mean ± SEM (n=9-10). HFD, high fat diet; BAT, 
brown adipose tissue; TH, tyrosine hydroxylase.
Supplementary figure 4. Tlr4 expression is absent in TLR-/- mice and increased upon high fat diet 
feeding in wild-type mice. Wild-type and TLR4-/- mice were fed a chow or a HFD for 7 days to study the 
involvement of TLR4 in the effect of a HFD on brown fat. Tlr4 expression in BAT was determined. Values are 
mean ± SEM (n=7-8). Gene expression was corrected for the housekeeping gene B2m. ** P<0.01 indicates 
significant differences between chow and HFD fed in WT mice. HFD, high fat diet; ND, not detectable; TLR4, 
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ABSTRACT
The endocannabinoid system (ECS) controls energy balance by regulating both energy 
intake and energy expenditure. Endocannabinoid levels are elevated in obesity suggest-
ing a potential causal relationship. This study aimed to elucidate the rate of dysregula-
tion of the ECS, and the metabolic organs involved, in diet-induced obesity. Eight groups 
of age-matched male C57Bl/6J mice were randomized to receive a chow diet (control) 
or receive a high fat diet (HFD, 45% of calories derived from fat) ranging from 1 day up 
to 18 weeks before euthanasia. Plasma levels of the endocannabinoids 2-AG and AEA, 
and related N-acylethanolamines, were quantified by UPLC-MS/MS and gene expression 
of components of the ECS was determined in liver, muscle, white adipose tissue (WAT) 
and brown adipose tissue (BAT) during the course of diet-induced obesity development. 
HFD feeding gradually increased 2-AG (+132% within 4 weeks, P<0.05), accompanied by 
upregulated expression of its synthesizing enzymes Daglα and ß in WAT and BAT. HFD 
also rapidly increased AEA (+81% within 1 week, P<0.01), accompanied by increased 
expression of its synthesizing enzyme Nape-pld, specifically in BAT. Interestingly, Nape-
pld expression in BAT correlated with plasma AEA levels (R2=0.171, β=0.276, P<0.001). 
We conclude that a HFD rapidly activates adipose tissue depots to increase the synthesis 





Obesity is becoming a global epidemic and the need for development of novel 
therapeutic interventions is high. The endocannabinoid system (ECS) is regarded as a 
potential therapeutic target since it regulates energy balance by influencing appetite 
[1, 2], intracellular lipolysis and energy expenditure (reviewed in [3, 4]). The ECS con-
sists of cannabinoid receptors, their endogenous ligands, the endocannabinoids, and 
the enzymes that synthesize and degrade the endocannabinoids. The cannabinoid 
receptors are G-protein-coupled receptors, comprising the cannabinoid receptor type 
1 (CB1R) and cannabinoid receptor type 2 (CB2R). The CB1R is expressed centrally and in 
peripheral metabolic tissues including white adipose tissue (WAT), brown adipose tissue 
(BAT), liver, skeletal muscle and the pancreas. In contrast, the CB2R is mainly expressed 
in immune cells [5].
The two main circulating endocannabinoids are anandamide (N-arachidonoyl-etha-
nolamine, AEA) and 2-arachidonoylglycerol (2-AG). Although they are both derived from 
cell membrane arachidonic acid derivatives, the levels of these endocannabinoids are 
differentially regulated. AEA can be generated via hydrolysis of N-acyl-phosphatidyleth-
anolamines (NAPE) by a NAPE-specific phospholipase D (NAPE-PLD) and its degradation 
is primarily regulated by fatty acid amide hydrolase (FAAH). 2-AG levels are regulated by 
the biosynthesis enzymes diacylglycerol lipase α and β (DAGL-α and β) and the degrada-
tion enzyme mono-acylglycerol lipase (MAGL) [6-8].
Activation of the CB1R in peripheral tissues inhibits fatty acid oxidation resulting in 
a positive energy balance and thus development of obesity in mice [9-11]. In addition, 
an increased tone of the ECS is associated with obesity in humans [12, 13]. Efforts have 
been made to reverse obesity by blocking the CB1R by small molecules such as the 
inverse agonist rimonabant [14]. Albeit that rimonabant was effective in humans as evi-
dent from sustained weight loss and reduction of dyslipidemia, centrally mediated side 
effects resulted in removal from the market [15, 16]. Nevertheless, blocking the actions 
of the ECS is still regarded a potent therapeutic strategy (reviewed in [17, 18]).
To develop novel therapeutics that target specific aspects of the ECS, it is crucial to 
obtain more insight in how fast and in which organs the dysregulation of the ECS sets 
off. In this study, we aimed at elucidating these questions by exposing mice to a high 
fat diet (HFD) ranging from one day up to 18 weeks, which finally causes diet-induced 
obesity (DIO). We analyzed endocannabinoid levels in plasma as well as the expression 





Eighty-six 7-week old male C57B1/6J mice (Charles River Laboratories, USA) were ob-
tained. All mice were group housed (3-4 mice per cage) under a 12h:12h light-dark cycle 
with ad libitum access to food and water. During the course of the experiment 7 out of 8 
groups of mice were switched from a regular chow diet (Special Diets Services, UK) to a 
high fat diet (HFD; 45% kcal fat, 35% kcal carbohydrate, 20% kcal protein, Special Diets 
Services, UK) in such a way that all mice were 25 weeks of age at the time of euthanasia. 
In total, the study consisted of 8 groups receiving HFD for 0 days (control group, remain-
ing on a regular chow diet), 1 day, 3 days, 1, 2, 4, 10 and 18 weeks (n=10-11 per group). 
At the end of the study, mice were fasted overnight and subsequently euthanized by 
an injection with 0.25 mg ketamine and 0.05 mg xylazine per gram body weight. Blood 
was collected via a cardiac puncture with EDTA filled syringes and several organs (liver, 
quadriceps muscle, gonadal WAT and interscapular BAT) were isolated. The organs were 
immediately snap frozen in liquid nitrogen and stored at -80℃ until further analysis. For 
BAT, a small piece was fixated for histological analysis. A second experiment was per-
formed in which 14-week old male C57Bl/6J mice (Charles River Laboratories, USA) were 
fed 0 days or 1 week HFD (n=8 per group) prior to euthanasia. Mice were fasted for 4 
hours and euthanized by CO2 suffocation. Blood was collected via cardiac puncture with 
EDTA filled syringes as described above. These studies were carried out in accordance 
with the recommendations of the animal experimentation guidelines of Amsterdam 
Medical Center (n=86 experiment) and Leiden University Medical Center (n=16 experi-
ment) and approved by the local ethical review boards on animal experimentation. 
Endocannabinoid plasma levels
A liquid-liquid extraction using methyl tert-butyl ether as an organic solvent was used 
to extract endocannabinoids from plasma. Levels of endocannabinoids (AEA, 2-AG), 
N-acylethanolamines (NAEs), and arachidonic acid (AA) were measured by ultra-perfor-
mance liquid chromatography coupled tandem mass spectrometry (UPLC-MS/MS, AB 
Sciex 6500 QTRAP) in 25 µL plasma samples. From the pool of individual study samples, 
quality controls (QCs) were used to generate calibration curves. Additionally, all samples 
were randomized and each batch of study samples included calibration samples, an 
even distribution of QC samples and blanks. The sample extraction procedure and 
method has been described in detail previously [19]. 
RNA isolation and RT-PCR analysis
RNA of liver and muscle was isolated using TriPure Isolation reagent (Roche, the Nether-
lands) and 1 µg of RNA was reverse transcribed using Moloney Murine Leukemia Virus 
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Reverse Transcriptase (Promega, the Netherlands). For WAT and BAT, RNA was isolated 
using Trizol (Invitrogen, USA) and cDNA was synthesized using an iScript cDNA synthesis 
kit (Bio-Rad, The Netherlands). RT-PCR was carried out on a CFX96 PCR machine (Bio-
Rad) using IQ SYBR-Green Supermix (Promega). mRNA expression was normalized to 
Hprt and 36b4 as household genes for liver, BAT and WAT; for muscle mRNA expression 
was normalized to the expression of 36b4 only. Changes in gene expression relative to 
basal expression levels were only calculated if the average expression of at least the 
control group were Ct < 32. Primer sequences are listed in Table 1. 
Histology and determination of lipid droplet content in BAT
After dissection, a small piece of interscapular BAT was immediately fixated in 4% para-
formaldehyde, subsequently dehydrated and embedded in paraffin. A Hematoxylin and 
Eosin staining was performed on paraffin sections using standard protocols. Intracellular 
lipid content was quantified with ImageJ (version 1.49). 
Statistical analysis
All data are expressed as mean ± SEM. Data analysis was performed with an IBM SPSS 
Statistics 23 software package. Analysis between multiple groups was done by a one-
way ANOVA with Dunnett’s post hoc test. For the analysis of plasma 2-AG in the second 
experiment we used an unpaired two-sided t-test. Furthermore, linear regression analy-
sis computed by Pearson’s correlation was used to determine correlations. Significant 
differences are expressed relative to the chow-fed (0 weeks HFD) control group.
Table 1 List of primer sequences for RT-PCR















HFD feeding rapidly increases plasma 2-Ag and AEA levels in mice 
To investigate the time course of the dysregulation of the ECS in the development of 
DIO, C57B1/6J mice were fed a HFD for 1 day up to 18 weeks. As expected, dietary in-
tervention increased body weight (up to +51% after 18 weeks, P<0.001, Table 2). Blood 
glucose levels rapidly increased in response to the HFD (+88% after one day of HFD, 
P<0.001), whereas plasma TG levels increased more gradually (+155% after two weeks 
of HFD, P<0.01) (Table 2).
First, we assessed plasma levels of the two main endocannabinoids in the course of 
DIO development (Fig. 1). HFD feeding gradually increased 2-AG levels, which reached 
significance after 4 weeks (+132%, P<0.05) and further increased up to 18 weeks (+201%; 
P<0.001) (Fig. 1A). Of note, in a few samples of the control group we observed extremely 
high 2-AG levels (>100 pmol/mL) that masked an initial increase in 2-AG levels upon HFD. 
To determine whether these high levels would represent (biological) outliers, we deter-
mined plasma 2-AG levels in a separate cohort of mice fed a HFD for 0 or 7 days. Indeed 
these values lie more than 6 standard deviations away from the average of the repeated 
control animals and could therefore be regarded as biological outliers. Importantly, 
we observed a trend towards elevated 2-AG plasma levels in the 7 days HFD fed group 
(+34%, P=0.055, not shown) compared to the 0 day group in the repeated experiment. 
Therefore, we excluded the mice of the control group with extremely high plasma 2-AG 
levels from calculation of the means of all endocannabinoids and related metabolites, 
and instead indicated these data in grey (Fig. 1, A-i). HFD feeding also rapidly increased 
levels of AEA, the other main endocannabinoid, which reached significance after one 
week (+81%, P<0.01) and further increased up to 18 weeks (+165%, P<0.001) (Fig. 1B). 
Next, we determined whether plasma endocannabinoid levels were related to body 
weight. Linear regression analysis on all data combined showed that body weight cor-
Table 2. General characteristics of the mice during diet-induced obesity development
Duration of HFD (weeks), mean ± SEM
0 1/7 3/7 1 2 4 10 18
N= 11 11 10 10 11 11 11 11
Body weight
(g)
27.3 ± 0.6 29.5 ± 0.6 31.1 ± 0.8~ 31.5 ± 0.5* 34.4 ± 0.9*** 36.5 ± 1.2*** 38.1 ± 0.9*** 41.3 ± 2.0***
Glucose 
(mg/dL)
69 ± 3 130 ± 15*** 118 ± 7*** 123 ± 4*** 104 ± 5* 91 ± 4 112 ± 9** 124 ± 7***
Triglycerides
(mM)
0.20 ± 0.02 0.25 ± 0.05 0.41 ± 0.09~ 0.34 ± 0.06 0.51 ± 0.07** 0.81 ± 0.08*** 0.54 ± 0.03** 0.60 ± 0.05***
Values are indicated in mean ± SEM. ~P<0.1; *P<0.05; **P<0.01; ***P<0.001 compared to the control group. 
These data were previously published elsewhere [20].
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related weakly but positively with 2-AG levels (R2=0.073, β=1.447, P=0.017, Fig. 1C) and 
much more strongly with AEA levels (R2=0.654, β=0.041, P<0.001, Fig. 1D).
Figure 1. High fat diet feeding time-dependently increases plasma levels of 2-Ag and AEA in mice. 
Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was used to determine plas-
ma levels of 2-AG (A), AEA (B), OEA (E), PEA (F), SEA (G), DEA (H) and AA (I). Data are mean ± SEM (n=10-11). 
Error bars were too small to be visible for several data points (in A, E, F, G and I). ~P<0.1; *P<0.05; **P<0.01; 
***P<0.001 compared to the control (0 weeks of HFD) group analyzed by one-way ANOVA with Dunnett’s 
post hoc test. In addition, linear regression analysis was performed on correlations between body weight 
and plasma levels of 2-AG (C) or AEA (D), for all samples depicted in black (n=81). Samples depicted in grey 
were regarded as biological outliers based on 2-AG and AA levels and therefore excluded from plasma data 
analyses.
130
NAPE-PLD does not only produce AEA, but generates a whole family of N-acylethanol-
amines (NAEs), including N-oleoylethanolamine (OEA), N-palmitoylethanolamine (PEA), 
N-stearoylethanolamine (SEA), and N-docosatetraenoylethanolamine (DEA). Similar to 
AEA, plasma concentrations of these non-cannabinoid fatty acid amides were raised 
in response to HFD feeding, albeit with different kinetics (Fig. 1, E-H). Plasma levels of 
arachidonic acid (AA), the precursor and degradation product of 2-AG and AEA [21], 
also rapidly increased in the first 2 weeks of HFD after which a plateau was reached 
(+89% after 18 weeks, P<0.001, Fig. 1i). Of note, the samples of the control group with 
extremely high 2-AG levels (Fig. 1A) also showed elevated AA levels (Fig. 1i).
HFD feeding increases expression of 2-Ag synthesis and degradation enzymes 
in WAT and BAT 
Next, we assessed gene expression of the enzymes responsible for the synthesis (Daglα 
and Daglβ) and degradation (Mgll) of 2-AG in liver, muscle, WAT and BAT (Fig. 2; an over-
view of all relative gene expressions of the enzymes involved in synthesis and degrada-
tion is shown in Suppl. Table 1). HFD feeding transiently increased Daglα expression in 
WAT after 3 days (+57%, P<0.05, Fig. 2A) and increased Daglα expression in BAT after 1 
and 4 weeks of HFD (Fig. 2B). HFD feeding also induced Daglβ expression in WAT (Fig. 
2C) and BAT (Fig. 2D), especially towards the end of the intervention (i.e. +246% in WAT 
and +38% in BAT after 18 weeks). Linear regression analyses between the expression lev-
els of DAG lipases in adipose tissues and plasma 2-AG levels showed inconclusive data 
(Suppl. Fig. 1). HFD feeding also transiently increased Mgll expression in WAT reaching 
a peak after 1 week of HFD (+75%, P<0.001), which normalized towards the end of HFD 
intervention (Fig. 2E). In contrast, HFD induced a sustained increase in Mgll expression 
levels in BAT from 1 day on (+28%, P<0.05, Fig. 2F). HFD feeding did not persistently 
affect gene expression of synthesis and degradation enzymes in liver and muscle. It only 
temporarily increased Daglα expression in muscle (at 2 weeks), increased Daglβ expres-
sion (at 3 days) and decreased Mgll expression (at 1 day) in liver (data in Suppl. Table 
1). Collectively, these data show that the rise in 2-AG levels during DIO development 
coincided with enhanced expression of synthesis and degradation enzymes specifically 
in WAT and BAT. 
HFD feeding increases Nape-pld expression in WAT and BAT 
We next assessed gene expression of the enzyme responsible for AEA and NAEs synthe-
sis (Nape-pld) in the various metabolic organs. HFD feeding tended to increase Nape-pld 
expression in WAT after 3 days, although expression levels normalized thereafter and 
were decreased after 18 weeks (-41%, P<0.01, Fig 3A). Surprisingly, linear regression 
analysis showed a small, but significant, negative correlation between Nape-pld expres-
sion in WAT and plasma AEA levels (R2=0.124, β=-0.235, P=0.002, Fig. 3B). Interestingly, 
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HFD feeding increased Nape-pld expression in BAT starting at 3 days (+102%, P<0.001, 
Fig. 3C), after which levels reached a plateau. Moreover, Nape-pld expression in BAT 
positively correlated with plasma AEA levels (R2=0.171, β=0.276, P<0.001, Fig. 3D), 
supporting a contribution of BAT Nape-pld expression to circulating AEA levels. HFD 
feeding decreased the expression of Nape-pld in muscle reaching significance from 4 
weeks onwards and did not affect Nape-pld expression in de liver (data in Suppl. Table 
1). We also determined the potential contribution of the expression of genes involved 
in the phospholipase A/acyltransferase (PLA/AT) family, which can produce NAPE in a 
Ca2+-independent manner, in the increase in AEA levels in DIO [22]. However, expression 
Figure 2. HFD feeding increases the expression of 2-Ag synthesis and degradation enzymes in WAT 
and BAT. Relative gene expression of 2-AG synthesis enzymes Daglα (A, B), Daglβ (C, D), and degradation 
enzyme Mgll (E, F) in WAT (A, C, E) and in BAT (B, D, F). The number in the column of the 0 weeks of HFD 
group indicates the average CT value of that treatment group for that gene. Data are mean + upper SEM 
(n=10-11) ~P<0.1; *P<0.05; **P<0.01; ***P<0.001 compared to the control (0 weeks of HFD) group analysed 
by one-way ANOVA with Dunnett’s post hoc test.
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of the PLA/AT (HRAS-like suppressor) gene family was either too low to detect (Pla/at1 in 
liver, WAT, BAT and Pla/at5 in liver) or did not show a clear or persistent rise in expression 
levels that could explain the rise in AEA levels (not shown). Alpha/beta hydrolase domain 
containing-4 (ABHD4) and glycerophosphodiesterase-1 (GDE1) have been suggested to 
be involved in AEA synthesis by BAT [23]. However, time-dependent expression levels of 
Abhd4 and Gde1 in BAT did not coincide with the HFD-induced rise in AEA and NAEs (not 
shown).
Next, we determined gene expression levels of Faah, the enzyme involved in AEA and 
NAEs degradation. HFD feeding decreased Faah expression levels in the liver after 18 
weeks (-41%, P<0.01, Suppl. Table 1). Expression levels of Faah in muscle, WAT and BAT 
were too low to be detected. Altogether, these data show that HFD robustly increased 
Figure 3. HFD feeding upregulates Nape-pld expression in WAT and in BAT. Relative gene expression of 
AEA synthesis enzyme Nape-pld in WAT (A) and BAT (C). The number in the column of the 0 weeks of HFD 
group indicates the average CT value of that treatment group for that gene. Data are mean + upper SEM 
(n=10-11). **P<0.01; ***P<0.001 compared to the control (0 weeks of HFD) group analysed by one-way 
ANOVA with Dunnett’s post hoc test. In addition, linear regression analysis was performed on correlations 
between Nape-pld expression relative to 0 weeks of HFD in WAT (B) or in BAT (D) and plasma levels of AEA, 
for all samples depicted in black (n=81). Samples depicted in grey were regarded as biological outliers 
based on 2-AG and AA levels and therefore excluded from linear regression analyses.
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the expression of Nape-pld in BAT, suggesting that this tissue may contribute to the 
increased plasma AEA and NAE levels during DIO development.
Plasma AEA levels positively correlate with lipid content of BAT 
Next, we aimed to gain more insight into the cell types within BAT that may have contrib-
uted to the robust increased Nape-pld expression and plasma AEA levels in DIO develop-
ment. Because macrophages have been shown to produce AEA [24], we first determined 
gene expression levels of the macrophage marker Cd68 in BAT. Linear regression analysis 
showed a weak positive correlation between Cd68 expression and Nape-pld expression 
in BAT (R2=0.113, β=0.170, P=0.002, Fig. 4A) and plasma AEA levels (R2=0.088, β=0.088, 
P=0.009, Fig. 4B). Besides macrophages, brown adipocytes might also be involved. 
Since intracellular lipid droplets have been shown to co-localize with intracellular AEA 
[25], we quantified BAT lipid droplet content in H&E stained BAT sections (Suppl. Fig. 
Figure 4. Both macrophage marker expression in BAT and lipid content of BAT positively correlate 
with plasma AEA levels. Linear regression analysis was performed on correlations between Cd68 expres-
sion relative to 0 weeks of HFD in BAT and Nape-pld expression in BAT (A) or plasma levels of AEA (B). 
Also, linear regression analysis was performed on correlations between lipid content of BAT and Nape-pld 
expression relative to 0 weeks of HFD in BAT (C) or plasma levels of AEA (D). Correlations are shown for 
all samples depicted in black (n=86 in A, C and n=81 in B, D). Samples depicted in grey were regarded as 
biological outliers based on 2-AG and AA levels and therefore excluded from linear regression analyses.
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2). Compared to Cd68, BAT lipid droplet content showed a more pronounced positive 
correlation with Nape-pld expression levels in BAT (R2=0.385, β=0.021, P<0.001, Fig. 4C) 
as well as plasma AEA levels (R2=0.172, β=0.010, P<0.001, Fig. 4D).
DiSCuSSiON
In this study, we demonstrated that HFD feeding increases circulating levels of endocan-
nabinoids, with a rapid initial increase in AEA and a more gradual increase in 2-AG, in 
the course of DIO development. These changes were accompanied by increased gene 
expression of the synthesis and degradation enzymes of 2-AG in both WAT and BAT, and 
with increased expression of the AEA synthesis enzyme Nape-pld in BAT. Taken together, 
these data indicate that the dysregulation of the ECS in the development of obesity 
occurs rapidly and that WAT and BAT might contribute to these effects. 
The observed increases in endocannabinoids in the development of DIO are in agree-
ment with previous studies in mice that showed increased plasma 2-AG and AEA levels 
after 9 weeks [26] and 36 weeks [27] of HFD feeding and increased plasma AEA levels in a 
model for glucocorticoid induced obesity [28]. These data also are concordant with data 
in humans, since obese individuals have higher 2-AG levels compared to lean individuals 
[12, 13, 29]. It was somewhat surprising that a subset of the control group that were not 
fed a HFD showed very high 2-AG levels in addition to AA levels, the reason of which is 
currently unclear to us. By performing a second study in mice we confirmed that HFD 
feeding induced an initial rise rather than decrease in 2-AG levels. Thus, although the 
reason for the very high 2-AG levels in a subgroup is intriguing, we regarded those mice 
as biological outliers. Besides 2-AG and AEA, HFD feeding also increased the plasma 
levels of AA. Since AA is constituent and degradation product of 2-AG and AEA, elevated 
AA levels may either be a cause or consequence of the increased levels. HFD feeding 
also increased plasma levels of other N-acylethanolamines, including OEA, PEA, SEA 
and DEA. These NAEs have other biological targets involved in controlling the energy 
balance, such as peroxisome proliferator-activated receptors-α (PPARα), PPARγ and G 
protein-coupled receptor 119 [30]. 
Currently, it is unknown which organs contribute to the increased plasma endocan-
nabinoid levels in HFD-induced obesity [31]. We showed that body weight positively 
correlates with plasma endocannabinoid levels, albeit that the correlation with AEA 
(R2=0.654) is stronger than with 2-AG (R2=0.073). Since body weight differences in the 
range of approximately 30-50 g, as observed in this study, are mainly caused by differ-
ences in body fat [32], it was considered likely that engulfment of lipids by adipocytes 
and/or expansion of the adipocyte pool would contribute to the increase in endocan-
nabinoids. Insulin resistance, which is closely linked to increased intracellular lipid 
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deposition [33] is also associated with a dysregulated ECS [34]. By performing gene ex-
pression analysis in metabolically active organs, we could demonstrate that expression 
of enzymes involved in endocannabinoid synthesis increased in WAT as well as BAT. This 
is in full agreement with a previous study in which 3 and 8 weeks of HFD feeding, with 
a diet closely resembling the HFD used in our experiments, resulted in increased local 
levels of endocannabinoids (AEA and 2-AG) in BAT [35]. The increase in plasma 2-AG 
coincided with increased gene expression of DAGLα and DAGLβ in both WAT and BAT. 
Given the different time-course of expression, where the increase in Daglα seems to pre-
cede the increase in Daglβ, we postulate that DAGLα may be responsible for the initial 
rise in 2-AG, while DAGLβ may mediate the late increase in 2-AG. Similarly, the increase 
in plasma AEA coincided with increased gene expression of its synthesizing enzyme 
NAPE-PLD in BAT. Moreover, plasma AEA correlated positively with Nape-pld expression 
in BAT but not in WAT. It is therefore likely that BAT rather than WAT contributes to the 
rise in AEA levels. In this respect, it is interesting that expression of Nape-pld is higher in 
BAT than in WAT, as evident from lower Ct values. The expression levels of most of the 
enzymes showed a sharp increase in the first week of HFD feeding, which coincided with 
the timing of the largest increase in lipid deposition in BAT. In BAT, ABHD4 and GDE1 
were shown to also be involved in AEA synthesis and their expression respond to BAT 
activating agents [23], although we did not find the expression levels of these enzymes 
to coincide with the increase in circulating AEA and NAEs levels with prolonged HFD 
feeding. Of note, expression of the endocannabinoid degradation enzymes Faah and 
Mgll in the adipose tissues were either undetectable or increased. Although we have 
not been able to measure actual enzyme activities due to technical reasons, it is tempt-
ing to speculate that net whole body endocannabinoid synthesis exceeds degradation 
since circulating levels increase in the course of DIO. Synthesis enzymes of 2-AG in liver 
and skeletal muscle were only transiently increased, and the synthesis enzyme of AEA 
was decreased in skeletal muscle. Thus, although we cannot exclude the contribution of 
other organs as source for plasma endocannabinoid levels (e.g. brain and intestine), our 
data suggest that WAT and BAT are likely important organs that release 2-AG and AEA 
levels in HFD-induced obesity.
It is interesting to speculate on the cellular source within the adipose tissue depots that 
is involved in endocannabinoid synthesis. HFD-induced development of DIO causes ac-
cumulation of macrophages in WAT [32] as well as BAT (Van den Berg S.M., unpublished). 
Macrophages are able to produce AEA [24], and we found a positive correlation between 
macrophage marker Cd68 and Nape-pld expression in BAT as well as with AEA levels 
in plasma. However, the concentration of macrophages in adipose tissue is relatively 
low, even in obesity, and stronger positive correlations were found between the lipid 
content in BAT and both Nape-pld expression and plasma AEA levels. Therefore, adipo-
cytes likely contribute substantially more to the circulating endocannabinoid pool than 
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macrophages. This hypothesis is corroborated by previous findings that AEA co-localizes 
with adiposomes or lipid droplets in vitro [25] and that specific deletion of NAPE-PLD 
in adipocytes of mice decreased levels of PEA, OEA and SEA in WAT, despite increased 
inflammation and influx of macrophages [36]. In our study, HFD feeding increases the 
cellular mRNA levels of the synthesizing enzymes in adipose tissue. In addition, expan-
sion of the total number of adipocytes in the time course of DIO further increases whole 
body expression of these enzymes. The rapid increases in gene expression in BAT may 
be explained by the rapid whitening of BAT as induced by HFD feeding [37]. Indeed, BAT 
lipid droplet content positively correlated with Nape-pld expression and AEA plasma 
levels. Furthermore, these data are in line with the recent observation that acute activa-
tion of BAT decreases Nape-pld expression [23]. Interestingly, the concentration of 2-AG 
and AEA is higher in BAT than WAT [23], suggesting at least a role of BAT in determining 
circulating endocannabinoid levels. Collectively, it is likely that lipid-filled adipocytes 
rather than macrophages within the adipose tissues contribute to circulating plasma 
endocannabinoid levels.
In our study, we found no evidence for a contribution of decreased degradation 
pathways of 2-AG and AEA in adipose tissues determining plasma levels of endocan-
nabinoids. Specifically, we were unable to detect any expression of AEA degradation 
enzyme Faah in WAT, BAT and muscle, and found decreased liver Faah expression after 
18 weeks of HFD feeding. This is in line with the fact that FAAH was reported to play an 
important role in obesity. Notably, a missense polymorphism in the FAAH gene is associ-
ated with obesity in humans [38] and FAAH deficient mice have increased AEA levels 
in e.g. the liver and show increased fat mass and body weight [39]. On the other hand, 
Bartelt and colleagues [40] found that HFD feeding for 16 weeks in mice caused a de-
crease in Faah expression and FAAH enzymatic activity in WAT which was accompanied 
by increased AEA in this tissue. To what extend catabolism of AEA and 2-AG by adipose 
tissue determines circulating levels of these endocannabinoids warrants further study.
It is tempting to speculate on the biological role of the increases of 2-AG and AEA 
in the time course of HFD-induced obesity. Endocannabinoids are known to decrease 
insulin sensitivity [34] and to reduce sympathetic responses by inhibiting noradrenergic 
signaling [23, 41], and thereby decrease lipolysis in WAT and thermogenesis in BAT. Pos-
sibly, in case of acute lipid overload, as mimicked by a switch from regular chow to a HFD, 
initial accumulation of lipids in WAT and BAT drives the synthesis pathways of endocan-
nabinoids that can have autocrine and even paracrine effects on these organs to inhibit 
sympathetic signaling. This sequence of events reduces intracellular lipolysis in BAT and 
WAT, thereby resulting in reduced thermogenesis in BAT and increased triglyceride 
storage in WAT. Such as a feed-forward mechanism may thus allow the body to store 
excess lipids effectively in adipose tissues. Interestingly, we have shown that inhibition 
of endocannabinoid signaling by strictly peripheral CB1R antagonism activates BAT and 
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reduces adiposity in HFD-fed mice [42]. In theory, HFD induced lipid accumulation can 
lead to increased endocannabinoid synthesis which attenuates BAT and WAT activity 
and results in a positive energy balance.
In conclusion, in the time course of HFD-induced obesity plasma endocannabinoid 
levels rapidly rise as most probably explained by increased synthesis pathways in 
adipose tissue depots. We speculate that this sequence of events may attenuate sym-
pathetic signaling in these tissues by CB1R agonism, which would result in reduced 
thermogenesis and increased storage of excess lipids in WAT. Given the fact that strictly 
peripheral CB1R antagonism activates BAT and reduces adiposity in mice, we anticipate 
that strategies inhibiting CB1R selectively on (brown) adipocytes or reducing endocan-
nabinoid synthesis by adipocytes may be a worthwhile strategy to pursue in combating 
obesity and associated disorders.
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Supplementary figure 1. Linear regression analysis was performed on correlations between DAG lipase 
expression in the adipose tissues and plasma 2-AG levels. Linear regression analysis for Daglα expression 
relative to 0 weeks of HFD in WAT (A) and BAT (B) and 2-AG levels and linear regression analysis for Daglβ 
expression relative to 0 weeks of HFD in WAT (C) and BAT (D) and 2-AG levels. Correlations are shown for all 
samples depicted in black (n=81). Samples depicted in grey were regarded as biological outliers based on 
2-AG and AA levels and therefore excluded from linear regression analyses.
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Supplementary figure 2. BAT sections were stained for H&E and representative images are shown (A). 
Pictures were analyzed in ImageJ to determine the lipid droplet content (B). Data are represented as mean 
± SEM (n=9-11) **P<0.01; ***P<0.001 compared to the control (0 weeks of HFD) group analyzed by one-way 
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ABSTRACT
Obesity and dyslipidemia are major risk factors for the development of cardiovascular 
diseases (CVD). Quercetin, a natural flavonoid, lowers plasma triglycerides (TG) in human 
intervention studies and its intake is associated with lower CVD risk. The aim of this study 
was to elucidate the mechanism by which quercetin lowers plasma TG levels in diet-
induced obesity. C57Bl/6J mice received a high-fat diet (45% of calories derived from fat) 
with or without quercetin (0.1% w/w) for 12 weeks. Quercetin decreased plasma TG levels 
from 9 weeks onwards (-19%, P<0.05), without affecting food intake, body composition 
or energy expenditure. Mechanistically, quercetin did not reduce intestinal fatty acid 
(FA) absorption. Rather, quercetin induced a slight reduction in liver Apob expression 
(-13%, P<0.05), which suggests decreased VLDL-TG production. Interestingly, quercetin 
also markedly increased uptake of [3H]oleate derived from glycerol tri[3H]oleate-labeled 
lipoprotein-like particles by subcutaneous white adipose tissue (sWAT, +60%, P<0.05) 
together with markedly increased mRNA expression of Ucp1 (+229%, P<0.05) and 
Elovl3 (+138%, P<0.05) specifically in sWAT. Accordingly, only quercetin-treated animals 
showed UCP-1 protein-positive cells in sWAT, which is fully compatible with increased 
browning. Taken together, the TG-lowering effect of quercetin may, at least in part, be 




Cardiovascular diseases (CVD) are the number one cause of death worldwide. Obesity 
and dyslipidemia are major risk factors for developing CVD [1-3]. Super foods and other 
natural products including flavonoids have become increasingly popular as potential 
strategies to target these risk factors. Quercetin is a naturally occurring flavonoid that 
is present in fruits and vegetables [4]. Interestingly, epidemiological studies show that 
increased quercetin intake is associated with a reduced risk for developing CVD [5]. In a 
preclinical study quercetin supplementation indeed reduced atherosclerosis develop-
ment [6]. Furthermore, quercetin supplementation attenuates body weight gain [7-9] 
and lipid deposition in the liver [10, 11] as well as white adipose tissue depots [12] of 
animals on a high fat diet. In addition, quercetin lowers plasma triglyceride (TG) levels in 
mice [7, 9, 13] and in humans [14] thereby targeting another risk factor for CVD. 
The exact mechanism underlying the TG-lowering effect of quercetin and the organs 
involved have not yet been elucidated. Interestingly, a recent in vitro study showed that 
quercetin induces browning of 3T3-L1 white adipocytes [15], as they adapted a more 
brown-like phenotype including higher mRNA expression of the uncoupling protein 1 
(UCP-1) [16]. Of note, we recently showed that browned white adipose tissue (WAT) de-
pots increase their uptake of TG-derived fatty acids (FA) from the circulation compared 
to the same WAT depots in mice that lack the browning stimulus [17, 18]. In addition, 
brown adipose tissue (BAT) is a major contributor to TG metabolism [19, 20]. When 
activated by e.g. cold, BAT enhances oxidation of intracellular FA in both mice [17] and 
humans [21], which causes rapid depletion of intracellular TG stores. As a consequence, 
BAT takes up large amounts of TG-derived FA in a lipoprotein lipase (LPL) dependent 
manner and combusts these to generate heat in a process dependent on mitochondrial 
UCP-1 [20, 22]. 
Whether BAT and (browned) WAT are involved in the beneficial effects of quercetin 
with respect to reduction of plasma TG remains to be determined. Therefore, in the cur-
rent study, we aimed at elucidating the mechanism by which quercetin lowers plasma 




Male C57Bl/6J mice (n=18, Charles River Laboratories, USA), 9 weeks of age, were placed 
on a run-in high fat diet (HFD, 45% of calories derived from fat, D12451, Research Diets) 
for three weeks. Next, mice were randomized based on body weight and plasma TG 
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levels to receive a HFD with or without quercetin (0.1% w/w) for 12 weeks. Mice were 
housed individually under standard conditions with ad libitum access to food and water. 
Mouse experiments were performed in accordance with the Institute for Laboratory 
Animal Research Guide for the Care and Use of Laboratory Animals and have received 
approval from the University Ethical Review Board (Leiden University Medical Center, 
Leiden, the Netherlands).
Body weight, body composition and food intake
Body weight and body composition were determined weekly by using an EchoMRI-100 
analyzer (EchoMRI, TX, USA). Food intake was measured weekly by subtracting the 
amount of food that was left in the cage from the amount given at the previous weigh-
ing. 
Plasma parameters
Before randomization and every three weeks thereafter, mice were fasted for four hours 
and blood was drawn from the tail vein. Blood was collected in paraoxon (Sigma, St. 
Louis, MO) coated capillaries that were immediately placed on ice and centrifuged to 
obtain plasma. TG, total cholesterol (TC) and glucose were determined using commer-
cially available enzymatic kits (Roche Diagnostics, Mannheim, Germany for TG and TC 
and Instruchemie, Delfzijl the Netherlands for glucose). FFA were measured using NEFA 
C kit (Wako Diagnostics, Instruchemie, Delfzijl, the Netherlands). 
Lipoprotein profiles 
Plasma samples obtained after 12 weeks of intervention were pooled to determine 
cholesterol distribution over plasma lipoproteins by fast performance liquid chromatog-
raphy (FPLC). Plasma was placed onto a Superose 6 column (ÄKTA System, Amersham 
Pharmacia Biotech, Piscataway, NJ, USA) and eluted at a constant flow of 50 µL/min with 
PBS pH 7.4. Individual fractions were measured for TC as described above.
indirect calorimetry and physical activity
During the third week of treatment, mice (n=8 per group) were placed in fully automatic 
metabolic cages (LabMaster System, TSE Systems, Bad Homburg, Germany) to assess en-
ergy expenditure and physical activity levels. After 20 h acclimatization, oxygen uptake 
(VO2) and carbon dioxide production (VCO2) were measured for 5 consecutive days. Total 
energy expenditure (EE) was calculated from VO2 and VCO2 using the Weir equation [23]. 
Fat and glucose oxidation rates were calculated from VO2 and VCO2 as described previ-
ously [24]. Physical activity was measured using infrared sensor frames.
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Feces collection and fecal FFA concentration
After two and ten weeks of intervention, feces was collected by placing the mice in 
cages with new bedding and removing feces 24 hours later. Feces was then dried and 
weighed, approx. 30 mg was ground, and fecal FFA were determined after methyl esteri-
fication using the NEFA C kit (Wako Diagnostics) as described previously [25]. 
RNA isolation and RT-PCR analysis
Total RNA was isolated using TriPure Isolation reagent (Roche, the Netherlands) fol-
lowing the manufacturer’s protocol. cDNA was made using Moloney Murine Leukemia 
Virus Reverse Transcriptase (Promega, The Netherlands). Real-time PCR (RT-PCR) was 
performed with SYBR green (Promega) on a CFX96 PCR Machine (Bio-Rad, Veenendaal, 
The Netherlands). mRNA expression levels were normalized to β2-microglobulin or 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and hypoxanthine guanine phos-
phoribosyl transferase (Hprt) as reference genes. Primer sequences are listed in Table 1.
In vivo clearance of radiolabeled lipoprotein-like particles
Lipoprotein-like particles (80 nm) labeled with glycerol tri[3H]oleate (triolein, [3H]TO) 
were prepared and characterized as described previously [26]. Mice were fasted for 4 h 
and injected (t = 0) with 200 µL of [3H]TO-labeled lipoprotein-like particles (1.0 mg TG 
Table 1 List of primer sequences for RT-PCR



















per mouse) via the tail vein. Blood samples were taken 2, 5, 10 and 15 min after injection 
to determine the plasma decay of [3H]TO (using calculations described in [27]). Next, 
mice were sacrificed by means of cervical dislocation and perfused with ice-cold heparin 
solution (0.1% v/v in PBS) via the heart. Organs were harvested, weighed and the uptake 
of [3H]TO-derived radioactivity was quantified and expressed per gram or whole organ 
wet tissue weight.
Histology
Interscapular BAT (iBAT), gonadal WAT (gWAT), subcutaneous WAT (sWAT), visceral WAT 
(vWAT) and liver were removed and directly placed in 4% paraformaldehyde, dehy-
drated and embedded in paraffin. Hematoxylin and Eosin staining was performed using 
standard protocols. An overview of the studied fat depots can be found in Suppl. Fig. 
1. Relative cell size and intracellular lipid content was quantified using ImageJ (version 
1.49). UCP-1 staining on sWAT and BAT were performed as described before [27]. 
quantification of lipid content in liver 
Liver samples (approx. 50 mg) were homogenized in 10 µL of ice-cold methanol per mg 
tissue. Lipids were extracted as described before [27]. Hepatic TG, TC and PL concentra-
tions were measured using commercial kits (as explained in Plasma parameters). Liver 
lipids were expressed per milligram of protein, which was determined using Pierce BCA 
protein assay kit (Thermo Scientific, Rockford, IL, USA). 
Protein isolation and western blot
sWAT samples were lysed in buffer containing 50 mM HEPES (pH 7.6), 50 mM NaF, 50 
mM KCl, 5 mM NaPPi, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 5 mM β-glycerophosphate, 1 
mM sodium vanadate, 1% Nonidet P-40, and protease inhibitors using cocktail tablets 
(Roche). Protein concentration was determined using the Pierce BCA Protein Assay kit 
(Thermo Scientific) and extracts were diluted in Laemli buffer. Next, 10 µg protein of 
sWAT was separated on a 10% polyacrylamide gel (#456-8035, Bio-Rad) by electropho-
resis and turbo-blotted on nitrocellulose membranes (#170-4159, Trans-blot Turbo, 
Bio-Rad). Membranes were blocked for 1 h at room temperature in Tween-20 buffer with 
5% non-fat dry milk. Next membranes were incubated overnight with 1:1000 or 1:5000 
(only for UCP-1 in BAT) diluted specific primary antibodies. Primary antibodies specific 
for AMPKα (#2532), p-AMPKα (Thr172, #2535) and α/β-Tubulin (#2148) were purchased 
from Cell Signalling Technology (Leiden, The Netherlands) and the antibody specific for 
UCP-1 (#U6382) was purchased from Sigma (St. Louis, MO). A primary antibody specific 
for GAPDH was purchased from Santa Cruz Biotechnology (Heidelberg, Germany). Mem-
branes were incubated with horseradish peroxidase-conjugated secondary antibodies 
for 1 h. Super Signal West Pico Chemiluminescent Substrate (Thermo Scientific, Rock-
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ford, IL, USA) was used to visualize bands on the ChemiDocTM Touch imaging system 
(Bio-Rad). The images were analyzed with Image lab software (version 5.2, Bio-Rad) and 
protein content was corrected for GAPDH (housekeeping protein).
Determination of mtDNA/nDNA ratio
Total DNA was isolated from sWAT with QIAamp DNA Mini Kit (no. 51306; Qiagen, Hilden 
Germany) following the provided manufacturer’s protocol. The PCR reaction was per-
formed in a LightCycler 480 (Roche). The reaction mix contained 500 pg DNA, 1.25 µM 
forward and reverse primer, and 4 µL 2x SYBR green master mix (Roche) in a final volume 
of 8 µL. 16S and Cox2 were used as mitochondrial encoded genes, Hk2 and Ucp2 for 
nuclear encoded genes. Primer sequences are listed in Table 2. Data were analyzed with 
LightCycler software release 1.5.0 (Roche). The mean PCR efficiency was calculated to 
assess gene expression levels using LinRegPCR program version 12.17 [28].
Statistical analysis
All data are expressed as mean ± SEM. Statistical analysis was performed with an IBM 
SPSS Statistics 23 software package and Microsoft Excel 2010. Differences between con-
trol and quercetin was determined using an unpaired two-tailed t-test. Plasma decay in 
the clearance was analyzed using repeated measurements ANOVA with Sidak’s post hoc 
test. A P-value < 0.05 was considered statistically significant.
RESuLTS
quercetin reduces plasma triglyceride levels without affecting body 
composition, food intake and energy expenditure
In order to assess the effect of quercetin on body composition, plasma lipids and energy 
balance, C57Bl/6J mice were fed a high fat diet (HFD) with or without 0.1% (w/w) quer-
cetin for 12 weeks. Quercetin neither affected body weight (mean body weight after 
12 weeks 45.2±2.5 g in control and 47.4±3.3 g in quercetin treated animals; Fig. 1A) 
nor body composition with respect to lean and fat mass (Fig. 1B). In line with these 
data, organ weight of spleen, gWAT and iBAT at necropsy were unaffected by quercetin. 
Table 2. List of PCR primer sequences






We only found liver weight to be increased (+13%, P<0.05; Suppl. Fig. 2A). Of note, 
quercetin lowered plasma TG levels from 9 weeks onwards (up to -19%, P<0.05; Fig. 1C). 
Furthermore, quercetin treatment increased plasma total cholesterol levels, which was 
mainly due to increased cholesterol in the HDL fraction (Suppl. Fig. 2B, C), decreased 
plasma free FA (FFA) levels, and did not affect plasma glucose (Suppl. Fig. 2D, E). The 
lowering in plasma TG levels by quercetin could not be explained by a lower daily food 
intake, since daily food intake was not persistently affected by quercetin (Fig. 1D) and 
cumulative food intake was not different between the two groups (data not shown). To 
determine whether quercetin influenced whole body energy expenditure and substrate 
utilization, mice were placed in metabolic cages in the third week of treatment. Quer-
cetin did not affect total energy expenditure (EE), fat or glucose oxidation (Fig. 1E-g). 
Respiratory exchange ratio (RER) and physical activity were also unaltered (Suppl. Fig. 
Figure 1. quercetin reduces plasma triglyceride levels without affecting body composition, food in-
take and energy expenditure. C57Bl/6J mice were fed a high-fat diet (HFD) +/- quercetin (0.1% w/w) for 
12 weeks. Body weight was measured weekly (A). Body composition was determined (B). Plasma triglycer-
ides were determined before and every 3 weeks during de intervention (C). Food intake was determined 
weekly (D). In the third week of treatment, animals were placed in fully automatic metabolic cages for as-
sessment of total energy expenditure (E), fat oxidation (F) and glucose oxidation (G). Data are represented 
as mean ± SEM (n=8-10), *P<0.05 versus control.
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2F, g). Taken together, quercetin reduced plasma TG without affecting body weight, 
body composition, food intake and energy expenditure.
quercetin reduces hepatic ApoB expression and increases uptake of Tg-derived 
FA by sWAT 
Plasma TG levels are determined by the balance between intestinal TG uptake, hepatic 
VLDL-TG production and VLDL-TG clearance by LPL-expressing peripheral organs. We 
first assessed total fecal output, measured over 24 h, which was unaltered after 2 and 10 
weeks of quercetin treatment (Fig. 2A). Interestingly, FFA content in feces was reduced 
after 10 weeks of quercetin treatment (-39%, P<0.05; Fig. 2B), suggesting enhanced 
rather than decreased intestinal TG absorption. We next focused on the effect of quer-
cetin on liver lipid metabolism. Albeit that quercetin increased liver weight (Suppl. Fig. 
2A), quercetin did not affect liver lipid content (Suppl. Fig. 3A, B). Activation of xeno-
biotic sensing nuclear receptor pregnane X receptor (PXR), as underlying cause for the 
increased liver weight, was excluded since Pxr expression and the expression of the PXR 
target gene Cyp3a11 remained unchanged (Suppl. Fig. 3C). Hepatic expression of lipid 
synthesis and oxidation marker acyl-CoA synthetase long-chain family member 1 (Acsl1) 
was unaffected and lipid synthesis marker acetyl-CoA carboxylase 2 (Acc2) tended to be 
increased after quercetin treatment (Fig. 2C). 
To assess the effect of quercetin on VLDL-TG production, we determined the mRNA 
expression of hepatic microsomal triglyceride transfer protein (Mttp) and apolipopro-
tein B (Apob), both involved in hepatic VLDL assembly and secretion (Fig. 2C). Of note, 
quercetin decreased Apob expression (-13%, P<0.05; Fig. 2C), which may indicate lower 
VLDL production.
To investigate whether quercetin reduced plasma TG levels due to increased clearance 
of TG-rich lipoproteins, we determined the kinetics of intravenous injected [3H]TO la-
beled TG-rich lipoprotein-like particles, and studied the plasma clearance of [3H]TO and 
organ uptake of [3H]TO-derived [3H]oleate in mice treated with quercetin for 12 weeks. 
The plasma clearance of [3H]TO was slightly accelerated in the quercetin treated group 
(Fig. 2D). The uptake of 3H per gram organ was decreased in the liver (-22%, P<0.05), but 
this effect disappeared when data were corrected for whole organ weight (Suppl. Fig. 
3D). Interestingly, quercetin markedly increased (+60%, P<0.05; Fig. 2E) the uptake of 
3H per gram organ by sWAT, while the uptake by the two studied classical BAT depots 
(interscapular and subscapular) were not changed. All in all, our data suggest that 
quercetin decreases plasma TG levels by decreasing VLDL-TG production and increasing 
TG-derived FA uptake by sWAT.
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quercetin increases Ucp1 gene expression specifically in sWAT
Since increased uptake of TG-derived FA by sWAT might point to increased browning 
of this depot [17, 18], we next determined whether quercetin had induced browning 
of sWAT. Indeed, quercetin markedly increased the expression of Ucp1 in sWAT (+229%, 
P<0.05) as well as the brown fat marker fatty acid elongase 3 (Elovl3, +138%, P<0.05, Fig. 
3A). Expression of other markers of BAT-like metabolism, including the transcriptional 
coregulators PR domain containing 16 (Prdm16) and Cell Death-inducing DFFA-like Effec-
tor A (Cidea), the central inducer of mitochondrial biogenesis peroxisome proliferator-
Figure 2. quercetin reduces hepatic Apob expression and increases uptake of Tg-derived FA by sub-
cutaneous white adipose tissue. In week 2 and week 10 of the intervention, 24 hours feces was collected 
(A) and used to determine fecal free fatty acid (FFA) concentration (B). Gene expression in the liver was 
determined by qRT-PCR for Acsl1, Acc2, Mttp and Apob (C). After 12 weeks, mice were injected with glycerol 
tri[3H]oleate-labeled lipoprotein-like particles and clearance from plasma (D) and uptake per gram organ 
(E) were determined by 3H-activity analysis. Data are represented as mean ± SEM (n=8-10); expression of 
genes was corrected for the reference gene β2-microglobulin, *P<0.05 versus control. (g,s,v)WAT, gonadal, 
subcutaneous, visceral white adipose tissue; (i,s)BAT, interscapular, subscapular brown adipose tissue; qua, 
quadriceps muscle; sol, soleus muscle.
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activated receptor γ coactivator 1 (Pgc1α) and markers involved in lipid uptake, includ-
ing lipoprotein lipase (Lpl), the LPL regulator angiopoietin like 4 (Angptl4) and fatty acid 
translocase (Cd36) were unaltered in sWAT (Fig. 3A). Also, p-AMPK (Thr172)/AMPK ratio 
in sWAT did not differ between quercetin and the control group (Suppl. Fig. 4A). Fur-
thermore, quercetin did not increase expression of Ucp1, Elvol3, Pgc1α, Lpl, Angptl4 and 
Cd36 in BAT (Fig. 3B), gWAT (Suppl. Fig. 5A) and visceral WAT (vWAT, Suppl. Fig. 5B). To 
Figure 3. quercetin increases Ucp1 gene expression specifically in subcutaneous white adipose tis-
sue. Gene expression in sWAT (A) and BAT (B) was determined by qRT-PCR. H&E staining was performed 
on paraffin embedded sWAT sections and representative pictures are shown (C). Pictures were analyzed in 
ImageJ to determine the relative cell size (D). sWAT sections were stained for UCP-1 (E) as well. BAT sections 
were stained for H&E (F) and used to quantify lipid droplet content in ImageJ (G). BAT sections were also 
stained for UCP-1 (H). Data are represented as mean ± SEM (n=8-10); expression of genes was corrected for 
the reference gene β2-microglobulin (sWAT), Gapdh and Hprt (BAT), *P<0.05 versus control. Bars (C, E, F, H) 
indicate 200 µm.
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verify browning on a morphological level, sWAT sections were stained with H&E (Fig. 3C) 
and for UCP-1 (Fig. 3E). While relative cell size did not differ between the two treatment 
groups (Fig. 3D), quercetin did induce the presence of UCP-1 positive cells (indicated 
by the arrows) while these were completely absent in the control animals (Fig. 3E). We 
also attempted to measure UCP-1 content in sWAT via western blot, but the content 
appeared too low to draw conclusions (data not shown). Quercetin did not increase 
mitochondrial abundance since only the mitochondrial DNA versus nuclear DNA ratio of 
16s/Hk2 tended to be increased (P=0.08, Suppl. Fig. 4B) in the quercetin treated animals 
while Cox2/Ucp2, Cox2/Hk2 and 16S/Hk2 were unaffected. In line with the qRT-PCR data, 
quercetin did not affect histological appearance and lipid droplet content of BAT (Fig. 
3F, g), gWAT (Suppl. Fig. 5C, D), and vWAT (Suppl. Fig. 5E, F). Also, quercetin did not 
affect UCP-1 content in BAT (Fig. 3H) or UCP-1 protein content as measured via western 
blot (data not shown). All in all, our data shows that quercetin increases expression of 
BAT markers and UCP-1 content specifically in sWAT.
Figure 4. Proposed mechanism by which quercetin lowers plasma triglycerides (Tg). Plasma TG levels 
are regulated by intestinal TG absorption, hepatic VLDL-TG production and the clearance of TG-derived 
fatty acids (FA) by peripheral organs such as sWAT in a process that is dependent on lipoprotein lipase (LPL) 
(left). Quercetin induces browning of sWAT resulting in increased uptake of TG-derived FA by sWAT. This 
may contribute to lowering of plasma TG levels. Moreover, quercetin may also lower lipolysis from (s)WAT, 
which may contribute to lower plasma free FA (FFA) levels and lower VLDL-TG production by the liver, also 
contributing to lower plasma TG levels. Lastly, quercetin increases uptake of lipids by the intestine, which 
apparently does not counteract the reduction in plasma TG levels (right). Bold arrows indicate increased 





Previous studies in humans and animals have shown that quercetin is a possible new 
agent to improve metabolic health, since it lowers plasma TG levels [7, 13, 14]. The 
organs involved in the TG-lowering effect of quercetin remained obscure so far. In the 
current study, we demonstrated that quercetin reduces plasma TG as well as FA levels ac-
companied by increased flux of TG-derived FA towards sWAT, but not BAT, and induction 
of browning of this depot. Quercetin probably lowers VLDL-TG production as indicated 
by lower Apob expression. We conclude that the TG-lowering effect of quercetin may, 
at least in part, be due to increased TG-derived FA uptake by sWAT as a consequence of 
browning (Fig. 4). 
Our finding that quercetin lowers plasma TG levels has been repeatedly shown by oth-
ers [7, 11, 13, 29]. Of note, in all of these studies quercetin lowers plasma TG levels even 
though different concentrations (ranging from 0.025% to 0.33% w/w) of quercetin were 
added to a high fat and/or high fructose diet. This indicates that quercetin is a potent 
modulator of plasma TG levels and exerts metabolically beneficial effects at a wide dose 
range. In contrast to our study, several of these studies also reported a reduction in body 
weight following quercetin treatment, again in a dose range [7, 11]. This discrepancy 
might be explained by a difference in age of the animals at the start of the intervention. 
Studies that describe weight reduction after quercetin treatment used animals of 4-5 
weeks of age, which are not yet developed into adult mice and might therefore be more 
susceptible to body weight changes caused by the intervention compared to the 9 week 
old animals as used in this study. 
To gain insight into the mechanism underlying the TG-lowering effect of quercetin, we 
determined the effect of quercetin on several metabolic organs and performed kinetic 
studies to assess FA fluxes. To assess whether quercetin affected intestinal FA absorp-
tion, we measured fecal FA output. A previous study in Caco-2 cells, which mimic human 
intestinal epithelial cells, shows that quercetin increases 3H-FA uptake, but only when 
initial 3H-FA uptake was reduced under conditions of oxidative stress [30]. However, 
fecal FA in our study was lower rather than higher in the quercetin treated group. This 
suggests higher rather than lower intestinal FA absorption, which therefore cannot ex-
plain the observed reduction in plasma TG levels. Interestingly, we found that quercetin 
reduced liver Apob expression, which might indicate lower VLDL production. In support 
of this hypothesis, Gnoni et al. [31] found that stimulation of isolated rat hepatocytes 
with quercetin decreases TG synthesis and VLDL-TG formation due to lower ACC and 
diacylglycerol acyltransferase activity. A lower VLDL-TG production might underlie the 
increase in liver weight in the quercetin treated animals by inducing a trend towards 
higher TG accumulation. Of note, this is in contrast to previous literature in which liver 
weight was shown to be unaffected [32] or even decreased, due to a reduction in liver 
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TG [11]. Next to a direct effect of quercetin on hepatocytes, a lower VLDL production in 
vivo might also be the consequence of lower FA flux towards the liver due to reduced FA 
liberation by lipolysis in WAT. In line with this, we showed that quercetin lowered plasma 
FFA levels, although we did not find any effect of quercetin on expression of markers of 
lipolysis in white adipose tissue (not shown). Rather, others have shown that quercetin 
increases lipolysis in white adipocytes [15, 33]. Alternatively, lower plasma FFA levels 
might also be a consequence of increased FFA uptake by adipose depots, since not only 
TG-derived FA but also FFA can be taken up by BAT [34] and possibly also by browned 
white adipose tissue.
Our kinetic study using labeled lipoprotein-like TG-rich particles showed that 
quercetin increases the uptake of TG-derived FA specifically by sWAT, the depot that 
is especially prone to browning [35]. This metabolic effect along with increased Ucp1 
and Elovl3 expression and the presence of UCP-1 positive cells in sWAT, is fully compat-
ible with increased browning. In agreement with our results, Lee and colleagues [15] 
recently showed that onion peel, with quercetin as a main component, induces Ucp1 
expression in white adipose tissue of mice. In that study, effects on plasma TG levels 
were not reported. Of note, we found that quercetin solely increased Ucp1 expression 
and TG-derived FA uptake in sWAT and did not affect uptake by BAT in our study. Adipose 
depot-specific responses to intervention have been observed before. For instance, mice 
with genetically increased levels of bone morphogenetic protein 4 are protected from 
obesity due to a phenotype with sWAT browning despite the fact that BAT accumulates 
lipids and adapts a beige/brite phenotype [36]. It can be questioned whether adipose 
tissue browning has the capacity to reduce plasma TG levels, also since the UCP-1 
content in sWAT is quite low. Interestingly, inactivating the classical BAT depot by se-
lective inhibition of lipid droplet lipolysis induces WAT browning and lowers TG levels 
in peripheral organs, which indeed demonstrates the potency of browning per se to 
affect TG distribution [37] and possibly also to reduce plasma TG levels. Our data thus 
suggest that quercetin induces browning that could, at least in part, be responsible for 
the improved plasma TG levels (Fig. 4). Future studies are evidently needed to clarify 
the extent to which adipose tissue browning contributes to the metabolically beneficial 
effects induced by quercetin. 
How quercetin might induce browning of sWAT has not yet been fully elucidated. Lee 
et al. [15] propose a mechanism by which quercetin acts directly on the adipocyte and 
induces browning at least in part via the AMP-activated protein kinase (AMPK)/SIRT1/
PGC1α pathway. Activation of this pathway results in increased Pgc1α expression, sug-
gesting to increase mitochondrial biogenesis. Although quercetin tended to slightly 
increase one of the four mtDNA/nDNA ratios in sWAT in our study, quercetin did not 
affect sWAT p-AMPK/AMPK ratio and Pgc1α expression. Interestingly, quercetin is known 
as a phytoestrogen because of its binding capacity to the estrogen receptor (ER) [38]. 
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Pharmacological activation of the ER subtype β (ER-β) in mice reduces body weight and 
adiposity with concomitant enhanced oxygen consumption and elevated core body 
temperature [39]. Moreover, ER-β ligand LY3201 induces browning of sWAT by modulat-
ing the sympathetic ganglia and the adipocytes directly [40]. The mechanism underlying 
the quercetin induced browning of specifically sWAT and possible involvement of the 
ER-β remains to be determined and is an interesting avenue to pursue in future studies. 
In addition, whether quercetin induces browning in humans, and whether this mediates 
the improvement of TG metabolism, remains to be studied. 
In conclusion, our study shows that quercetin induces browning of sWAT, which results 
in an increased flux of TG-derived FA towards sWAT and which may, at least in part, un-
derlie the TG-lowering effect of quercetin (Fig. 4). The mechanism behind these effects 
and the ability of quercetin to induce browning in humans remains to be determined.
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Supplementary figure 1. Schematic overview of studied fat depots. Subscapular BAT (sBAT), interscap-
ular BAT (iBAT), mesenteric visceral WAT (vWAT), gonadal WAT (gWAT) and subcutaneous WAT (sWAT).
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Supplementary figure 2. quercetin increases liver weight, plasma total cholesterol and decreases 
plasma free fatty acids. Organ weight of liver, spleen, iBAT and gWAT (A) was determined at the end of 
the intervention. Plasma total cholesterol (B), free fatty acids (D) and glucose (E) were analyzed at the indi-
cated time points. Cholesterol distribution over lipoproteins after separation from pooled plasma after 12 
weeks of treatment was assessed by FPLC (C). In the third week of treatment, animals were placed in fully 
automatic metabolic cages and respiratory exchange ratio (F) and activity (G) were determined. Data are 
represented as mean ± SEM (n=8-10), *P<0.05 versus control.
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Supplementary figure 3. quercetin does not affect liver lipids or whole liver Tg-derived FA uptake. 
Liver was analyzed for content of triglyceride (TG), total cholesterol (TC) and phospholipid (PL) (A). Rep-
resentative pictures of liver sections stained for H&E from control and quercetin treated animals (B, bar 
indicates 200µm). Gene expression in the liver was determined by qRT-PCR (C). After 12 weeks, mice were 
injected with glycerol tri[3H]oleate-labeled lipoprotein-like particles and uptake was determined by 3H-
activity corrected for whole organ weight (D). Data are represented as mean ± SEM (n=8-10); expression of 
genes was corrected for the reference gene β2-microglobulin.
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Supplementary figure 4. quercetin does not affect the p-AmPK/total AmPK ratio and tends to in-
crease the 16s/Hk2 ratio in subcutaneous white adipose tissue. Protein levels were determined by 
western blot in sWAT (A). Total DNA was isolated from sWAT and primers for mitochondrial and nuclear 
encoded genes were used to determine the mitochondrial DNA versus nuclear DNA ratio (mtDNA/nDNA, 




Supplementary figure 5. quercetin does not affect browning markers in gonadal and visceral white 
adipose tissue. Gene expression was determined by qRT-PCR in gWAT (A) and vWAT (B). H&E staining was 
performed on sections of gWAT (C) and vWAT (E) from control and quercetin treated animals and repre-
sentative pictures are shown and all pictures were used to determined relative cell size in gWAT (D) and 
vWAT (F) in ImageJ. Data are represented as mean ± SEM (n=8-10); expression of genes was corrected for 
the reference gene β2-microglobulin. ND (not detected) indicates the average CT values were >32. *p<0.05 
versus control. Bars (A and E) indicate 200 µm.
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The current worldwide obesity epidemic demands the development of novel preventive 
and curative approaches that aim at reducing obesity and its related diseases includ-
ing type 2 diabetes (T2D) and cardiovascular diseases (CVD). Obesity is a multifactorial 
disease initiated by an energy imbalance where energy intake exceeds expenditure. 
Energy-combusting brown adipose tissue (BAT) has been identified as an important 
player in energy balance, at least in rodents and likely also in humans.
In this thesis, we first describe substrate flux experiments that were conducted in a 
currently available murine brown adipocyte cell line. Furthermore, we generated new 
in vitro brown adipocyte models for mice and humans, with the aim to better under-
stand energy metabolism of brown adipocytes and potential species differences. Since 
obesity and the subsequent development of T2D and CVD are closely linked to systemic 
inflammation, strategies aimed at inhibiting pro-inflammatory cytokines are extensively 
studied for their therapeutic effectiveness. To gain more insight in the potential role 
of the anti-inflammatory cytokine IL-37, we studied the effect of IL-37 on the energy 
balance. Next, we investigated the effect of diet-induced obesity (DIO) development 
on BAT function in relation to yet another important regulator of the energy balance, 
the endocannabinoid system (ECS). Finally, we studied the therapeutic potential of the 
dietary compound quercetin on triglyceride metabolism.
From this thesis, novel insights into the pathophysiology of obesity have arisen, with 
the emphasis on BAT and white adipose tissue (WAT), which will be discussed in this 
final chapter. Furthermore, therapeutic implications, translational limitations and future 
perspectives will be addressed.
SuBSTRATE uSE By BROWN ADiPOCyTES
Lessons from in vitro and in vivo studies
From in vivo studies it is known that brown adipocytes take up both glucose, free fatty 
acids (FA) and triglyceride-derived FA. While activated BAT primarily burns FA to produce 
heat, it also takes up large amounts of glucose. In fact, glucose uptake by BAT as visu-
alized by positron emission tomography-computed tomography (PET/CT) scan is the 
current ‘gold’ standard to determine BAT activity in humans (discussed below). However, 
why brown adipocytes take up a substantial amount of glucose upon activation is not 
entirely known. Therefore, one of our objectives was to better understand brown adi-
pocyte metabolism by studying how activated brown adipocytes handle glucose and 
free FA. In Chapter 2 we studied the metabolic fluxes of glucose, FA and glutamine in 
differentiated T37i brown adipocytes after activation with the β3-adrenergic receptor 
(AR) agonist CL316,243 (Fig. 1 of this discussion). By measuring oxygen consumption 
of T37i brown adipocytes in the presence of specific substrate inhibitors, we confirmed 
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that FA were the main substrate for oxidation, both in resting and activated conditions. 
Besides FA, T37i brown adipocytes simultaneously oxidize glucose and glucose is also 
utilized for alternative metabolic pathways such as glycerol synthesis. This indicated that 
although FA are the main substrate for activated brown adipocytes, glucose also has a 
central role in their energy metabolism. In fact, Albert et al. [1], showed that glucose 
uptake is essential for BAT thermogenesis in mice since defective glucose uptake and 
glycolysis through inactivation of the kinase mTOR Complex 2 in adipose tissue results 
in cold intolerance. Restoration of glucose uptake, by overexpression of the glycolysis 
enzyme hexokinase II, also restores cold tolerance. Pyruvate dehydrogenase (PDH) is a 
central regulator in intracellular glucose metabolism. Active PDH, as rapidly induced in 
brown adipocytes after β3-AR activation in Chapter 2, couples glycolysis in the cytosol 
to oxidative metabolism by forming acetyl-CoA from pyruvate which can support the 
tricarboxylic acid (TCA) cycle in mitochondria [2]. In addition, the generated acetyl-
CoA can also be used for lipogenesis. Indeed, we found that glucose not only directly 
contributed to uncoupled respiration, but also ended up in the glycerol backbone of 
triglycerides and not in the FA. In contrast, others have reported that glucose taken up 
WAT
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Figure 1. Dietary modulation of adipose tissue and energy balance. See text for explanation. BAT, 
brown adipose tissue; WAT, white adipose tissue.
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by primary brown adipocytes and immortalized murine BAT cells, is primarily used to 
generate de novo FA which are used to generate triglycerides [3]. This discrepancy might 
be the result of diff erences in experimental set-up (i.e. brown adipocyte model, glucose 
concentration, intracellular lipid content). Taken together, we provided evidence that 
besides FA also glucose contributes to uncoupled respiration in activated T37i brown 
adipocytes in vitro and, at least in these brown adipocytes, also to glycerol synthesis 
for triglyceride production. To evaluate substrate use by brown adipocytes in absence 
of proliferation pressure and to reveal potential species diff erences, future studies on 
substrate use in our newly developed diff erentiated brown preadipocytes (BPAs) from 
murine and human origin (Chapter 3) are warranted.
BAT activation not only enhances glucose and FA catabolism, but also increases the 
expression of glycogen synthesis genes [4, 5]. Glycogen is a glucose polymer and is, 
besides triglycerides, another form of long-term energy storage in the body. Although 
glycogen is primarily found in the liver and skeletal muscle, it can thus also be found in 
BAT. Already 20 years ago, Farkas et al. [6] showed that cold exposure of rats led to an ini-
tial decrease of the glycogen content in BAT followed by glycogen accumulation in the 
recovery period. This compensation in glycogen storage is also observed in muscle upon 
exercise [7]. Increased glycogenesis after BAT activation has been proposed to provide 
a readily available pool of glucose to ensure avid glycolysis and acetyl-CoA turnover [4] 
and is therefore probably an indirect consequence of BAT activation. However, the exact 
role of glycogen in BAT metabolism is still elusive and would be interesting to further 
explore in future studies.
It should be noted that in vivo, the total infl ux of FA into BAT is highly regulated 
by lipoprotein lipase (LPL) [8, 9]. Functionally, LPL liberates FA from triglyceride-rich 
lipoproteins, which can subsequently be taken up by BAT via FA transporters cluster of 
diff erentiation 36 (CD36) and FA binding protein (FABP). Although brown adipocytes 
express LPL, in vivo translocation and anchoring of LPL to the luminal side of capil-
lary endothelium by the protein glycosylphosphatidylinositol-anchored high-density 
lipoprotein-binding protein 1 (GPIHBP1) is required [10, 11]. By studying monocultures 
of brown adipocytes, LPL will be released from the cells as inactive LPL monomers. 
Therefore, by using monocultures of brown adipocytes the uptake of FA is likely highly 
underestimated, as triglyceride-derived FA uptake does not occur. To better mimic the 
physiological in vivo situation, future studies should preferably study nutrient handling 
using organ-on-chip models of BAT, in which e.g. diff erentiated BPAs as described in this 
thesis are co-cultured with endothelial cells. Such a dual cell culture system will probably 
also enable studying the pathophysiology of a fatty acid overload, as in DIO, on brown 
adipocytes in more detail. Furthermore, since LPL-activating strategies are currently 
being developed to lower TG and reduce cardiovascular disease risk, such ‘BAT-on-chip’ 
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models may be valuable to screen small molecules for LPL-activating properties, which 
can become leads for development of new drugs to combat CVD.
Assessment of BAT activity in vivo
Nutrient uptake by BAT is currently used as an indirect assessment of BAT activity in 
mice and humans. The most used technique to determine BAT activity in humans is by 
means of [18F]fluorodeoxyglucose ([18F]FDG) uptake measured by PET/CT. However, this 
technique has several limitations. The fact that the uptake of glucose heavily relies on 
proper insulin signaling, hampers its applicability in insulin resistant persons. Moreover, 
the primary energy source for brown adipocyte thermogenesis is FA rather than glucose 
(Chapter 2 and [4]), and a major fraction of the injected [18F]FDG ends up in the brain. 
As an alternative, the FA tracer 14(R,S)-[18F]fluoro-6-thia-heptadecanoid acid (FTHA) 
has been used to detect BAT [12]. Although uptake by the brain is prevented, [18F]FTHA 
binds to albumin in the blood and is largely taken up by the liver, which limits potential 
uptake of [18F]FTHA by BAT and at the same time results in a large background signal 
in PET/CT scans. Moreover, our previous mouse studies have shown that BAT primarily 
and specifically takes up triglyceride-derived FA [13], without uptake by brain and only 
low uptake by liver, and we have no reason to doubt this is also the case in humans. 
Although the uptake of triglyceride-derived FA by BAT may also, at least partly, be 
dependent on insulin signaling, future studies are thus warranted to investigate the 
applicability of an 18F-labeled FA incorporated into triglycerides that are packed inside 
reconstituted triglyceride-rich lipoproteins [14] to specifically determine triglyceride-
derived FA uptake by BAT also in humans. Such a novel radiotracer will enable studying 
lipoprotein kinetics and uptake by BAT similar to our rodent studies (Chapter 5 and 7), 
without having to take biopsies of the tissues or collect tissues post mortem. Another, 
possibly even more appropriate method to determine overall BAT activity determines 
the oxidative metabolism of tissue, rather than the substrate uptake, by making use of a 
[11C]acetate tracer for oxidative metabolism by PET/CT [15]. However, all of these PET/CT 
techniques make use of radioactive tracers and the resulting radioactive exposure limits 
repeated measurements, while multiple measurements would be needed to monitor 
the effect of an intervention.
Another non-invasive indirect imaging method that is being developed for assessing 
BAT activity is magnetic resonance imaging (MRI). A main advantage of MRI over PET/CT 
is that it does not involve radioactive exposure and it can therefore be repeatedly used. 
MRI makes use of water-fat separation to determine the fat fraction and this enables to 
discriminate between BAT with a low fat fraction and WAT with a higher fat fraction [16]. 
By determining the fat fraction before and after cold exposure, which induces intracellu-
lar lipolysis and FA combustion [17], the decrease in fat fraction might be a suitable mea-
sure for BAT activity [18]. However, replenishment of the lipid stores with nutrients from 
177
8
the circulation [13] will most likely rapidly compensate for the decreased fat fraction and 
thereby underestimate the BAT activity when only assessing fat fraction using MRI. MRI 
can also be used to observe blood flow [16]. Since BAT activation increases blood flow to 
BAT [19], monitoring perfusion might provide additional insight into the activation state 
of the tissue, possibly in relation with nutrient uptake as discussed above.
Since the primary function of active BAT is to produce heat, in many rodent studies 
rectal or core body temperature have been registered as a more direct approach to as-
sess BAT activity [20-22]. Transponders, that locally measure temperature within or in 
the vicinity of the BAT depot, have also been used in different studies [23-25]. Although 
higher rectal temperature, core body temperature or even the temperature near BAT in 
a BAT-stimulated setting compared to a control situation might suggest increased BAT 
activity, contribution of other organs or tissues to the increase in temperature cannot 
be excluded. In Chapter 5, we used a dual-lead telemetry transmitter to simultaneously 
measure interscapular BAT temperature and core body temperature, and observed that 
both leads measured similar temperatures. Hence, this method of assessing BAT temper-
ature might be less specific for BAT thermogenesis and more sensitive to temperature 
changes caused by blood flow, providing BAT with blood of higher temperature. This 
may be a mouse-specific phenomenon, as in humans BAT activation does increase skin 
temperature in the supraclavicular area without affecting the core body temperature 
[26], which may be related to substantial differences in metabolic rate between humans 
and mice (i.e. heart rate is 10-fold higher in mice than humans).
Another promising and non-invasive approach to assess BAT activity is infrared 
thermography (IRT) which has been used in rodent [27] and human [28] studies. Cold 
exposing healthy lean human subjects increases supraclavicular skin temperature, 
as measured with IRT, which positively correlates with the uptake of [18F]FDG by BAT 
measured by PET/CT [28]. Although IRT is a promising and non-invasive method, IRT is 
restricted to detecting surface temperature only. More research should be conducted to 
assess the applicability of IRT in measuring BAT activity in overweight and obese indi-
viduals who have more insulation as a result of subcutaneous WAT in the supraclavicular 
area. Another approach to measure (supraclavicular) skin temperature is by the use of 
iButtons [29, 30]. However, a drawback of the use of either IRT or iButtons is vasodilation 
following heat production by active BAT as this might interfere with IRT and iButtons 
measurements.
Aside from imaging techniques, many labs are searching for easily accessible circulating 
biomarkers for BAT activity. We showed that pre-cooling serum lysophosphatidylcholine 
(lysoPC)-acyl C16:0 levels correlate with BAT volume and metabolic activity assessed by 
[18F]FDG PET/CT in healthy lean men [31]. However, we [31] as well as Lynes et al. [32] 
found no increase in lysoPC-acyl C16:0 levels in plasma in a small cohorts of healthy lean 
humans upon cold exposure. BAT excretes small lipid vesicles called ‘exosomes’ that con-
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tain e.g. lipids, proteins, messenger RNAs and micro RNAs (miRNAs), which are used for 
cell-to-cell communication [33]. Interestingly, cold exposed and CL316,243 treated mice 
had lower miRNA miR-92a levels when compared with controls, and miR-92a showed a 
modest negative correlation with BAT activity in humans. This suggests that less miR-92a 
is released by BAT upon activation, but additional studies in larger cohorts are needed to 
confirm this finding. As a third example, cold exposure increases fibroblast growth factor 
21 (FGF21) levels in mice [34] and men [35, 36]. A challenge is to determine whether 
the biomarker is exclusively expressed and secreted by active BAT. For instance, FGF21 
is also expressed and secreted by the liver [37]. The recently developed technique of 
microdialysis [38], which enables the measurement of arterio-interstitial differences 
in substrates and intermediates in human BAT, will be a valuable tool to advance the 
search for suitable BAT biomarkers. However, a major downside of this technique is the 
invasive nature and the radiation exposure from PET/CT scanning which is needed for 
correct placement of the catheter. Finding a specific BAT activity biomarker is however 
relevant as it can also help to decipher the relative contribution of BAT and the muscle 
in thermogenesis and whether we are activating BAT maximally (discussed below). Also, 
biomarkers will be valuable tools to select those individuals with low BAT activity who 
will probably benefit most of BAT-activating strategies, and to monitor the success of 
BAT activation.
In conclusion, as yet there is no optimal measure for BAT activity in vivo. The various 
currently used approaches as discussed above hold several limitations. Finding a (set of ) 
BAT specific biomarkers is of great scientific interest and the most promising avenue to 
pursue. In the meantime, the use of IRT and developing triglyceride-rich lipoproteins 
with a radiolabeled FA incorporated into a triglyceride to determine BAT activity seem 
promising alternatives.
mODiFiERS OF BAT FuNCTiON AND CARDiOmETABOLiC HEALTH
The endocannabinoid system
Many endogenous factors have been shown to modulate energy metabolism by 
regulating BAT activity. For example, BAT is activated by hormones such as norepi-
nephrine, T3, FGF21, and secretin [39, 40]. In addition, BAT activity is modulated by 
the endocannabinoid system (ECS), consisting of the endocannabinoids anandamide 
(N-arachidonoyl-ethanolamine, AEA) and 2-arachidonoylglycerol (2-AG), their receptors 
cannabinoid 1 receptor (CB1R) and cannabinoid 2 receptor (CB2R) and the enzymes 
that synthesize and degrade the endocannabinoids. In fact, the ECS modulates energy 
balance at several levels; it regulates appetite, lipogenesis in adipose tissue and energy 
expenditure [41, 42]. An overactive ECS has been associated with obesity and T2D [43-
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45]. Interestingly, the inverse CB1R antagonist rimonabant profoundly reduced fat mass 
and dyslipidemia in clinical trials [46-48], although psychiatric side effects unfortunately 
prevented further development as a weight loss drug. Of note, previous studies from our 
group showed that rimonabant activates BAT in lean as well as DIO mice [49].
We now aimed to gain more insight into the derailment of the ECS towards overactivity 
in obesity development, as such information could be used to develop e.g. tissue-specific 
inhibitors of endocannabinoid synthesis to improve energy metabolism without adverse 
effects in the brain as was induced by rimonabant. Therefore, in Chapter 6, we fed differ-
ent groups of mice a high fat diet (HFD) for a duration of 1 day up to 18 weeks as a model 
to study the effects of DIO development on the ECS. We found increased plasma levels 
of the two endocannabinoids AEA and 2-AG, within 1-2 weeks of HFD feeding. Increased 
circulating endocannabinoid levels in obesity have also been reported in mice [50, 51] 
and men [43, 44, 52] by others. However, it remained unclear which organs contribute to 
the increased plasma endocannabinoid levels. We found rapidly increased expression of 
endocannabinoid synthesis enzymes N-acylphosphatidylethanolamine-phospholipase 
D (NAPE-PLD) and diacylglycerol lipase-α/β (DAGLA/B) in WAT and BAT, suggesting that 
at least these two organs are involved in enhanced endocannabinoid synthesis in the 
development of obesity (Fig. 1). Since endocannabinoids are lipid derivatives [53], it is 
likely that the increased flux of HFD-derived fatty acids to adipocytes induces the syn-
thesis of endocannabinoids, which are then secreted from adipocytes and accumulate 
in plasma. The increased production of endocannabinoids in the development of DIO 
is most likely the reason why systemic, but also strictly peripheral, CB1R antagonism is 
effective in reducing fat mass and dyslipidemia [49, 54, 55].
Besides antagonism of CB1R, an alternative promising approach to target the ECS 
in obesity treatment is to modulate the activity of the enzymes involved in the endo-
cannabinoid biosynthesis and degradation. Based on results presented in Chapter 6, 
inhibiting biosynthesis enzymes NAPE-PLD and DAGLA/B in WAT and BAT might be a 
worthwhile strategy to pursue. The last couple of years several DAGLA/B inhibitors have 
been generated [56], which thus have high potential for treating metabolic disorders 
such as obesity and diabetes. It should however be noted that endocannabinoids 
have a wide range of effects. Besides their role in the regulation of the energy bal-
ance, they are also involved in regulating pain and inflammation. Actually, inhibitors 
of the endocannabinoid degradation enzymes fatty acid amide hydrolase (FAAH) and 
monoacylglycerol lipase (MAGL) are being tested for the treatment of inflammatory 
pain and anxiety disorders [57]. Because of the wide-range of processes in which the 
ECS is involved, modulating endocannabinoid synthesis and degradation to counteract 
the increased endocannabinoid levels as observed in obesity will thus probably require 
a tissue-specific approach. Based on the notion that hepatocyte-specific downregula-
tion of gene expression can already be achieved in the clinic using asialoglycoprotein 
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receptor-targeted short interfering RNA [58], WAT/BAT-specific silencing of genes 
involved in endocannabinoid synthesis can probably be achieved in a similar way once 
tissue-specific targetable cell surface receptors have been identified.
BAT mitochondrial dynamics
Long-term HFD feeding of mice results in insulin resistance and whitening of BAT [23, 
59]. Interestingly, in the time course of HFD feeding the largest increase in lipid content 
in BAT was observed already in the first week of HFD feeding after which intracellular 
lipid levels reached a plateau. Hence, we studied the effect of one week HFD feeding 
on BAT in more detail in Chapter 5. We found increased lipid deposition in BAT, one of 
the characteristics of BAT whitening, already after a single day of HFD feeding (Fig. 1). 
Mechanistically, HFD feeding immediately induced BAT insulin resistance resulting in 
decreased uptake of both glucose and triglyceride-derived FA by this tissue. We also 
observed alterations in the BAT mitochondrial morphology markers upon HFD feeding 
in Chapter 5. Mitochondria are dynamic organelles, and as a part of their mitochondrial 
quality control pathways, fuse and fragment based on the energy status of the cell. In 
fact, the name mitochondrion is inspired by their heterogeneous morphology; mitos 
means ‘thread’ and chondrion means ‘granule’ [60]. Fusion of mitochondria is regulated 
by mitofusins (MFN1 and MFN2) and optic-atrophy gene 1 (OPA1 or mitochondrial 
dynamin like GTPase) and fission or fragmentation of mitochondria is mediated by fis-
sion 1 protein (FIS1) and dynamin-related protein 1 (DRP1). Activation of BAT, e.g. by 
cold or G-protein coupled receptor (GPR)-120 agonism, is associated with mitochondrial 
fragmentation [61, 62], in which DRP1 mediated fission is required for mitochondrial 
uncoupling and energy expenditure [61]. Forced mitochondrial fragmentation in brown 
adipocytes, by knocking down MFN2, did not affect the norepinephrine-stimulated 
energy expenditure but did increase the ability of FFA to increase energy expenditure 
[61]. As such, in vivo knock out of MFN2 in BAT [63] and in total adipose tissue [64] led to 
BAT dysfunction resulting in impaired cold tolerance, while insulin sensitivity upon HFD 
feeding was, surprisingly, improved in both models. Boutant et al. [64] proposed that 
MFN2 is important for mediating interaction between mitochondria and lipid droplets; 
MFN2 deletion results in impaired FA catabolism and, as a result, in increased glucose 
uptake and glycolysis. In Chapter 5, we found indications for a more fused mitochon-
drial network after three days of HFD feeding, with increased levels of OPA1 and phos-
phorylated DRP1 that inhibits mitochondrial fission. Since fragmentation is associated 
with enhanced BAT function, a more fused mitochondrial network might indicate an at-
tenuation of BAT function. Although the role of mitochondrial dynamics in BAT has only 
recently become topic of investigations, various studies underscore the importance of 
this process in BAT function [61-64]. Further studies are evidently needed to determine 
whether mitochondrial fragmentation can be promoted specifically in BAT, for instance 
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by using antisense oligonucleotides against MFN2 and OPA1 or a pharmacological ap-
proach, in order to increase BAT uncoupling potential and improve insulin sensitivity. In 
addition, electron microscopy imaging techniques, such as serial block face scanning 
electron microscopy [65], may be helpful in future studies to visualize the effects of BAT 
activation on the mitochondrial network morphology of BAT.
Receptor involvement in the activation of BAT
Generation of the murine and human BPA cell lines (Chapter 3) also enabled us to 
study species differences in the activation of brown adipocytes. In mice, it has become 
clear that the β3-AR is predominantly involved in cold-induced BAT activation [17]. BAT 
activation with the highly selective β3-AR agonist CL316,243 increases energy expendi-
ture, prevents fat accumulation, improves dyslipidemia and attenuates atherosclerosis 
development in mice [66]. Human studies, so far, have been less conclusive. Cypess et al. 
[67] showed that a single dose of 200 mg of mirabegron, a moderately selective β3-AR 
agonist, led to increased [18F]FDG uptake by BAT as measured by PET/CT imaging ac-
companied by an increased resting energy expenditure (REE). However, a dose of 50 mg 
mirabegron, which is the pharmacological dose to activate the β3-AR and prescribed to 
patients with an overactive bladder, appeared insufficient to activate BAT and increase 
REE [68]. In addition, the high dose of mirabegron also increased heart rate and blood 
pressure [67] [Nahon et al., submitted], which suggests cross reactivity of mirabegron 
with other β-ARs such as β1-AR that is expressed by the heart. Unexpectedly, upon incu-
bation of the murine and the human BPAs generated in Chapter 3 with either vehicle, 
CL316,243 or the non-specific agonist norepinephrine, only the murine cells responded 
to CL316,243 with enhanced intracellular lipolysis and increased oxygen consumption 
(OCR) compared to vehicle [Blondin, Kuipers et al., unpublished]. In contrast, norepi-
nephrine activated BPAs of both species. Since this indicates that human brown adi-
pocytes are unresponsive to the β3-AR agonist CL316,243, it seems likely that another 
receptor, such as the β1-AR or the β2-AR, is involved in human BAT activation. Indeed, 
the human BPAs showed increased intracellular lipolysis and UCP1 expression upon 
stimulation with the β2-AR agonist formoterol. Moreover, treatment of human BPAs with 
the β2-AR antagonist ICI118,551 almost completely abolished the effects of formoterol, 
norepinephrine and mirabegron. Based on these in vitro data, it is likely that the high 
dose of mirabegron required to activate human BAT acts via activating the β2-AR rather 
than the β3-AR. Although this finding warrants studying the effect of a specific β2-AR 
agonist on BAT activity in humans, therapeutic application may be hampered because of 
effects of β2-AR activation on the cardiovascular and pulmonary system.
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Anti-inflammatory strategies
Obesity, T2D and CVD are associated with inflammation. Several pro-inflammatory 
cytokines are upregulated in obesity, including interleukin-1β (IL-1β), IL-6 and tumor 
necrosis factor-α (TNF-α) and have been targeted in preclinical studies to assess thera-
peutic applicability to combat metabolic diseases. Salsalate, by inhibiting NF-κB, inhibits 
transcription of many pro-inflammatory cytokines and exerts beneficial metabolic ef-
fects such as improved glucose and lipid levels and increased energy expenditure in 
humans [69, 70]. Furthermore, tocilizumab, a humanized monoclonal antibody against 
the IL-6 receptor, improved glucose metabolism as evidenced by decreased glycated 
hemoglobin (HbA1c) levels in a small cohort of rheumatoid arthritis patients with T2D 
[71]. However, IL-6 targeting is complex because IL-6 appears to be a pleiotropic cy-
tokine that functions as a pro-inflammatory cytokine involved in obesity-associated 
insulin resistance as well as a myokine involved in insulin-sensitizing effects [72]. The 
different effects of IL-6 are mediated via different routes of IL-6 signaling, therefore 
therapeutic intervention should rather focus on specifically inhibiting the deleterious 
signaling route of signaling rather than merely targeting the upstream signaling such as 
circulating IL-6 levels [73].
In contrast to pro-inflammatory cytokines, the anti-inflammatory cytokines such as 
IL-10 and IL-37 are less well studied. IL-10 overexpression has beneficial effects on body 
weight and insulin sensitivity in mice when fed a HFD [74]. However, clinical studies on 
the association between IL-10 levels and clinical outcomes in terms of cardiovascular 
morbidity and mortality are less consistent [75, 76]. Another, potentially more interest-
ing, anti-inflammatory cytokine is IL-13. IL-13 circulating levels are lower in T2D patients 
[77] and mouse studies show that IL-13 has a direct role in maintaining glucose homeo-
stasis during obesity [78]. Transgenic overexpression of yet another anti-inflammatory 
cytokine, IL-37, protects mice from DIO and associated dyslipidemia, inflammation and 
insulin resistance [79]. To decipher underlying mechanisms, in Chapter 4 we showed 
that transgenic overexpression of IL-37 reduced food intake in mice (Fig. 1). Based 
on our data, it is thus likely that a part of the described beneficial effects of IL-37 are 
mediated via induction of satiety. Interestingly, intracerebral infusion of recombinant 
pro-inflammatory IL-18 reduces food intake [80], and both IL-37 and IL-18 bind to the 
IL-18Rα. Therefore, the effects of IL-37 on food intake may well be mediated via IL-18Rα. 
It would thus be interesting to investigate the effects of centrally administered recombi-
nant IL-37 on food intake and other metabolic parameters, and to elucidate the potential 
mediating role of IL-18Rα. Mediators of satiety are valuable for the clinic, especially since 
one of the major reasons for the low adherence to dietary interventions is drive to eat 
[81]. Humans naturally express IL-37, however, whether targeting IL-37 in humans to 
induce satiety has therapeutic potential requires further investigation.
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To conclude, targeting inflammation will most likely improve cardiometabolic disor-
ders. In fact, a landmark study recently showed that a monoclonal antibody targeting 
IL-1β lowered the rate of recurrent cardiovascular events independent of lipid lowering 
[82]. Targeting anti-inflammatory cytokines as a therapy in cardiometabolic disease 
requires more clinical investigation. Currently, salsalate seems to be the most promising 
option as it is already prescribed in the clinic, with favorable metabolic outcome.
ORgAN CROSSTALK iN THERmOgENESiS
The function of active BAT is to produce heat and is therefore part of the body’s ther-
moregulation. There are several thermoregulatory processes involved in maintaining 
temperature homeostasis in mammals, such as vasodilation/constriction, sweating and 
(non)shivering thermogenesis. When core body temperature drops, extra heat must be 
generated to maintain temperature homeostasis. This heat is produced by contraction 
of muscles resulting in thermogenesis due to shivering, and the initiation of nonshiver-
ing thermogenesis in muscles and BAT [83]. In neonates, nonshivering thermogenesis in 
BAT is particularly important because they have a relatively large body surface area to 
lose heat and little capacity to shiver as a result of underdeveloped muscles [17].
As with every homeostatic mechanism, also body temperature regulation relies on 
feedback/forward loops [84]. Studies in rodents from which interscapular BAT was re-
moved, which leads to reduced capacity for nonshivering thermogenesis [85], showed 
that the body compensates by increasing browning of WAT [86] and increasing ther-
mogenesis by other BAT depots [87]. In addition, impaired bone morphogenic protein 
(BMP) signaling in mice, by genetic ablation of type 1A BMP receptor, results in severely 
impaired BAT thermogenesis, with thermogenic capacity being restored by subsequent 
browning of WAT [88]. Conversely, during exercise, which is a heat generating process, 
BAT is hypothesized to be hypoactive because there is a decreased necessity for BAT 
derived heat [17]. The concept that cross-talk exists between tissues involved in thermo-
genesis has also been demonstrated in humans. Blondin et al. [89] showed that reducing 
BAT activity during cold exposure, by preventing triglyceride hydrolysis in adipose tissue 
using nicotinic acid, resulted in earlier shivering and with increased intensity. In Chapter 
5, we observed that core body temperature immediately increased upon switching mice 
from chow to HFD feeding, while BAT became inactivated. It is thus conceivable that 
induction of thermogenesis elsewhere in the body, in this case by the metabolic organs 
that process the excess of dietary lipids (i.e. intestine and liver), inactivates BAT by a 
negative feedforward mechanism. Thus, thermoregulation is a multifactorial process 
where the loss or production of heat by a certain thermogenic system is compensated 
for by another system.
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Central in thermoregulation are the temperature sensitive receptors such as tran-
sient receptor potential (TRP) channels. Cold stimulates TRP channels of the subfamily 
melastatin 8 (TRPM8) present on sensory nerves in the skin [90], which signal to the 
hypothalamus. The TRP channels of the melastatin subtype [91], but also the TRP vanil-
loid (TRPV) subtype [92, 93] are present on several peripheral organs including BAT 
(reviewed in [94]). The TRPM8 agonist menthol induces a brown-like phenotype in white 
adipocytes in vitro [95] and menthol mixed through the diet activates BAT thermogen-
esis in vivo [91]. In contrast to TRPM channels which are activated by cold, TRPV channels 
are activated by heat. Activation of TRPV1 by dietary compound capsaicin most likely 
activates and recruits human BAT (reviewed in [96]). In addition, TRPV2 KO mice are cold 
intolerant, have impaired BAT thermogenesis and are prone to develop obesity when 
fed a HFD [92]. The fact that endocannabinoids, which have profound effects on energy 
metabolism as outlined above, are able to bind to TRP channels makes these receptors 
even more interesting for future research into BAT function specifically and systemic 
thermoregulation in general [97].
Thus, in the search for tools to increase energy expenditure as a potential target for 
therapy of adiposity and related cardiometabolic disorders, BAT activation might be 
even more beneficial when combined with activation of other thermogenic processes, 
e.g. in skeletal muscles to prevent potentially negative feedforward loops.
THERAPEuTiC EFFECTivENESS OF BROWN(iNg) ADiPOSE TiSSuE
Many attempts are being made to activate BAT by cold exposure or pharmacologic 
intervention, however the therapeutic applicability of BAT activation in cardiometabolic 
disease in humans is still a matter of debate. Beneficial effects of cold-induced BAT acti-
vation on plasma glucose and lipid levels have been shown in animal models [8, 17, 66, 
98] and in humans [99-102]. In mice, BAT activation also results in reduced body weight. 
Although BAT activation by means of cold acclimation in humans did reduce fat mass to 
a modest extent [99], cold exposure did not result in weight loss [101, 103, 104]. This can 
be explained by either a modest effect of BAT activation to total energy expenditure or 
by compensatory increased energy intake. 
A main contributor to the different effects of BAT activation between mice and humans 
is the relative amount of BAT in the body. While mice have a relatively large BAT depot 
in the interscapular area resembling that of human newborns, human adults probably 
have much smaller relative amounts of BAT [105], although quantifying BAT volume in 
humans is challenging due to limitations of the imaging techniques as discussed above. 
In mice prolonged cold exposure or β3-AR agonism not only activates BAT but also in-
duces browning of WAT [66] and thereby increases the total number of energy dissipat-
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ing adipocytes. On the other hand, we showed that browning can contribute to lower 
plasma triglyceride levels in mice (Chapter 7). Considering the fact that metabolically 
compromised humans often have large amounts of WAT, and strategies to convert white 
adipocytes into beige adipocytes are actively searched for, inducing browning could be 
of high value to combat metabolic disorders in humans. As a highly interesting example 
of nature, extreme browning of visceral fat in patients with a catecholamine-secreting 
paraganglioma highly increases energy expenditure and leads to weight loss [106]. 
Whether such an extent of browning can be achieved in humans by cold acclimation 
or pharmacological intervention, is still controversial and requires further study [105].
In my opinion, activating BAT, and inducing browning of WAT via for instance dietary 
compounds, as discussed below, still holds potential to combat adiposity and related 
diseases. Small shifts in energy balance that are sustained over time can have major 
effects on health [105]. Thus, inducing a sustained negative energy balance with slightly 
increased energy expenditure, due to activation of BAT or browning, can certainly 
exert beneficial effects. Indeed, moderate (5%) weight loss in obese patients already 
has considerable health benefits including increased insulin sensitivity [107], probably 
related to a decrease in ectopic fat. Since long-term cold exposure is probably not a 
suitable treatment option for most metabolically compromised individuals, alternative 
treatment modalities such as dietary compounds or pharmacological strategies to 
activate BAT and induce browning of WAT are wanted. Combining BAT activation and/or 
browning with attempts to also counteract compensatory increases in energy intake will 
probably further increase beneficial effects of BAT activation and browning. However 
it must be noted that promoting a healthy lifestyle, rather than pharmacological ap-
proaches, should always be the first line of treatment and the cornerstone of for the 
prevention and treatment of obesity and related metabolic diseases.
DiETARy mODuLATiON
As stated above, central in the therapeutic approaches to combat obesity is lifestyle 
modification of which adapting a healthy diet is an important part. Several studies have 
focused on elucidating which dietary measures are most effective in ameliorating or 
preventing metabolic diseases. Comparing the effects of low-carbohydrate interven-
tions with low-fat-diet interventions in overweight individuals (BMI 28-40) without T2D, 
showed that both diets induced weight loss after 12 months to a similar degree [108]. 
On the other hand, in T2D patients low carbohydrate diets improve glycemic control 
[109] and low-carbohydrate interventions are slightly better than low-fat diets [110]. 
Short-term consumption of a low-carbohydrate diet led to a greater decrease in HbA1c 
in T2D patients, than consumption of a low-fat diet [110]. However, on the long-term 
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this difference between diets disappeared most likely due to limited long-term adher-
ence to the dietary inventions. Collectively, in T2D patients reduction in carbohydrate 
consumption may thus be favorable compared to reduction in fat consumption, but also 
the sort of fat or carbohydrate matters. Intake of trans fats is strongly associated with 
higher mortality rates whereas intake of polyunsaturated FA was associated with lower 
mortality rates [111]. Also refined grains and sugar as a carbohydrate source should 
probably be replaced by carbohydrates from whole grains, fruits or vegetables in order 
to decrease the risk of developing T2D and CVD [112-114]. Very recently, Willet et al. 
[115] estimated that transformation to a healthy diet, where red meat and sugars are 
replaced by nuts, fruits and vegetables, will avert around 11 million premature deaths 
per year. 
Increasing consumption of fruits and vegetables will increase the ingestion of dietary 
fibers and a series of systematic reviews and meta-analyses convincingly show that fiber 
intake is dose-dependently associated with reduced incidence and mortality from T2D 
and CVD [114]. Dietary fibers are fermented by gut bacteria to produce short chain FA 
including butyrate. Oral butyrate administration prevents DIO, hyperinsulinemia and 
hypertriglyceridemia in mice [116]. This is attributed to reduced food intake, in addition 
to increased BAT activity by increased sympathetic outflow [116]. Butyrate consumption 
stimulates the production of glucagon-like peptide 1 (GLP-1) by intestinal L cells [117] 
[Li, Rensen et al., unpublished], and GLP-1 signaling is likely involved in these beneficial 
metabolic effects. Also in T2D patients, dietary fibers increase short chain FA-producing 
gut microbiota and improve HbA1c levels, at least partly via increased GLP-1 secretion 
[118]. Activating the GLP-1 pathway with GLP-1 receptor agonists (i.e. liraglutide and 
exenatide) is a strategy that is already widely used for the treatment of T2D [119] and 
shown to reduce CVD [120]. In fact, a recent study showed that treating obese individu-
als with a dual GLP1 receptor and glucose-dependent insulinotropic polypeptide (GIP) 
receptor agonist results in massive weight loss at least similar to that observed with 
rimonabant [121]. However, as dietary approaches to combat metabolic disorders are 
preferred over pharmacological approaches, highly increasing the intake of dietary 
fibers may be a promising strategy to pursue in the fight against obesity and related 
cardiometabolic diseases. 
In addition to fibers, fruits and vegetables also contain polyphenols, to which benefi-
cial metabolic effects have been attributed [122]. The polyphenol resveratrol induces 
browning of WAT [123], improves lipid profiles and reduces atherosclerosis develop-
ment in mice [124]. Although clinical studies on resveratrol are less consistent, trials 
with T2D patients show that resveratrol improves glycemic control [125]. Quercetin, a 
dietary compound that belongs to the polyphenol subclass of flavonoids, lowers plasma 
triglyceride levels in mice [126, 127] and men [128] and thereby targets one of the risk 
factors for developing CVD [129, 130]. In Chapter 7 we now revealed that the quercetin-
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induced lowering of plasma triglyceride levels could at least in part be due to browning 
of WAT (Fig. 1). Since we did not find a stimulatory effect of quercetin on BAT, this sug-
gests that WAT browning is able to reduce plasma triglyceride levels by increasing the 
utilization of triglyceride-derived FA by this tissue. Indeed, BAT inactivation by selective 
inhibition of lipid droplet lipolysis induces WAT browning and lowers triglyceride levels 
in peripheral tissues [131]. Although not reported, this strategy likely also decreased 
plasma triglycerides. Future studies are needed to determine whether WAT browning 
is also involved in the triglyceride lowering effects of quercetin in humans. However, 
since the relative amounts of polyphenols like resveratrol and quercetin in fruits and 
vegetables are small, they should probably be administered as dietary supplements to 
be metabolically effective.
These data reveal that adapting a healthy diet, with a high intake of fruits and veg-
etables, is able to improve metabolic health, at least partly via increased fiber intake. 
However, it is unlikely that a single dietary regime will be effective for every person, 
e.g. since responses in blood glucose to an identical meal show great interindividual 
variability [132]. In conclusion, while lifestyle modification should be central in the treat-
ment of metabolic disorders, with adapting a healthy diet as central intervention, the 
formula of this modification likely requires a personalized approach.
CONCLuDiNg REmARKS AND FuTuRE PERSPECTivES
Obesity and related T2D and cardiovascular diseases are multifactorial diseases that 
lead to high morbidity and mortality. Since current treatment options for obesity are 
either not effective on the long-term, invasive or reported to give adverse effects, new 
treatment options are needed. BAT activation is a promising tool because of its ability to 
combust nutrients and thereby improving lipid and glucose metabolism and increasing 
energy expenditure. However, in order to develop drugs aimed at activating BAT, we 
need to better understand the pathophysiology of DIO on BAT function and whole body 
metabolism.
This thesis has provided novel insights into the metabolism of brown adipocytes and 
the pathophysiology of DIO. Generating cell lines for mouse and human BPAs will en-
able us to investigate species differences. These cell lines also provide opportunities for 
future studies into the involvement of various receptors in BAT activation (e.g. TRP chan-
nels or β-ARs), and uptake of triglyceride-derived FA, especially when cocultured with 
endothelial cells in a BAT-on-chip setting. Moreover, we identified the endocannabinoid 
synthesis enzymes in adipose tissue as potential leads for therapeutic intervention. 
Strikingly, besides affecting the ECS, HFD feeding also rapidly affected BAT by induc-
ing lipid accumulation, insulin resistance and alterations in mitochondrial dynamics 
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markers. Future studies into for instance endocannabinoid modulation, TRP channels 
and mitochondrial dynamics are needed determine whether these avenues are able to 
enhance BAT activation. However, in order to determine the effectiveness and degree of 
BAT activation we need to improve our methods for detecting BAT activation. Therefore, 
novel FA tracers incorporated in triglyceride-rich lipoprotein-like particles and non-
invasive methods such as IRT and biomarkers need further study.
BAT activation will probably only be beneficial when there is no compensatory 
decrease in energy-consuming processes, or increase in energy intake. Based on cur-
rently available data, therapeutic modalities that target these different aspects of the 
energy balance, such as GLP-1 pathway activators, are of special interest and hold great 
therapeutic potential. Besides pharmacological therapy, also dietary modulation (i.e. 
increased ingestion of dietary fibers and possibly polyphenols derived from fruits and 
vegetables) has many beneficial effects on food intake, BAT activation, browning of WAT 
and cardiometabolic disease as a whole. The greatest challenge in life-style modulation 
is long-term adherence to these programs, therefore to prolong the beneficial effects 
of dietary modulation more research should be conducted into personalized dietary 
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The 24-hour society we are currently living in with food readily available, together with 
the fact that we have adapted a more sedentary lifestyle, has led to a dramatic increase 
in the number of people suffering from obesity. Obesity is a multifactorial disease and 
has a great impact on society as it contributes to the development of type 2 diabetes 
(T2D) and cardiovascular diseases (CVD). Current treatment options for obesity, mainly 
aimed at reducing caloric intake, have proven largely unsuccessful. In the previous 
decennium, it was discovered that adult humans have functional brown adipose tissue 
(BAT), which is able to contribute substantially to energy expenditure by combusting 
glucose and fatty acids upon activation, resulting in dissipation of energy stored in 
those macronutrients as heat. Since then, increasing energy expenditure via activation 
of BAT is seen as a novel strategy to combat adiposity and its related disorders. In order 
to develop novel compounds or methods to activate BAT especially in obese humans, 
a better understanding of the pathophysiology of diet-induced obesity on BAT func-
tion and whole body metabolism is required. The research described in this thesis was 
performed 1) to generate in vitro brown adipocyte models for mice and humans to study 
and better understand nutrient handling by brown adipocytes in relation to their role 
in energy metabolism, 2) to gain more insight into the effect of the anti-inflammatory 
cytokine IL-37 on energy balance, 3) to study the effect of diet-induced obesity on BAT 
function and the endocannabinoid system (ECS), and 4) to study the therapeutic poten-
tial of the dietary compound quercetin on triglyceride metabolism. Chapter 1 gives a 
broad introduction to the pathophysiology of obesity, the role of the different types of 
adipose tissue and other organs in the etiology of obesity, and the current treatment 
options for obesity.
Activated BAT increases the clearance of lipids and glucose from the circulation, but 
how BAT accommodates the large influx of multiple substrates was not well defined. 
The aim of Chapter 2 was to assess the metabolic fluxes in brown adipocytes during β3-
adrenergic receptor (β3-AR) activation. T37i murine preadipocytes were differentiated 
into brown adipocytes and Seahorse respirometry employing a set of specific substrate 
inhibitors was used in the presence or absence of the β3-AR agonist CL316,243. The 
main substrate used by these brown adipocytes were fatty acids, which were oxidized 
equally during activation as well as during resting condition. [U-13C]-glucose tracer-
based metabolomics revealed that the flux of glucose through the tricarboxylic acid 
cycle (TCA) cycle was enhanced upon β3-AR activation, and regulated by pyruvate 
dehydrogenase (PDH) activity. Based on assessment of incorporation of [U-13C]-glucose-
derived radioactivity into lipids, it appeared that some internalized glucose was utilized 
for glycerol-3-phosphate synthesis to replenish the triglyceride pool while most glucose 
was oxidized via TCA cycle activity. From these data we concluded that while brown 
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adipocytes mainly use fatty acids as substrate for oxidation, glucose is also oxidized to 
meet the increased energy demand during short term β3-AR activation and that PDH 
plays an important role in directing glucose carbons towards oxidation.
Cellular and molecular investigation of BAT in humans is hampered by the limited 
availability of cell material and the heterogeneity of BAT between and within individuals. 
In Chapter 3, monoclonal lines of conditionally immortalized brown preadipocytes (iB-
PAs) of both mouse and human origin were generated. Conditional immortalization was 
achieved by doxycycline-controlled expression of simian virus 40 large T antigen with 
a Tet-On system. In the presence of doxycycline, both the murine and human cell lines 
showed long-term proliferation capacity with a cell doubling time of approximately 24 h. 
Shutdown of large T expression by removal of doxycycline and concomitant exposure 
to an adipogenic differentiation cocktail, resulted in the acquirement of mature brown 
adipocyte properties in cells of both species. This was evidenced by the accumulation 
of multilocular lipid droplets, the upregulation of brown adipocyte markers including 
uncoupling protein 1 and the induction of lipolysis and oxygen consumption following 
adrenergic stimulation. Notably, shutdown of large T expression prior to the onset of 
differentiation appeared to be only critical to induce adipogenesis in the human iBPAs, 
while their murine counterparts showed adipogenesis upon exposure to the adipogenic 
differential cocktail regardless of large T expression. We suggest that conditionally iBPAs 
represent an easy-to-use model for fundamental and applied research into (modulation 
of ) energy metabolism by BAT.
Inflammation plays an important role in the development of obesity-induced insulin 
resistance. Research has primarily focused on the role of pro-inflammatory cytokines in 
this pathology and only recently was attention drawn to the anti-inflammatory cytokine 
IL-37. Transgenic expression of IL-37 in mice protects them from diet-induced obesity 
and associated metabolic complications including dyslipidemia, inflammation and insu-
lin resistance. The precise mechanism leading to these beneficial metabolic effects was 
not entirely known. Therefore, in Chapter 4, we aimed to assess in detail the effect of 
transgenic IL-37 expression in mice on energy balance, including food intake and energy 
expenditure. Feeding homozygous IL-37 transgenic mice and wild-type (WT) control 
mice a high-fat diet (HFD) for 6 weeks showed that transgenic IL-37 expression reduced 
body weight related to a marked decrease in food intake. Subsequent mechanistic 
studies in mice with heterozygous IL-37 expression versus WT littermates, fed the HFD 
for 18 weeks, confirmed that IL-37 reduces food intake, which led to a decrease in lean 
body mass, but did not reduce fat mass and plasma lipid levels or alterations in energy 
expenditure independent of lean body mass. This suggests that IL-37 reduces lean body 
mass by reducing food intake.
Next, we studied the pathophysiology of diet-induced obesity on BAT and the ECS. 
Long-term HFD feeding results in so-called ‘whitening’ of BAT characterized by increased 
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lipid deposition, mitochondrial dysfunction and reduced fat oxidation. The aim of Chap-
ter 5 was to unravel the rate and related mechanisms by which HFD induces BAT whiten-
ing and insulin resistance. Mice were fed a HFD for 0, 1, 3 or 7 days. Within one day of 
HFD feeding BAT weight and lipid content were already increased. HFD also immediately 
reduced insulin-stimulated glucose uptake by BAT, indicating rapid induction of insulin 
resistance. This was accompanied by reduced uptake of triglyceride-derived fatty acids 
by BAT after 1 day of HFD. Mitochondrial mass and Ucp1 expression were unaltered, 
while after 3 days of HFD markers of mitochondrial dynamics suggested induction of 
a more fused mitochondrial network. After 3 days of HFD, macrophage markers also 
increased in BAT. Counterintuitively, the switch to HFD was accompanied by an acute 
rise in core body temperature. Thus, a single day of HFD feeding is sufficient to induce 
the first signs of whitening and insulin resistance in BAT, which reduces the uptake of 
glucose and triglyceride-derived fatty acids. BAT whitening and insulin resistance is 
likely sustained by reduced mitochondrial oxidation due to changes in mitochondrial 
dynamics and macrophage infiltration, respectively. Likely, the switch to HFD swiftly 
induces thermogenesis in other metabolic organs, which allows attenuation of BAT 
thermogenesis.
The ECS is seen as a potential therapeutic target to combat cardiometabolic diseases 
because it controls the energy balance by regulating both energy intake and energy 
expenditure. Moreover, an increased tone of the ECS is associated with obesity. In order 
to develop novel therapeutics, more insight is needed in how fast and in which organs 
the dysregulation of the ECS in obesity development sets off. Therefore, the aims of 
Chapter 6 were to elucidate the rate of dysregulation of the ECS, and the metabolic or-
gans involved, in diet-induced obesity. Eight groups of mice were randomized to receive 
a chow diet (control) or a HFD ranging from 1 day up to 18 weeks. Plasma levels of the 
endocannabinoids 2-arachidonoylglycerol (2-AG) and anandamide (N-arachidonoyl-
ethanolamine, AEA), and related N-acylethanolamines, were quantified and gene 
expression of components of the ECS was determined in liver, muscle, white adipose 
tissue (WAT) and BAT during the course of diet-induced obesity development. HFD 
feeding gradually increased plasma 2-AG, accompanied by upregulated expression of 
its synthesizing enzymes Dagla and Daglb in WAT and BAT. HFD feeding also rapidly 
increased plasma AEA, accompanied by increased expression of its synthesizing enzyme 
Nape-pld, specifically in BAT. Interestingly, Nape-pld expression in BAT correlated with 
plasma AEA levels. Based on these data we concluded that HFD feeding rapidly activates 
adipose tissue depots to increase the synthesis pathways of endocannabinoids that 
may aggravate the development of HFD-induced obesity. Future research is required to 
determine whether inhibiting endocannabinoid signaling specifically in adipose tissue 
is a worthwhile strategy to pursue in combating obesity and related diseases.
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Quercetin is a natural flavonoid which lowers plasma triglycerides in human interven-
tion studies, and its intake is associated with lower CVD risk. The aim of Chapter 7 was 
to elucidate the mechanism by which quercetin lowers plasma triglyceride levels in 
diet-induced obesity. Mice received a HFD with or without quercetin (0.1% w/w) for 12 
weeks. Quercetin decreased plasma triglyceride levels from nine weeks onwards, with-
out affecting food intake, body composition, or energy expenditure. Mechanistically, 
quercetin did not reduce intestinal fatty acid absorption. Rather, quercetin induced a 
slight reduction in liver Apob expression, which suggests decreased very-low density 
lipoprotein-triglyceride production. Interestingly, quercetin also markedly increased 
the uptake of triglyceride-derived fatty acids by subcutaneous white adipose tissue 
(sWAT). Furthermore, quercetin markedly increased mRNA expression of Ucp1 and 
Elovl3, specifically in sWAT. Accordingly, only quercetin-treated animals showed UCP-1 
protein-positive cells in sWAT, which is fully compatible with increased browning. Taken 
together, the triglyceride-lowering effect of quercetin may, at least in part, be due to 
increased triglyceride-derived fatty acid uptake by sWAT as a consequence of browning.
To conclude, in Chapter 8 the results of this thesis were evaluated within context 
of current literature, and novel insights into the pathophysiology of obesity and T2D 
were discussed, as well as therapeutic implications and translational challenges. Col-
lectively the studies described in this thesis have increased our insight into brown 
adipocyte metabolism, the mechanism underlying the beneficial metabolic effects of 
the anti-inflammatory cytokine IL-37, the pathophysiology of diet-induced obesity and 




Tegenwoordig leven we in een 24-uurs samenleving, waarin voedsel gemakkelijk en op 
zijn zachtst gezegd in overvloed beschikbaar is. Samen met het feit dat we een meer 
zittende levensstijl hebben ontwikkeld waarin we minder bewegen, heeft deze leef-
omgeving ertoe geleid dat het aantal mensen met obesitas dramatisch is toegenomen. 
Obesitas is een complexe ziekte en heeft grote impact op onze samenleving, omdat 
het bijdraagt aan de ontwikkeling van suikerziekte, ook wel diabetes type 2 genoemd, 
en hart- en vaatziekten. Huidige behandelmethoden voor obesitas zijn voornamelijk 
gericht op calorische beperking, en zijn op de langer termijn vaak niet effectief. Daarom 
is onderzoek nodig naar de ontstaansmechanismen van obesitas, om op basis van die 
kennis nieuwe behandelstrategieën te ontwikkelen en het risico het ontwikkelen van 
suikerziekte en hart- en vaatziekten te verminderen.
Obesitas ontstaat door een zogenaamde ‘positieve energiebalans’, waarbij de inname 
van energie (in de vorm van voedsel) gedurende langere tijd hoger is dan de energie die 
verbruikt wordt (door bijvoorbeeld beweging). De organen in ons lichaam gebruiken 
voornamelijk suikers en vetten als energiebron. In het geval van een positieve energie-
balans, zullen de overtollige suikers en vetten vanuit het bloed worden opgenomen en 
opgeslagen in vetweefsel. Er zijn twee typen vetweefsel: wit en bruin vet. De voornaam-
ste functie van wit vet is die opslag van overtollige vetten in de vorm van triglyceriden. 
Bruin vet daarentegen verbrandt juist suikers en vetten om warmte te produceren en 
verhoogt daarmee het energieverbruik. In eerste instantie werd aangenomen dat alleen 
pasgeboren baby’s bruin vet hebben, om hun lichaamstemperatuur op peil te houden. 
Maar iets meer dan tien jaar geleden is ontdekt dat volwassen mensen ook actief bruin 
vet hebben. Terwijl wit vet vooral in de buik en rond de heupen zit, bevindt bruin vet 
zich in baby’s vooral tussen de schouderbladen en in volwassenen in het gebied boven 
de sleutelbeenderen en rond de grote lichaamsslagader (de ‘aorta’). Sindsdien wordt het 
verhogen van het energieverbruik door activatie van bruin vet gezien als een nieuwe 
methode om vetstapeling en de daaraan gerelateerde ziektes aan te pakken. Om nieuwe 
methoden die bruin vet activeren te kunnen ontwikkelen, is meer inzicht nodig in het 
effect van obesitas op de functie van bruin vet en op de stofwisseling van het gehele 
lichaam.
Hoofdstuk 1 geeft een uitgebreide introductie over de verschillende organen en pro-
cessen die betrokken zijn bij de ontwikkeling van obesitas. Het onderzoek in dit proef-
schrift werd uitgevoerd om 1) bruin vetcellijnen van muizen en mensen te genereren, 
die gebruikt kunnen worden voor het bestuderen van het energiemetabolisme van die 
cellen, 2) meer inzicht te krijgen in het effect van het ontstekingsremmende cytokine 
interleukine-37 (IL-37) op de energiebalans, 3) het effect van obesitas, dat is ontstaan 
door teveel vetrijk voedsel te eten, op de functie van bruin vet en het endocannabinoï-
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densysteem te onderzoeken, en (4) het onderliggende mechanisme te onderzoeken van 
het triglyceridenverlagende effect van quercetine dat van nature voorkomt in groenten 
en fruit.
Zoals eerder aangegeven neemt geactiveerd bruin vet grote hoeveelheden vetten en 
suikers op uit het bloed, maar wat er vervolgens met deze verschillende macronutriënten 
gebeurt na opname door bruine vetcellen was nog niet geheel bekend. Daarom hebben 
we in Hoofdstuk 2 onderzocht wat er gebeurt met de verschillende macronutriënten in 
bruine vetcellen na stimulatie door een activator van de β3-adrenerge receptor. Hiertoe 
zijn T37i cellen, voorlopercellen van bruin vet afkomstig uit muizen, gekweekt en gedif-
ferentieerd tot bruine vetcellen. Met deze gedifferentieerde bruine vetcellen zijn in de 
aan- en afwezigheid van de β3-adrenerge receptoractivator CL316,243, metingen uit-
gevoerd aan het zuurstofverbruik als uitleesmaat voor de energiestofwisseling. Hierbij 
werd gebruik gemaakt van specifieke remmers van de verschillende macronutriënten. 
We ontdekten dat de bruine vetcellen voornamelijk vetzuren verbranden, zowel in rust 
als na stimulatie. Door gebruik te maken van radioactief suiker (‘glucose’) ontdekten we 
dat gestimuleerde bruine vetcellen glucose gedeeltelijk gebruiken voor het maken van 
triglyceriden. Glucose bleek echter voornamelijk verbrand te worden via de citroen-
zuurcyclus waarbij het enzym pyruvaatdehydrogenase een belangrijke rol speelt.
Onderzoek naar bruin vet in mensen vordert gestaag maar relatief langzaam, ener-
zijds omdat het niet eenvoudig is de activiteit van bruin vet te bepalen en anderzijds 
doordat zeer weinig bruin vet voor onderzoek beschikbaar is. Daarnaast zijn er veel 
verschillen in bruin vet tussen verschillende mensen, maar ook binnen een persoon 
kan het bruin vet tussen de diverse locaties verschillen. Om onderzoek naar bruin vet 
buiten het lichaam om mogelijk te maken hebben anderen eerder al cellijnen van 
bruin vet uit muizen en mensen gemaakt. Deze cellen zijn genetisch gemodificeerd 
om hen ‘onsterfelijk’ te maken door herhaaldelijk te delen wanneer ze in kweek worden 
gebracht. Door de genetische aanpassing brengen deze cellen continu een soort tumo-
reiwit tot expressie, wat ze normaal gesproken niet zouden doen en dit zou mogelijk 
een negatief effect kunnen hebben op de functie van de vetcellen. Daarom hebben 
we in Hoofdstuk 3 voorlopercellen van bruin vet van muizen en mensen genomen en 
door genetische modificatie ervoor gezorgd dat de cellen alleen deze tumoreiwitten 
tot expressie brengen wanneer doxycycline aan het kweekmedium wordt toegevoegd. 
Dit noemen we voorwaardelijke onsterfelijkheid. De bruin vetcellijnen van zowel de 
muis als mens konden in aanwezigheid van doxycycline langdurig in kweek gehouden 
worden waarbij het aantal cellen ongeveer elke 24 uur verdubbelde. Door doxycycline 
uit het kweekmedium weg te halen en door de cellen vervolgens bloot te stellen aan 
een cocktail van stimulerende stoffen, veranderden de voorlopercellen in volgroeide 
bruine vetcellen. Dit proces nemen we ‘differentiatie’. Deze gedifferentieerde bruine 
vetcellen toonden de diverse karakteristieke eigenschappen van bruin vet: opstapeling 
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van vet in diverse kleine vetdruppeltjes, hoge expressie van bruin vetgenen (zoals ont-
koppelingseiwit-1, UCP-1) en verhoging van lipolyse en zuurstofverbruik als reactie op 
activatie van de adrenerge receptor. Daarnaast vonden we dat het wegnemen van het 
tumoreiwit cruciaal was voor differentiatie van de menselijke voorlopercellen, terwijl de 
muizenvoorlopercellen ongeacht de expressie van het tumoreiwit differentieerden. In 
de toekomst kunnen deze nieuwe bruin vetcellijnen van grote betekenis zijn in zowel 
fundamenteel als toegepast onderzoek rond de energiestofwisseling van bruin vet.
Bij de ontwikkeling van obesitas-gerelateerde insulineresistentie speelt het immuun-
systeem een belangrijke rol. In deze context is er tot op heden voornamelijk onderzoek 
gedaan naar het remmen van de ontstekingsbevorderende cytokines. Recent werd 
echter de aandacht getrokken door de ontstekingsremmende cytokine IL-37. Eerder 
onderzoek heeft aangetoond dat transgene muizen die IL-37 tot expressie brengen zijn 
beschermd tegen de ontwikkeling van overgewicht en de daaraan gerelateerde ontste-
king en insulineresistentie. Omdat niet geheel bekend was hoe dit werkte hebben we 
in Hoofdstuk 4 het effect van IL-37 op beide kanten van de energiebalans, inname en 
verbruik, verder onderzocht. Gedurende 6 weken voerden we muizen die IL-37 al dan 
niet homozygoot tot expressie brengen een vetrijk dieet en ontdekten dat expressie 
van IL-37 het lichaamsgewicht verlaagde en voedselinname remde. Vervolgens hebben 
we heterozygote IL-37 transgene muizen en controle muizen, afkomstig uit dezelfde fok 
als de heterozygote muizen, gedurende 18 weken een vetrijk dieet gevoerd. Wederom 
vonden we dat de IL-37 transgene muizen minder voedsel aten. Dit leidde tot een ver-
laging van het vetvrije lichaamsgewicht maar niet tot een verlaging van de vetmassa of 
bloedvetconcentratie. We vonden ook geen verschillen in het energieverbruik wanneer 
we corrigeerden voor het vetvrije lichaamsgewicht. Uit deze studie konden we dus 
concluderen dat IL-37 het vetvrije lichaamsgewicht verlaagt door de voedselinname te 
verminderen.
Vervolgens hebben we onderzocht wat er met bruin vet en het endocannabinoïden-
systeem gebeurt tijdens de ontwikkeling van obesitas, door muizen een vetrijk dieet 
te eten te geven. Eerdere studies lieten zien dat het voeren van een vetrijk dieet aan 
muizen gedurende een lange tijd resulteert in zogeheten ‘verwitting’ van bruin vet, 
gekarakteriseerd door verhoogde vetafzetting, slecht werkende mitochondriën en 
verlaagde vetverbranding. Zoals in Hoofdstuk 5 beschreven hebben we onderzocht 
hoe snel verwitting van bruin vet optreedt en welke mechanismen daarbij betrokken 
zijn, door muizen een vetrijk dieet te geven gedurende één, drie of zeven dagen. Het 
vetrijke dieet deed het gewicht van het bruin vet en de vetstapeling in bruin vet al bin-
nen één dag toenemen. Dit ging samen met een sterk verlaagde insuline-gestimuleerde 
opname van glucose door bruin vet, wat erop duidt dat het weefsel binnen slechts één 
dag insulineresistent is geworden. Ook leek de opname van vetzuren vanuit triglyce-
ridenrijke lipoproteïne-achtige deeltjes door bruin vet binnen één dag lager te zijn. 
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Hoewel het aantal mitochondriën en de genexpressie van UCP-1 niet veranderd waren, 
zagen we na drie dagen vetrijk dieet een verhoogde expressie van genen en eiwitten 
die betrokken zijn bij het fuseren en verlengen van het mitochondriële netwerk. Na 
drie dagen leidde het vetrijk dieet ook tot verhoogde expressie van macrofaaggenen 
in bruin vet. Onverwachts zagen we dat de omschakeling naar voeren van het vetrijke 
dieet de lichaamstemperatuur van de muizen acuut deed stijgen. Op basis van deze 
data concludeerden we dat één dag vetrijk voedsel eten al voldoende is om de eerste 
tekenen van verwitting en insulineresistentie in bruin vet te veroorzaken, wat ervoor 
zorgt dat de opname van glucose en vetzuren door bruin vet sterk afneemt. Verlaagde 
vetzuurverbranding door het gefuseerde mitochondriële netwerk en de aanwezigheid 
van macrofagen in het bruin vetweefsel zorgen waarschijnlijk voor het in stand houden 
van de verwitting en insulineresistentie in bruin vet. De omschakeling naar het vetrijke 
dieet zorgt waarschijnlijk voor warmteproductie in andere organen die betrokken zijn 
bij de verwerking van het vele vet uit het voedsel, waaronder de dunne darm en de 
lever, waardoor bruin vet minder actief hoeft te zijn. 
Het endocannabinoïdensysteem speelt een belangrijke rol in de energiebalans omdat 
dit systeem betrokken is bij zowel de energie-inname als het energieverbruik. Om deze 
redenen wordt het endocannabinoïdensysteem gezien als mogelijk aangrijpingspunt 
voor nieuwe therapieën om obesitas tegen te gaan. Het was al bekend dat hoge concen-
traties van endocannabinoïden in het bloed geassocieerd zijn met obesitas. Maar nog 
onduidelijk was hoe snel het endocannabinoïdensysteem ontregelt en welke organen 
hieraan bijdragen. Daarom hebben we muizen verdeeld over acht groepen, waarbij één 
groep een regulier controledieet kreeg en de overige zeven groepen een vetrijk dieet 
kregen gedurende één dag tot 18 weken om zo de ontwikkeling van obesitas in relatie 
tot het endocannabinoïdensysteem te kunnen bestuderen. De resultaten hiervan staan 
beschreven in Hoofdstuk 6. We vonden dat de concentratie van de endocannabinoïd 
2-arachidonoylglycerol (2-AG) in het bloedplasma geleidelijk steeg en dat dit gepaard 
ging met verhoging van de genexpressie van DAGLA en DAGLB, betrokken bij de aan-
maak van 2-AG, in wit en bruin vet. Daarnaast zagen we dat de concentratie van het en-
docannabinoïd anandamide (N-arachidonoylethanolamine, AEA) in het bloedsplasma 
snel steeg en dat dit eveneens gepaard ging met een verhoogde genexpressie van 
NAPE-PLD, betrokken bij de synthese van AEA, maar dan specifiek in bruin vet. Tevens 
bleek er een positief verband te zijn tussen de plasmaniveaus van AEA en de genexpres-
sie van NAPE-PLD in bruin vet. Op basis van deze resultaten concludeerden we dat het 
eten van een vetrijk dieet in vetweefsels snel de enzymen activeert die betrokken zijn bij 
de aanmaak van endocannabinoïden, die vervolgens vetstapeling en daarmee de ont-
wikkeling van obesitas kunnen verergeren. Het zou interessant zijn om in aanvullende 
studies te onderzoeken of het specifiek remmen van het endocannabinoïdensysteem 
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in vetweefsels een mogelijk aangrijpingspunt kan zijn tegen obesitas en de daaraan 
gerelateerde ziektes als diabetes type 2 en hart- en vaatziekten.
Quercetine is een stofje dat aanwezig is in groente en fruit en waarvan is aangetoond 
dat het in mensen de triglyceridenconcentratie in het bloedplasma verlaagt. De inname 
van quercetine is geassocieerd met verlaging van het risico op het ontwikkelen van 
hart- en vaatziekten. In Hoofdstuk 7 hebben we onderzocht wat het achterliggende 
mechanisme is waardoor quercetine triglyceriden in het bloed verlaagt. Hiertoe hebben 
we muizen 12 weken een vetrijk dieet gevoerd met of zonder quercetine. Zoals verwacht 
verlaagde quercetine na negen weken de triglyceridenconcentratie in het bloed, zonder 
effect te hebben op de voedselinname, lichaamssamenstelling of het energieverbruik. 
We hebben onderzocht of de opname van vetten in de darmen veranderd was door 
quercetine, maar dit bleek niet het geval. Daarentegen vonden we een lichte verhoging 
van expressie van het Apob gen in de lever, dat betrokken is bij de productie van zeer 
lage dichtheid lipoproteïnen die rijk zijn aan triglyceriden. Quercetine verhoogde ook 
aanzienlijk de opname van vetzuren afkomstig van triglyceriden door onderhuids wit 
vet, het depot dat het meest gevoelig is voor ‘verbruining’. Tevens verhoogde querce-
tine de expressie van de bruin vetgenen Ucp1 en Elovl3 specifiek in onderhuids wit vet. 
Hiermee overeenkomend ontwikkelden alleen de met quercetine behandelde dieren 
cellen in het onderhuidse wit vetdepot die positief waren voor UCP-1, wat suggereert 
dat dit wit vetdepot kenmerken heeft gekregen van bruin vet. Het triglyceridenverla-
gende effect van quercetine kan dus vermoedelijk voor een deel worden verklaard door 
een hogere opname van vetzuren vanuit deze triglyceriden door het onderhuidse wit 
vetdepot als gevolg van verbruining.
Tenslotte werden de bevindingen van dit proefschrift bediscussieerd in de context 
van de huidige kennis beschreven in de wetenschappelijke literatuur in Hoofdstuk 8. 
Daarnaast werden in dit hoofdstuk de door dit proefschrift verkregen inzichten in de 
ontwikkeling van obesitas en diabetes type 2, de gevolgen voor de klinische praktijk 
en de uitdagingen in het onderzoek naar bruin vet in relatie tot obesitas behandeld. De 
studies die beschreven zijn in dit proefschrift hebben ons inzicht vergroot in de energie-
stofwisseling van de bruine vetcel en de manier waarop de ontstekingsremmende cyto-
kine IL-37 gunstige metabole effecten geeft. Maar ze hebben ook meer inzicht gegeven 
in de mechanismen die betrokken zijn bij de ontwikkeling van dieet-geïnduceerde 
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Voor het bijwonen van de 
openbare verdediging 
van mijn proefschrift
Op woensdag 25 
september 2019 om 16:15 
uur in het Groot Auditorium 
van het Academiegebouw, 
Rapenburg 73 te Leiden. 
U wordt verzocht een 
kwartier voor aanvang 
aanwezig te zijn. 
Geïnteresseerden zijn 
van harte welkom om het 
'lekenpraatje' bij te wonen 
dat zal aanvangen om 
15:15 uur in zaal 01 in het 
Academiegebouw. 
Na afloop van de promotie 
bent u van harte welkom 
op de receptie, deze zal 
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